Molecular basis of TAPBPR-mediated peptide editing on MHC class I molecules by Ilca, Florin Tudor
Molecular basis of TAPBPR-mediated peptide 
editing on MHC class I molecules 
 
Florin Tudor Ilca 
 
Department of Pathology 
University of Cambridge 




Corpus Christi College 
 
 








This thesis is strictly the result of my own work and does not include any work performed in 
collaboration, except where specifically mentioned in the text.  
 
It is not substantially the same as any that I have submitted, or, is being concurrently submitted 
for a degree or diploma or other qualification at the University of Cambridge or any other 
University or similar institution except as declared in the Preface and specified in the text. I 
further state that no substantial part of my dissertation has already been submitted, or, is 
being concurrently submitted for any such degree, diploma or other qualification at the 
University of Cambridge or any other University or similar institution except as declared in the 
Preface and specified in the text. 
 
This thesis is in compliance with the word limit imposed by the Degree Committee of the 





Florin Tudor Ilca 
 
Cambridge 
September 2019  
  
Abstract 
Major histocompatibility complex (MHC) class I molecules present fragments of the cellular 
proteome, in the form of short peptides, to the cell surface for the inspection by cytotoxic T 
cells. This process is a crucial immunosurveillance mechanism used to induce appropriate 
immune responses against intracellular pathogens and cancer. In order to generate optimal T 
cell-mediated immune responses, prior to their export to the cell surface, MHC class I 
molecules undergo a process known as peptide selection. Optimal peptide selection is 
facilitated by two intracellular peptide editors, tapasin and TAPBPR. TAPBPR was shown to 
shape the peptide repertoire presented on MHC class I at the cell surface, either by directly 
catalysing peptide exchange on MHC class I molecules or by associating with the quality control 
enzyme UDP-glycoprotein glucosyltransferase 1 (UGT1), which selects optimally-loaded MHC 
class I molecules for export to the cell surface.  
Given that unlike tapasin, TAPBPR could catalyse peptide editing on MHC class I on its own in 
solution, I sought to test whether TAPBPR could also function as a peptide exchange catalyst on 
MHC class I molecules present on the surface of cells. By examining the artefactual expression 
of TAPBPR at the cell surface upon over-expression, I developed two novel cellular assays which 
allowed me to explore the function of TAPBPR as a peptide exchange catalyst on plasma 
membrane-expressed MHC class I molecules. I showed that, when given access the cell surface, 
TAPBPR can promote efficient peptide exchange on surface expressed MHC class I molecules. 
These assays allowed me to demonstrate that the 22-35 loop of TAPBPR was essential for its 
peptide exchange function. Moreover, I revealed that residue L30 within the loop was both 
necessary and sufficient for the efficient ability of TAPBPR to dissociate peptides from MHC 
class I molecules that typically accommodate hydrophobic anchor residues in their F pocket. 
This enabled me to propose a new mechanistic model for TAPBPR-mediated peptide editing. I 
further addressed the molecular basis governing the compatibility between TAPBPR and MHC 
class I molecules, by screening a wide panel of human leukocyte antigen (HLA) class I allotypes 
for their relative propensities to undergo peptide editing by TAPBPR. TAPBPR displayed a clear 
functional preference for HLA-A molecules, particularly for members of the A2 and A24 
supertypes, over HLA-B and -C molecules. This preference appears to be driven by specific 
molecular features of the MHC class I F pocket, in particular residues H114 and Y116.  
Finally, I explored the potential translational applications of using TAPBPR as a peptide 
exchange catalyst on surface-expressed MHC class I molecules. I demonstrated that 
recombinant TAPBPR can be utilised to load immunogenic peptides of choice directly onto 
plasma-membrane expression MHC class I, thus overriding the internal antigen presentation 
pathway. Subsequently, I revealed that, TAPBPR can be used to induce T cell-mediated killing of 
tumour cells. These findings highlight a potential therapeutic application of TAPBPR in 
increasing the immune recognition of tumours.  
  
Acknowledgements  
The completion of the research presented in this thesis would not have been possible without 
the help and support of many people. First and foremost, I would like to thank my supervisor, 
Dr. Louise Boyle, first of all, for offering me the opportunity to be part of her group and second, 
for her continuous guidance and inspiration throughout the course of my projects. I am 
particularly grateful to her for allowing me to implement my own ideas and for constantly 
pushing me to reach beyond my comfort zone. Second, Dr. Andreas Neerincx was absolutely 
vital for the progress of my research, equipping me with a variety of methods and techniques 
as well as with practical and diligent work ethic.  
I am extremely grateful for the privilege of working with Dr. Janet Deane, who provided 
assistance and guidance with protein expression and purification experiments, as well as 
valuable insight into the structural biology aspect of the project. Moreover, I would like to 
thank Dr. Mark Wills and Dr. Maike the la Roche, who taught and assisted me in performing 
various primary T cell assays. Many thanks also to Dr. Gemma Brewin and Dr. Sarah Peacock, 
who provided us access to the facilities at the Tissue Typing Labs, as well as supervision during 
my experiments there. Finally, I had the pleasure of supervising Linnea Drexhage, a very 
talented master student, who helped me characterise the impact of polymorphisms in MHC 
class I molecules on their interactions with TAPBPR.  
A few key results presented in this thesis were only possible with the help of our external 
collaborators, Prof. Stefan Stefanovic and Ana Marcu, from the University of Tübingen, as well 
as Dr. Clemmens Hermann, from the University of Cape Town, who performed the peptide 
elution and analysis work presented here. In addition, I would like to thank Prof. Paul MacAry, 
from the University of Singapore, and Prof. Peter Cresswell, from Yale University, for providing 
reagents essential for this work. 
In the Department of Pathology, I am particularly grateful to Prof. John Trowsdale for his 
constant support, useful discussions and feedback sessions throughout my PhD programme. I 
am also grateful to the members of the Trowsdale and Kaufman groups for useful 
conversations and for providing regents. I would particularly like to thank to Dr. Stephen 
Graham for being my mentor and providing guidance and support with my academic progress 
as well as with career prospects in science.  
Finally, I am extremely grateful to Wellcome and to the University of Cambridge, for the 
funding provided and for offering me the opportunity to undertake my PhD.  
  
Table of Contents 
 
1. Chapter 1: Introduction  ........................................................................................................... 1 
1.1. Role of MHC molecules in the immune system................................................................. 1 
1.1.1.   Antigen presentation ............................................................................................... 1 
1.1.2.   Function in innate immunity ................................................................................... 2 
1.2. MHC in health and disease ................................................................................................ 2 
1.3. The MHC region ................................................................................................................. 3 
1.4. The structure of MHC class I molecules ............................................................................ 4 
1.5. Polymorphisms in MHC class I molecules and relevance in immune responses  ............. 6 
1.6. The canonical MHC class I antigen processing and presentation pathway  ...................... 6   
1.6.1. Generation of antigenic peptides.............................................................................. 6 
1.6.2. Transport of peptides into the ER ............................................................................. 7 
1.6.3. Peptide trimming in the ER ....................................................................................... 9 
1.6.4. Early folding and assembly of MHC class I dimers  ................................................. 10 
1.6.5. The peptide loading complex .................................................................................. 10 
1.7. Function of tapasin on MHC class I molecules  ............................................................... 11 
1.7.1. Assembly of the PLC and binding to MHC class I  ................................................... 12 
1.7.2. Bridging TAP and MHC class I .................................................................................. 13 
1.7.3. Peptide editing on MHC class I molecules .............................................................. 13 
1.7.3.1. Optimisation of peptide presentation on MHC class I .................................. 13 
1.7.3.2. Proposed mechanisms of peptide editing ..................................................... 14 
1.7.4. Allelic dependence of HLA class I on tapasin .......................................................... 15 
1.8. Non-canonical MHC class I antigen presentation pathways ........................................... 16 
1.8.1. TAP-independent peptide loading of MHC class I molecules ................................. 16 
1.8.2. Cross-presentation .................................................................................................. 17 
1.9. Discovery of TAPBPR, a novel MHC class I-dedicated chaperone ................................... 19 
1.9.1. Binding to MHC class I molecules ............................................................................ 19 
1.9.2. Cellular trafficking ................................................................................................... 20 
1.9.3. Peptide editing ........................................................................................................ 21 
1.9.4. Interaction with UGT1 ............................................................................................. 22 
1.9.5. Shaping the peptide repertoire presented on MHC class I ..................................... 22 
1.10. Similarities between MHC class I and class II pathways  ................................................ 24 
1.11. Aims ................................................................................................................................ 27 
2. Chapter 2: Materials and methods  ....................................................................................... 28 
2.1. Constructs  ....................................................................................................................... 28 
2.2. Cell lines  ..................................................................................................................................... 31 
2.3. Lentiviral transduction and transfections .............................................................................. 31 
2.4. Antibodies ........................................................................................................................ 31 
2.5. MHC class I-binding peptides ........................................................................................... 32 
2.6. Expression and purification of TAPBPR protein ............................................................... 33 
2.7. Differential scanning fluorimetry (DSF)  .......................................................................... 34 
2.8. Flow cytometry ................................................................................................................ 34 
2.9. Single antigen bead screen .............................................................................................. 34 
2.10. BFA decay assays............................................................................................................ 35 
2.11. Immunoprecipitation, gel electrophoresis and western blotting ................................. 35 
2.12. Peptide binding .............................................................................................................. 36 
2.13. Peptide exchange ........................................................................................................... 36 
2.14. FluoroSpot T cell assay ................................................................................................... 37 
2.14.1. Expansion of HCMV specific CD8+ T cells ............................................................. 37 
2.14.2. Experimental set up .............................................................................................. 37 
2.15. Mice ............................................................................................................................... 38 
2.16. Cytotoxicity assay ........................................................................................................... 38 
2.17. Isolation of HLA peptides ............................................................................................... 39 
2.18. Analysis of HLA ligands by LC-MS/MS ............................................................................ 39 
2.19. Database search and HLA annotation ........................................................................... 40 
2.20. Label-free quantitation .................................................................................................. 40 
3. Chapter 3: Designing an assay to identify functional regions of TAPBPR involved in peptide 
editing ..................................................................................................................................... 41 
3.1. Background ...................................................................................................................... 41 
3.2. Results .............................................................................................................................. 42 
3.2.1. TAPBPR is present at the cell surface when over-expressed in HeLaM cells  ......... 42 
3.2.2. TAPBPR over-expression significantly promotes peptide binding to cells  ............. 44 
3.2.3. Over-expressed TAPBPR mediates peptide loading onto MHC class I molecules 
present at the cell surface ........................................................................................ 47 
3.2.4. TAPBPR present at the cell surface facilitates peptide loading onto MHC class I 
molecules  ................................................................................................................. 49 
3.2.5. TAPBPR present on the plasma membrane associates with MHC class I molecules 
at the cell surface ..................................................................................................... 51 
3.2.6. Surface-expressed tapasin does not promote substantial peptide loading of MHC 
class I molecules ....................................................................................................... 52 
3.2.7. TAPBPR functions as a peptide exchange catalyst on MHC class I molecules at the 
cell surface ................................................................................................................ 54 
3.2.8. Soluble TAPBPR binds to cell surface HLA-A*68:02 class I molecules .................... 59 
3.2.9. Soluble TAPBPR facilitates peptide exchange onto surface-expressed HLA-A*68:02
 .................................................................................................................................. 60 
3.2.10. Soluble TAPBPR dissociates from HLA-A*68:02 upon loading high-affinity 
peptides .................................................................................................................... 63 
3.2.11. Soluble TAPBPR mediates peptide exchange on MHC class I molecules in a 
peptide affinity-based manner ................................................................................. 65 
3.3. Discussion ........................................................................................................................ 67 
4. Chapter 4: Characterising the involvement of the K22-D35 loop of TAPBPR in its peptide 
editing function  ............................................................................................................................... 69 
4.1. Background ...................................................................................................................... 69 
4.2. Results .............................................................................................................................. 71 
4.2.1. Designing and expressing TAPBPR loop mutants  ................................................... 71 
4.2.2. The K22-D35 loop of TAPBPR is an essential region for mediating peptide 
dissociation from HLA-A*68:02 ................................................................................ 73 
4.2.3. L30 is a crucial residue for the peptide exchange function of TAPBPR on HLA-
A*68:02 ..................................................................................................................... 75 
4.2.4. Mutation of L30 residue severely impairs the peptide exchange ability of soluble 
TAPBPR on HLA-A*68:02 .......................................................................................... 76 
4.2.5. L30 residue is essential for the stable association of soluble TAPBPR with peptide-
loaded MHC class I molecules .................................................................................. 78 
4.2.6. Mutation of the K22-D35 loop of TAPBPR alters the peptide repertoire presented 
on MHC class I .......................................................................................................... 83 
4.2.7. L30 enables TAPBPR to mediate efficient peptide exchange on MHC class I 
molecules that accommodate hydrophobic residues in their F pocket ................... 87 
4.2.8. TAPBPR cannot use the L30 residue to mediate efficient peptide exchange on 
MHC class I molecules that accommodate charged residues in their F pocket ....... 91 
4.2.9. Mutation of residue 116 in the MHC class I F pocket alters TAPBPR binding ......... 92 
4.2.10. Modifying the F pocket specificity of MHC class I alters TAPBPR-mediated 
peptide editing .......................................................................................................... 94 
4.3. Discussion ......................................................................................................................... 97 
5. Chapter 5: Exploring the allelic susceptibility of HLA class I to peptide editing by TAPBPR ...  
 ................................................................................................................................................. 98 
5.1. Background ...................................................................................................................... 98 
5.2. Results .............................................................................................................................. 98 
5.2.1. TAPBPR shows binding preference for HLA-A over -B and -C molecules ................ 98 
5.2.2. The strongest TAPBPR binders are members of the HLA-A2 and A24 superfamilies
 ................................................................................................................................ 103 
5.2.3. TAPBPR shows the same HLA binding hierarchy in a cellular system ................... 104 
5.2.4. TAPBPR shows enhanced binding ability to intracellular species of HLA class I 
molecules ................................................................................................................ 107 
5.2.5. HLA class I molecules that bind strongly to TAPBPR are also strong tapasin binders
 ................................................................................................................................ 110 
5.2.6. Peptide exchange catalysed by TAPBPR is proportional to its ability to associate 
with HLA class I ....................................................................................................... 110 
5.2.7. The relative susceptibility of HLA class I molecules to undergo peptide editing by 
TAPBPR does not directly correlate with their relative stability at the cell surface
 ................................................................................................................................ 115 
5.2.8. Molecular properties of the F pocket of HLA class I correlate well with TAPBPR 
binding ability  ......................................................................................................... 116 
5.2.9. Residues H114 and Y116 are conserved across all members of A2 and A24 
superfamily and are not present in any other known HLA class I allotypes .......... 117 
5.2.10. The F pocket architecture governs the ability of HLA class I molecules to 
associate with TAPBPR ............................................................................................ 118 
5.2.11. The F pocket architecture strongly influences the susceptibility of MHC class I 
molecules to undergo peptide editing by TAPBPR ................................................. 123 
5.2.12. Disease-associated HLA class I allotypes that naturally differ in residue 116 alone 
show different propensities to undergo TAPBPR-mediated peptide editing ......... 124 
5.2.13. Residue M12 of HLA-A*68:02 is responsible for its distinct ability to interact with 
TAPBPR  ............................................................................................................................ 127 
5.3. Discussion ...................................................................................................................... 132 
6. Chapter 6: Investigating the therapeutic potential of using soluble TAPBPR as a peptide 
loading catalyst on cell surface MHC class I molecules ...................................................... 133 
6.1. Background .................................................................................................................... 133 
6.2. Results ............................................................................................................................ 133 
6.2.1. TAPBPR can be used to load immunogenic peptides onto human tumour cells . 133 
6.2.2. Peptides loaded by TAPBPR onto cell surface MHC class I are available for TCR 
recognition .............................................................................................................. 134 
6.2.3. TAPBPR-mediated loading of immunogenic peptides on MHC class I enhances 
recognition of tumour cells by CD8+ T cells ............................................................ 136 
6.2.4. Using TAPBPR to induce T cell-mediated killing of tumour cells .......................... 139 
6.3. Discussion ...................................................................................................................... 142 
7. Chapter 7: Discussion ........................................................................................................... 144 
7.1. Summary of results ........................................................................................................ 144 
7.2. Developing an improved assay for assessing TAPBPR-mediated peptide editing on MHC 
class I molecules ............................................................................................................ 145 
7.3. Peptide exchange mechanisms of TAPBPR on MHC class I ........................................... 146 
7.4. Criteria used by TAPBPR in selecting peptides .............................................................. 149 
7.5. Allelic preference of TAPBPR for MHC class I molecules  .............................................. 150 
7.5.1.  Molecular basis ..................................................................................................... 150 
7.5.2.  Comparison to tapasin ......................................................................................... 151 
7.6. Biological explanation for allelic dependency of HLA class I on TAPBPR-mediated 
peptide editing ............................................................................................................... 152 
7.6.1. Preference of TAPBPR for HLA-A2 and -A24 supertypes ...................................... 152 
7.6.2. Impact of TAPBPR in susceptibility to HLA-associated diseases ........................... 153 
7.7. Potential role of TAPBPR in the MHC class I pathway ................................................... 155 
7.7.1.  Function of TAPBPR inside the ER ........................................................................ 155 
7.7.2.  Function of TAPBPR outside the ER...................................................................... 155 
7.8. Potential therapeutic application of TAPBPR against cancer ........................................ 157 
8. References  ........................................................................................................................... 159 
 
  
List of Figures 
 
Figure 1: Structure of the MHC class I molecule  ............................................................................ 5 
Figure 2: Classical MHC class I antigen processing and presentation pathway  ............................ 8 
Figure 3: Proposed model of TAPBPR function in the MHC class I antigen presentation pathway 
....................................................................................................................................................... 24 
Figure 4: MHC class II presentation pathway  .............................................................................. 26 
Figure 5: Over-expressed TAPBPR is trafficked to the cell surface and down-regulates MHC class 
I surface expression  ..................................................................................................................... 43 
Figure 6: Progressive internalization of peptides into cells at 37°C  ............................................ 45 
Figure 7: Over-expressed TAPBPR facilitates peptide binding onto cell surface MHC class I 
molecules rapidly and at low peptide concentrations  ................................................................ 47 
Figure 8: Over-expressed TAPBPR promotes rapid peptide loading onto cell surface MHC class I 
molecules at 4°C  ........................................................................................................................... 48 
Figure 9: Over-expressed TAPBPR does not mediate loading of low-affinity peptides onto cell 
surface MHC class I molecules  ..................................................................................................... 49 
Figure 10: TAPBPR present at the cell surface enhances exogenous peptide association onto 
surface expressed MHC class I molecules  .................................................................................... 50 
Figure 11: Surface-expressed TAPBPR interacts with MHC class I molecules at the cell surface.52 
Figure 12: Over-expressed tapasin present at the cell surface does not mediate efficient peptide 
loading onto surface expressed MHC class I molecules  .............................................................. 53 
Figure 13: TAPBPR present at the cell surface actively mediates peptide exchange on surface-
expressed MHC class I molecules  ................................................................................................ 55 
Figure 14: Peptide loading by over-expressed TAPBPR with varying peptide exposure .............. 57 
Figure 15: Cell surface TAPBPR mediates peptide exchange on surface-expressed MHC class I 
molecules even at 4° ..................................................................................................................... 58 
Figure 16: Soluble TAPBPR associates with MHC class I molecules present at the cell surface.  60 
Figure 17: Soluble TAPBPR added exogenously enhances exogenous peptide association onto 
surface-expressed MHC class I molecules  ................................................................................... 62 
Figure 18: Soluble TAPBPR dissociates from surface-expressed MHC class I molecules upon 
binding of high-affinity peptides  .................................................................................................. 64 
Figure 19: Soluble TAPBPR facilitates efficient peptide loading onto surface-expressed HLA-
A*02:01 molecules, in an affinity-based manner  ........................................................................ 66 
Figure 20: Predicted interaction of the TAPBPR loop with the peptide binding groove of MHC 
class I  ............................................................................................................................................ 69 
Figure 21: The loop of TAPBPR was poorly modelled in the crystal structure of TAPBPR:MHC 
class I complex  .............................................................................................................................. 70 
Figure 22: Mutation of the loop does not alter expression levels of TAPBPR, nor its ability to 
interact with MHC class I and UGT1 .............................................................................................. 72 
Figure 23: The K22-D35 loop of TAPBPR is essential for mediating peptide dissociation  ........... 74 
Figure 24: The soluble versions of the TAPBPR loop variants show equivalent thermostability to 
TAPBPRWT  ..................................................................................................................................... 76 
Figure 25: Soluble TAPBPR loop mutants exhibit severe impairment in their ability to mediate 
peptide exchange on surface-expressed HLA-A*68:02 molecules  .............................................. 78 
Figure 26: Residues K22-D35 are essential for the ability of soluble TAPBPR to associate with 
peptide-loaded MHC class I molecules  ........................................................................................ 81 
Figure 27: Peptide priming to cell surface MHC class I inhibits the binding of TAPBPR with a 
mutated loop  ................................................................................................................................ 82 
Figure 28: Mutation of the TAPBPR loop alters the peptide repertoire presented on MHC class I 
in cells  ........................................................................................................................................... 85 
Figure 29: Technical reproducibility of the immunopeptidome analysis by LC-MS/MS  ............. 86 
Figure 30: TAPBPR edits peptides in a loop-dependent manner only on MHC class I molecules 
with F pocket specificities for hydrophobic peptide residues  ..................................................... 89 
Figure 31: Soluble TAPBPR-mediated peptide loading onto HLA-A*02:01 molecules  ................ 90 
Figure 32: Swapping residue 116 between HLA-A*68:01 and HLA-A*68:02 does not impair their 
surface expression  ........................................................................................................................ 93 
Figure 33: Mutation of the MHC class I F pocket significantly alters TAPBPR binding  ................ 94 
Figure 34: Residue 116 of MHC class I is crucial for the peptide editing ability of TAPBPR  ........ 96 
Figure 35: HLA-A molecules exhibit stronger interactions to TAPBPR compared to HLA-B and -C 
molecules  ................................................................................................................................... 100 
Figure 36: TAPBPR binding to HLA-B and -C molecules on the single HLA beads  ..................... 101 
Figure 37: Among HLA-A molecules, TAPBPR shows clear binding preference for members of 
the A2 and A24 superfamilies  .................................................................................................... 104 
Figure 38: Different HLA class I allotypes show stable and similar surface expression levels  .. 105 
Figure 39: HLA class I allotypes show a similar TAPBPR binding hierarchy in a cellular system as 
the one observed with the SABs  ................................................................................................ 106 
Figure 40: Intracellular species of HLA class I molecules reveal broader reactivity to TAPBPR, 
while confirming the TAPBPR binding hierarchy  ....................................................................... 108 
Figure 41: HLA class I molecules show a similar tapasin binding hierarchy as the one observed 
for TAPBPR  ................................................................................................................................. 109 
Figure 42: Schematic representation of the peptide exchange assay used to determine TAPBPR-
mediated peptide exchange across a panel of HLA class I allotypes  ......................................... 111 
Figure 43: Peptide exchange exerted by TAPBPR is proportional to its ability to bind HLA class I 
..................................................................................................................................................... 112 
Figure 44: Fluorescent peptides do not bind non-specifically to the surface of cells  ............... 113 
Figure 45: Dose-dependent peptide loading by soluble TAPBPR onto surface-expressed HLA 
class I molecules  ......................................................................................................................... 114 
Figure 46: Stability of HLA class I molecules at the cell surface does not correlate with their 
relative susceptibility to TAPBPR-mediated peptide editing  ..................................................... 116 
Figure 47: H114/Y116 residues are conserved exclusively across all HLA class I members of the 
A2 and A24 supertypes  .............................................................................................................. 118 
Figure 48: Designing F pocket mutants of HLA-A, -B and -C molecules and assessing their surface 
expression levels  ........................................................................................................................ 119 
Figure 49: The H114/Y116 residue combination promotes the interaction of HLA-A, -B and -C 
molecules to TAPBPR  ................................................................................................................. 120 
Figure 50: Mutating the F pocket impairs HLA class I binding to TAPBPR  ................................. 121 
Figure 51: Mutating the F pocket of HLA class I molecules does not necessarily alter their 
stability at the cell surface  ......................................................................................................... 122 
Figure 52: Residues H114 and Y116 promote the susceptibility of MHC class I molecules to 
peptide editing by TAPBPR  ......................................................................................................... 124 
Figure 53: Wild type HLA-B molecules that differ in residue 116 alone are similarly expressed at 
the cell surface  ........................................................................................................................... 125 
Figure 54: Natural differences in residue 116 across HLA-B allotypes do not significantly 
influence interaction with TAPBPR  ............................................................................................ 126 
Figure 55: Naturally-occurring differences in residue 116 alone across disease-associated HLA-B 
allotypes influence their susceptibility to peptide editing by TAPBPR  ...................................... 127 
Figure 56: Design of HLA-A*68:02 and HLA-A*02:01 chimeric mutants, by targeting residues 
M12 and P105 ............................................................................................................................. 128 
Figure 57: Residue M12 of HLA-A*68:02, promotes its high accessibility to TAPBPR  ............... 129 
Figure 58: M12 residue of HLA-A*68:02 does not seem to contribute to the direct interaction 
with TAPBPR  ............................................................................................................................... 131 
Figure 59: Soluble TAPBPR mediates loading of immunogenic peptides onto MHC class I 
molecules on the surface of tumour cell lines  ........................................................................... 134 
Figure 60: Antigenic peptides loaded onto tumour cells by soluble TAPBPR are available for TCR 
recognition  ................................................................................................................................. 135 
Figure 61: TAPBPR induces T cell recognition of tumour cells at low peptide concentrations  . 137 
Figure 62: TAPBPR-mediated antigenic peptide binding to tumour cells induces their 
recognition by T cells  .................................................................................................................. 138 
Figure 63: Soluble TAPBPR-mediated peptide loading enhances T cell killing of tumour cells  . 141 
Figure 64: Proposed model of the peptide exchange mechanism on MHC class I molecules, 
catalyzed by TAPBPR  .................................................................................................................. 148 
Figure 65: Varying susceptibility of classical HLA class I molecules to peptide editing by TAPBPR 
and its correlation with differences in immune responses  ....................................................... 154 
Figure 66: Similarities between the role of HLA-DM in the MHC class II pathway and the 
potential involvement of TAPBPR in the vacuolar pathway of cross-presentation ................... 157 
List of Tables 
 
Table 1: Panel of primers used to generate the TAPBPR chimeric constructs  ............................ 28 
Table 2: Panel of primers used to generate the TAPBPR loop mutants  ...................................... 29 
Table 3: Panel of HLA class I mutants  .......................................................................................... 30 
Table 4: Fluorescently-labelled MHC class I-binding peptides used in this study  ....................... 33 
Table 5: Panel of TAPBPR loop mutants generated on both full-length and soluble TAPBPR  .... 71 
Table 6: Binding of TAPBPR variants to each HLA class I allotype found in HeLaM cells  ............ 87 
Table 7: MHC class I levels on single antigen HLA beads detected using W6/32 ....................... 102 






ABC ATP-binding cassette 
AIDS Acquired immune deficiency syndrome 
APC Professional antigen presenting cell 
β2m Beta-2-microglobulin 
BSA Bovine serum albumine 
CD Cluster of differentiation 
CLIP Class II-associated invariant chain peptide 
cryo-EM Cryogenic electron microscopy  
CTL Cytotoxic T lymphocyte 
DC Dendritic cell 
DMSO Dimethyl sulfoxide 
EBV Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
ERAD Endoplasmic reticulum-associated protein degradation 
ERAP Endoplasmic reticulum aminopeptidase  
ERAAP Endoplasmic reticulum aminopeptidases associated with antigen processing 
ERp57 Endoplasmic reticulum protein 57 
FACS Fluorescence-activated cell sorting 
FCS Foetal calf serum 
GFP Green fluorescent protein 
HCMV Human cytomegalovirus 
HCV Hepatitis C virus 
HEK Human embryonic kidney 
HIV Human immunodeficiency virus  
HLA Human leukocyte antigen  
HRP Horseradish peroxidase 
IFN Interferon 
Ig Immunoglobulin 
Ii Invariant chain 
kDa Kilodalton 
KIR Killer cell immunoglobulin-like receptor 
LILR Leukocyte immunoglobulin-like receptors 
LMP Low molecular mass poylpeptides 
mAb Monoclonal antibody 
MACS Magnetic-activated cell sorting 
Mbps Megabase pairs 
MECL-1 Multicatalytic endopeptidase complex-like 1 
MHC Major histocompatibility complex 
MIIC MHC class II compartment 
NEM N-ethylmaleimide 
Ni-NTA Nickel-nitrilotriacetic acid 
NK Natural killer 
NMR Nuclear magnetic resonance 
PAGE Polyacrylamide gel electrophoresis 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin  
PLC Peptide loading complex 
pMHC Peptide-MHC complex 
PMSF phenylmethylsulfonyl fluoride 
SDS Sodium dodecyl sulfate  
TAMRA 5-carboxytetramethylrhodamine 
TAP Transporter associated with antigen processing 
TAPBP TAP-binding protein 
TAPBPR TAPBP-related 
TBS Tris-buffered saline 
TCR T cell receptor 
TNF-α Tumour necrosis factor α 
UGT1 UDP-glucose:glycoprotein glucosyltransferase 1 






1.1. Role of MHC molecules in the immune system 
 
1.1.1.  Antigen presentation 
The process of antigen presentation is crucial for T cell-mediated immune recognition of both 
extracellular and intracellular pathogens, as well as other cellular abnormalities. Antigen 
presentation is the process by which cells display small fragments of the cellular proteome at 
their surface, for inspection by T cells. The peptides presented at the cell surface are loaded 
onto major histocompatibility (MHC) molecules. By sampling the peptide pool presented on 
MHC molecules, T cells will recognise peptides derived from foreign or abnormal proteins and 
target these cells for destruction. Thus, the process of antigen presentation enables T cell 
immunosurveillance of infections and cancer and thus lies at the core of adaptive immunity.  
T cell receptors (TCRs), expressed on the surface of T cells, can recognize peptides presented on 
two different classes of MHC molecules, class I and class II (Katz et al., 1973a, Katz et al., 1973b, 
Rosenthal and Shevach, 1973, Shevach and Rosenthal, 1973, Zinkernagel and Doherty, 1974). 
MHC class I molecules are present in all nucleated cells in the body and present peptides to T 
cells that express the co-receptor CD8 (CD8+ T cells) (Swain, 1983, Emmrich et al., 1986, Gao et 
al., 1997). CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), are effector T cells that 
kill target cells upon recognition of foreign peptides bound to MHC class I molecules. MHC class 
I molecules present peptides mainly derived from intracellular sources and thus confer 
protection against intracellular pathogens, such as viruses, or against tumour development. In 
contrast, MHC class II molecules are only expressed in professional antigen presenting cells 
(APCs) and present peptides to T cells expressing the surface co-receptor CD4 (CD4+ T cells) 
(Janeway et al., 1988, Swain, 1983). CD4+ T cells are referred to as “helper” T cells, as they 
modulate the activation of other immune cells, such as B cells or macrophages. The peptides 
presented on MHC class II molecules are derived mainly from extracellular sources. Thus, MHC 
class II molecules protect against either extracellular or intravesicular pathogens, such as 





1.1.2.  Function in innate immunity 
In addition to their role in presenting antigenic peptides to T cells for the generation of 
adaptive immune responses, MHC class I molecules play a key role in the immunosurveillance 
mechanisms of natural killer (NK) cells. Killer cell immunoglobulin-like receptors (KIRs), found 
on the surface of NK cells, detect expression levels of MHC class I at the cell surface. In case a 
cell downregulates its MHC class I expression, for instance due to viral infection or 
tumorigenesis, it will fail to send inhibitory signals to the NK cells via KIR-mediated recognition 
and will hence be susceptible to killing by NK cells (Karre et al., 1986, Ljunggren and Karre, 
1990). Although the majority of KIRs serve inhibitory functions, there are a few KIRs that 
transmit activating signals upon recognition of specific MHC class I targets (Moretta et al., 1995, 
Stewart et al., 2005). Apart from KIRs, MHC class I molecules are also recognized by leukocyte 
immunoglobulin-like receptors (LILRs), found predominantly on the surface of myeloid lineages 
(Colonna et al., 1997, Cosman et al., 1997, Cella et al., 1997). LILRs expressed on professional 
APCs such as macrophages or dendritic cells (DCs) modulate cytokine release and expression of 
costimulatory molecules, thus influencing the signalling of these cells to the adaptive immune 
system. In contrast to the interactions of MHC class I molecules with T cell receptors (TCRs), 
which occur strictly in a peptide-dependent manner, the recognition of MHC class I by KIRs and 
LILRs are considerably less sensitive to the bound peptides (Natarajan et al., 2002).  
 
1.2. MHC in health and disease 
As its name suggests, the MHC was historically discovered in the field of transplantation. More 
than a century ago, the existence of a genetic basis of compatibility in tissue transplants was 
first proven by Little and Tizzier (Little and Tyzzer, 1916). Upon performing tumour 
transplantations in mice, they discovered that hybrid mice from two inbred strains allowed for 
the growth of tumour transplanted from either parental strain donor, however tumours 
transplanted between two unrelated mouse strains were rejected. Later, Gorer demonstrated 
that the observed transplant rejection was a result of an immune reaction from the donor 
(Gorer and Schutze, 1938). Following allogeneic and xenogeneic transplantations in rabbits, 
formation of antibodies specific for the donor tissues was observed in the serum of the 
recipient (Gorer and Schutze, 1938). Gorer attributed histocompatibility to a set of antigenic 




“strong H” locus and currently known as the H-2 locus (Snell, 1948), which is the equivalent of 
the MHC locus in mice. Intense efforts towards unravelling the genetic and immunological 
complexity of the MHC were made in the following decades, until Zinkernagel and Doherty 
demonstrated that T cells induced by viral infection recognize infected cells in an antigen-
specific, MHC-restricted manner (Zinkernagel and Doherty, 1974). It was later understood that 
in addition to their roles in viral infections and transplantation, MHC are crucial for conferring 
protection against other pathogens (e.g. bacteria or parasites), as well as cancer, and are 
generally responsible for the induction of autoimmune reactions (Bodmer, 1987, Trowsdale and 
Knight, 2013). 
Pathogens are considered to be the main drive for the extraordinary polymorphism in the MHC 
genes (Zinkernagel and Doherty, 1979, Lederberg, 1999). Studies in chickens, which, in contrast 
to mammals, possess only one dominantly expressed MHC class I allele, “the minimal essential” 
(Kaufman et al., 1999, Kaufman et al., 1995), have revealed a striking correlation between the 
dominant MHC class I allele expressed and their susceptibility to either Rous sarcoma virus and 
Marek’s disease virus (Kaufman and Wallny, 1996). The explanation for the observed 
association of a particular MHC allele with disease outcome was based on the distinct peptide 
repertoire presented on each MHC class I molecule, enabling highly allele-specific T cell 
responses.  
In humans, polymorphism in MHC molecules has been mainly associated with different 
progression levels of viral diseases, such as acquired immune deficiency syndrome (AIDS), and 
susceptibility to autoinflammatory conditions (ankylosing spondylitis, rheumatoid arthritis, type 
1 diabetes, systemic lupus erythematosus), drug hypersensitivity (e.g. abacavir) and cancer 
(Illing et al., 2012, Trowsdale and Knight, 2013, Naranbhai and Carrington, 2017). However, 
given that humans express a multigene family of MHC class I and class II molecules and are thus 
more capable of controlling pathogens, the majority of human MHC-associated diseases are 
autoimmune (Trowsdale and Knight, 2013).  
 
 
1.3. The MHC region 
Located on chromosome 6, the human MHC region, also known as the human leukocyte 




involved in immune response generation (Campbell and Trowsdale, 1993, Forbes and 
Trowsdale, 1999). The MHC gene family is divided into three subgroups, based on their 
distribution along the chromosome: class I, class II and class III. The class I region encodes the 
heavy chains of three classical HLA class I genes (HLA-Ia), namely HLA-A, -B and -C, and three 
non-classical HLA class I genes (HLA-Ib), namely HLA-E, -F and -G. The class II region includes the 
α- and β- chains of each of the three HLA class II molecules, HLA-DR, -DQ and DP, as well as 
various components of the cellular machinery responsible for the processing and loading of HLA 
class I molecules with peptide fragments. Finally, the class III region, which sits in between the 
class I and class II regions, does not contain any elements of the antigen presentation pathway, 
comprising mostly genes encoding for cytokines and elements of the complement system 
(Campbell and Trowsdale, 1993, Forbes and Trowsdale, 1999).  
 
1.4. The structure of MHC class I molecules  
MHC class I molecules consist of a transmembrane heavy α chain, which is highly polymorphic, 
and a non-covalently attached, conserved soluble light chain, beta-2-microglobulin (β2m) 
(Figure 1a) (Bjorkman et al., 1987). The α chain has a molecular weight of 45 kDa and consists 
of three domains: α1, α2 and α3. The α1 and α2 domains form the peptide binding groove, a 
membrane-distal superdomain which includes two antiparallel α helices on top of 8 β strands. 
The α3 is an immunoglobulin-like domain, which, together with β2m, forms the membrane-
proximal region of MHC class I molecules (Bjorkman et al., 1987). The peptide binding groove of 
MHC class I molecules is restrictive with respect to the peptide length, which is typically 
between 8 and 11 amino acids (Figure 1b) (Fremont et al., 1992, Madden et al., 1991). Specific 
amino acids of the groove typically compose six binding pockets (A-F) (Figure 1c) (Garrett et al., 
1989), which accommodate the corresponding side chains of the bound peptide, known as 
anchor residues. Therefore, the peptide specificity of a particular MHC class I molecule, also 
known as its peptide binding motif, is determined by the shape, depth and charge of its peptide 
binding groove and of its individual binding pockets. The affinity of a peptide for a particular 
MHC class I molecule is partly determined by the interactions between the anchor residues of 
the peptide and the pockets of the MHC class I groove (Falk et al., 1991, Madden et al., 1991, 
Matsumura et al., 1992, Guo et al., 1992). In addition, peptide affinity is also determined by the 




the groove (Madden et al., 1992). Consequently, both the shape/sequence and the length of 
the peptide are crucial for its ability to stably bind to an MHC class I molecule.   
In addition to determining the peptide’s ability to get stably anchored into the MHC class I 
binding groove, the sequence of the peptide is also crucial for the recognition of peptide-MHC 
(pMHC) class I complexes by the TCR (Madden et al., 1992, Zhang et al., 1992). Since each TCR 
recognizes a distinct pMHC conformation, both the overall shape of the peptide as well as its 
impact on the overall conformation of the class I binding groove is critical for the interaction 
with the TCR. Specifically, the peptide residues that generally play the highest impact on TCR 
recognition are either the anchor residues, usually found at positions 2 and 9 of the peptide, 
that drive the affinity of the peptide for MHC class I, or, typically the ones on positions 4-6, via 
their direct interactions with the TCR.    
 
Figure 1: Structure of the MHC class I molecule. Pymol image of the crystal structure of HLA-B27 
(PDB ID 1HSA) shown as (a) a side view of the entire MHC class I HC-β2m-peptide complex or (b) as a 
top view of the peptide binding groove. In b) highly polymorphic amino acid residues across different 
alleles are highlighted in yellow. (c) Representation of the specificity pockets A-F within the peptide 







1.5. Polymorphisms in MHC class I molecules and relevance in immune responses 
The MHC class I locus contains the most polymorphic genes in humans, comprising over 10,000 
alleles. The vast majority of polymorphisms found in HLA class I molecules, reside at the sites of 
the peptide binding groove that determine the peptide specificity of individual HLA class I 
molecules (Figure 1b). Consequently, although many different HLA class I allotypes are 
structurally similar, each individual allotype can bind and present a distinct set of peptides, thus 
eliciting highly specific CD8+ T cell responses. The peptide repertoire presented by a particular 
HLA class I molecule profoundly influences the susceptibility of an individual to infectious 
diseases or autoinflammatory conditions. For instance, specific pairs of HLA class I allotypes 
that differ in only one amino acid respectively, such as HLA-B*57:03 and HLA-B*57:02, HLA-
B*35:01 and -B*35:03 or HLA-B*42:01 and -B*42:02, are associated with significantly different 
progression rates of the human immunodeficiency virus (HIV), mainly via their different peptide 
sets presented for immune recognition (Gao et al., 2001, Kloverpris et al., 2012a, Kloverpris et 
al., 2012b). Similarly, single amino acid differences across different HLA class I pairs, at 
positions key for determining peptide specificity, have also been shown to strongly influence 
predisposition to specific autoinflammatory diseases. For instance, ankylosing spondylitis is 
associated with the presence of HLA-B*27:05, but not HLA-B*27:06 or B*27:09 (Fiorillo et al., 
1998), while birdshot chorioretinopathy shows a strong association with HLA-A*29:02, but not 
with HLA-A*29:01 (LeHoang et al., 1992).    
 
1.6. The canonical MHC class I antigen processing and presentation pathway  
 
1.6.1. Generation of antigenic peptides 
Antigenic peptides that bind in the peptide binding groove of MHC class I molecules are 
generated in the cytosol, as a result of proteasomal degradation (Figure 2). It is currently 
understood that these peptides originate from the turnover of self-proteins, defective 
ribosomal products and proteins of foreign origin, such as viral or from other intracellular 
parasites (Eisenlohr et al., 2007, Yewdell et al., 1996, Rock et al., 2014, Rock and Goldberg, 




appropriate length for translocation into the endoplasmic reticulum (ER) lumen. Upon exposure 
to inflammatory stimuli, such as IFNs or TNF-α, three constitutively expressed subunits of the 
proteasome are replaced by two specialized subunits encoded in the MHC region, namely the 
low molecular mass poylpeptides (LMP) 2 and 7 (Brown et al., 1991, Glynne et al., 1991, Kelly et 
al., 1991a, Ortiz-Navarrete et al., 1991), and by the multicatalytic endopeptidase complex-like 1 
MECL-1, which is not encoded in the MHC region (Groettrup et al., 1996, Nandi et al., 1996). 
This version of the proteasome is known as the immunoproteasome. The immunoproteasome 
displays a different cleavage profile compared to the constitutive proteasome, showing 
enhanced cleavage after hydrophobic amino acid residues (Driscoll et al., 1993, Gaczynska et 
al., 1994). Thus, the immunoproteasome is more efficient at degrading proteins of foreign 
origin (i.e. viral proteins) and at generating antigenic peptides. It is thus highly abundant in 
antigen presenting cells and plays a vital role during infection.  
 
1.6.2. Transport of peptides into the ER 
Following proteasomal degradation, peptides of appropriate length and sequence are 
transported from the cytoplasm into the ER lumen by the transporter associated with antigen 
processing (TAP) protein complex (Deverson et al., 1990, Spies et al., 1990, Trowsdale et al., 
1990). The TAP belongs to the ATP-binding cassette (ABC) transporter family and consists of 
two subunits, TAP1 and TAP2, encoded in the MHC region. TAP1 and TAP2 generally form 
heterodimers that are imbedded in the ER membrane.  
 It has been shown that in TAP1-deficient cells, the surface expression of MHC class I molecules 
is drastically reduced and that the rate of degradation of MHC class I molecules is enhanced 
(Salter and Cresswell, 1986, Spies et al., 1992, Spies and DeMars, 1991). Moreover, TAP1-/- mice 
are deficient of peripheral CD8+ T cells specifically, due to the severely impaired MHC class I 








Figure 2: Classical MHC class I antigen processing and presentation pathway, adapted from Blum et 
al. (Blum et al., 2013). Following their import into the ER lumen, nascent MHC class I heavy chain 
acquire N-linked glycan, which are subsequently trimmed to a single glucose residue (G) by 
glucosidases 1 and 2 (Gls I/GLS II). Calnexin (CNX) binds to the N-linked glucose residue of the MHC 
class I heavy chain and modulates its folding and subsequent assembly with β2m. Once assembled, 
the peptide-receptive MHC class I heterodimers associate with the PLC, composed of calreticulin 
(CRT), ERp57, TAP and tapasin, which ensures their proximity to the influx of peptide into the ER and 
loading with high-affinity peptides. MHC class I molecules loaded with high-affinity peptides are 
exported from the ER and trafficked to the cell surface. Sub-optimally loaded MHC class I molecules 
are recruited by UGT1, which reglucosylates them and recycles them to the PLC for a subsequent 
round of peptide editing. Peptides are generated from the proteasomal degradation of either DRiPs 
or native protein that are generated by the translation of mRNA of either self or foreign (e.g. viral) 
origin. These peptides are translocated into the ER by TAP and further trimmed by ER 






1.6.3. Peptide trimming in the ER 
Once translocated in the ER lumen, peptides undergo further processing by the endoplasmic 
reticulum aminopeptidases associated with antigen processing (ERAP1/2 in humans and ERAAP 
in mice) (Saric et al., 2002, Serwold et al., 2002) (Figure 2). ERAP1, either free or in complex 
with ERAP2 (ERAP1/2), was proposed to trim precursor peptides from their N-terminus to their 
correct length, allowing them to efficiently bind into the MHC class I peptide binding groove. 
Although some studies have proposed that ERAP works in synergy with the MHC class I 
molecule in trimming peptides to the correct length for binding, the crystal structures of both 
ERAP1 and ERAP2 suggest that these enzymes are more suited for processing free peptides 
rather than MHC class I-associated peptides (Nguyen et al., 2011). Based on these findings, it 
has been suggested that ERAP uses an “intrinsic ruler” to trim peptides to the proper length, 
point at which the peptides dissociate from ERAP and are ready for loading onto MHC class I 
molecules (Chang et al., 2005, Nguyen et al., 2011). Regarding the role of ERAP in the 
generation of immune responses, previous work has shown that in the absence of ERAP1 in 
mice, the CD8+ T cell-mediated immune responses to certain viral epitopes, of either vaccinia or 
lymphocytic choriomeningitis virus (LCMV) origin, are enhanced, however to others these 
responses are either reduced or unchanged (York et al., 2006). Thus, ERAP1 has only been 
shown to play a critical role in the hierarchy of immunodominance in viral infections, however 
it has not been proven so far to significantly affect the overall ability of the immune responses 
to combat viral infections. ERAAP however was demonstrated to confer protection against non-
viral infections, such as Toxoplasma gondii. ERAAP-/- mice were no longer able to present an 
immunodominant and protective epitope derived from Toxoplasma gondii and thus enabled 
the uncontrolled replication of the pathogen (Blanchard et al., 2008). Interestingly, apart from 
its role in infections, multiple studies have also proven the importance of ERAP1 in certain 
autoimmune diseases in humans, associated with specific MHC class I alleles (Evans et al., 2011, 
Pazar et al., 2010, Wellcome Trust Case Control et al., 2007). Namely, specific alleles of the 
highly polymorphic ERAP1, with increased catalytic activity, showed a high-association rate to 
ankylosing spondylitis in HLA-B27-positive patients (Evans et al., 2011, Pazar et al., 2010). 
Moreover, ERAP1 was revealed to influence psoriasis susceptibility across individuals carrying 
HLA-C*06:02 (Genetic Analysis of Psoriasis et al., 2010, Sun et al., 2010). These studies together 
highlight the extreme consequences of aberrant peptide trimming on MHC class I antigen 




1.6.4. Early folding and assembly of MHC class I dimers 
Upon translocation in the ER lumen, the MHC class I heavy chain undergoes N-linked 
glycoslylation at residue Asn-86 (Bjorkman et al., 1987, Parham et al., 1977). The glycosylated 
heavy chain then recruits the lectin chaperone calnexin, which facilitates its correct folding. 
Calnexin is a transmembrane protein and together with its soluble homologue, calreticulin, is 
involved in the chaperoning and quality control of glycoproteins in the ER (Hammond et al., 
1994, Hebert et al., 1995, Peterson et al., 1995). Calnexin also recruits ER protein 57 (ERp57), 
an ER-resident protein disulphide isomerase (PDI), which ensures the proper disulphide bond 
formation in the α3 domain of the MHC class I heavy chain, further stabilising the molecule 
(Zhang et al., 2006). The calnexin-ERp57 complex protects the folded MHC class I heavy chain 
from degradation and subsequently enables its association with the soluble subunit β2m 
(Vassilakos et al., 1996). Assembly of the MHC class I heavy chain with β2m was shown to be 
significantly reduced in the absence of calnexin (Vassilakos et al., 1996). A more recent study 
demonstrated the importance of the N-linked glycosylation for the chaperone-mediated folding 
and assembly of the MHC class I heavy chain-β2m dimer, as mutation of the N-linked 
glycosylation site on the MHC class I heavy chain (N86Q) abolished chaperone binding and 
hence severely impaired the dimer formation (Rizvi et al., 2011). Following assembly, the 
resulting highly unstable peptide-receptive MHC class I heterodimer recruits the peptide 
loading complex.  
  
1.6.5. The peptide loading complex 
As its name implies, the peptide loading complex (PLC) is responsible for the loading of empty 
MHC class I molecules with optimal peptides prior to their export from the ER (Figure 2). The 
PLC consists of the TAP transporter, the lectin chaperone calreticulin, ERp57 and tapasin. 
Within the PLC, calreticulin is associated to the monoglucosylated glycan of MHC class I 
molecules, tapasin is bound to the MHC class I heavy chain (Sadasivan et al., 1996, Ortmann et 
al., 1997), while ERp57 associates to both tapasin and calreticulin, acting as a bridge between 
the two chaperones (Frickel et al., 2002). TAP is linked to the MHC class I molecule by tapasin 
(Ortmann et al., 1997, Sadasivan et al., 1996). In contrast to calnexin, which was associated 
with early folding events of MHC class I molecules, calreticulin was suggested to participate in 




critical role of calreticulin in the peptide loading of MHC class I molecules rather than in the 
early assembly of MHC class I and β2m (Gao et al., 2002).  
Regarding the sequence of events leading to the assembly of the PLC, the current view is that   
calreticulin associates first to the MHC class I heavy chain, as it replaces calnexin following the 
association of β2m onto the heavy chain (Gao et al., 2002, Chapman and Williams, 2010, Hulpke 
and Tampe, 2013). Subsequently, the MHC class I-calreticulin complex recruits the 
preassembled ERp57-tapasin-TAP complex (Ortmann et al., 1997, Sadasivan et al., 1996, Hulpke 
and Tampe, 2013). The recently identified structure of the PLC, achieved using cryo-EM, 
enabled the direct visualisation of the different stages of PLC assembly onto MHC class I 
molecules (Blees et al., 2017). This study confirmed the previously proposed model of assembly 
of the PLC components onto peptide-receptive MHC class I molecules. 
Upon acquiring high-affinity peptides, MHC class I molecules are released from the PLC 
(Spiliotis et al., 2000, Chapman and Williams, 2010) and are then subjected to further quality 
control checkpoints in the pathway. One such checkpoint is represented by the UDP-
glycoprotein glucosyltransferase 1 (UGT1), which is responsible for reglucosylating MHC class I 
molecules loaded with sub-optimal peptides and for their subsequent recycling back to the PLC 
(Figure 2), for a subsequent round of peptide loading (Zhang et al., 2011, Wearsch et al., 2011). 
Despite UGT1 fulfilling a general role in the quality control machinery of glycoproteins (Sousa et 
al., 1992, Trombetta et al., 1989), this enzyme has been demonstrated to play a function role in 
the selection of optimally-loaded MHC class I molecules for export to the cell surface (Zhang et 
al., 2011, Wearsch et al., 2011).   
 
1.7. Function of tapasin on MHC class I molecules 
The TAP-binding protein (TAPBP), also known as tapasin, was the first-discovered molecular 
chaperone strictly dedicated to the MHC class I antigen presentation pathway. The gene 
encoding for tapasin is located in the MHC locus, more specifically within the MHC class II 
region, similarly to TAP1/2 and two of the immunoproteasome subunits. Tapasin plays a crucial 
role in the optimal loading of MHC class I molecules with high-affinity peptides and 
consequently on their efficient expression at the cell surface. Therefore, tapasin is crucial for 
the generation of optimal CD8+ T cell-mediated immune responses. Tapasin fulfils several 




1.7.1. Assembly of the PLC and binding to MHC class I 
The entire assembly of the PLC revolves around the presence of tapasin and its ability to 
interact with MHC class I molecules (Figure 2). Tapasin is a type I transmembrane glycoprotein 
that forms a direct interaction with each of the other components of the peptide loading 
complex, as well as with MHC class I (Frickel et al., 2002, Gao et al., 2002, Ortmann et al., 1997, 
Sadasivan et al., 1996, Blees et al., 2017), bringing all these molecules together for the loading 
process. Despite the ability of tapasin to form a direct interaction with the MHC class I heavy 
chain, it requires the presence of the entire PLC in order to stably associate with MHC class I 
molecules. Moreover, once tapasin can no longer access the MHC class I molecule, upon 
loading it with a high-affinity peptide, the entire PLC disassembles (Spiliotis et al., 2000).  
Despite the lack of a high-resolution structure of tapasin in complex with MHC class I, the 
interaction sites between the two proteins has been heavily investigated. On the MHC class I 
side, the affinity for tapasin has been attributed to the amino acid residues on positions 222-
229, found in the α3 domain (Suh et al., 1999, Yu et al., 1999). Upon mutation of these 
residues, MHC class I loses its ability to interact with tapasin and subsequently with TAP. 
Interestingly, the same residues of MHC class I were previously shown to be essential for the 
interaction with CD8 (Gao et al., 1997, Salter et al., 1990). In a more recent study, it was 
suggested that the residues 333-335 of the tapasin IgC domain are key for the interaction with 
the 222-229 loop of MHC class I (Turnquist et al., 2001, Turnquist et al., 2002).  
The second interaction site between the two proteins appears to be involving residues 122-134 
of MHC class I, spanning the two beta sheets and the loop connecting them, found underneath 
the α2-1 region (Beissbarth et al., 2000, Lewis et al., 1996, Paquet and Williams, 2002, Peace-
Brewer et al., 1996, Yu et al., 1999). Mutation of specific amino acids in this region has been 
shown to abolish tapasin binding as well as to severely impair surface expression of MHC class I 
molecules. Based on the solved crystal structure of tapasin in complex with ERp57 (Dong et al., 
2009), the 122-134 region of MHC class I has been suggested to interact with set of positively-







1.7.2. Bridging TAP and MHC class I 
Tapasin is able to bind simultaneously to the TAP transporter and to MHC class I, thus physically 
bridging the two main participants in the peptide loading process, namely the source of peptide 
and the peptide acceptor (Sadasivan et al., 1996, Blees et al., 2017). This ensures the proximity 
of the peptide-receptive MHC class I molecules to the site of peptide-influx into the ER lumen, 
providing the availability of a peptide-rich environment during the loading process. Moreover, 
by physically associating with TAP, tapasin was shown to be important for the stabilization and 
function of TAP in the cell. In the absence of tapasin, TAP was shown to undergo increased ER-
associated degradation (ERAD) (Lehner et al., 1998). These findings were further backed up by 
the observation that tapasin transfections into tapasin-deficient 721.220 cells, which are 
defective in MHC class I peptide presentation (Greenwood et al., 1994), rescued surface 
expression of MHC class I molecules, as well as their recognition by CD8+ T cells (Ortmann et al., 
1997, Lehner et al., 1998).   
 
1.7.3. Peptide editing on MHC class I molecules 
 
1.7.3.1. Optimisation of peptide presentation on MHC class I 
In addition to stabilizing peptide-receptive MHC class I molecules to facilitate their loading with 
peptide, tapasin is also responsible for ensuring that only high-affinity peptides bound to MHC 
class I molecules are exported for presentation (Howarth et al., 2004, Purcell et al., 2001, 
Williams et al., 2002). In doing so, tapasin catalyses the process referred to as “peptide 
editing”, actively exchanging sub-optimally loaded peptides of lower affinity for ones of higher 
affinity, until MHC class I molecules acquire optimal peptides. Tapasin-mediated peptide 
editing is thus crucial for the presentation of stably-bound antigens on MHC class I molecules at 
the cell surface and for generating the appropriate immune responses. In tapasin-deficient 
cells, a wide panel of MHC class I molecules suffer a significant decrease in their ability to load 
and present cargo at the cell surface. Moreover, tapasin-deficient mice display a severe 
impairment in the CD8+ T cell and NK cell-mediated immune responses, associated with 
reduced level of MHC class I surface expression and with an altered peptide repertoire towards 





1.7.3.2. Proposed mechanisms of peptide editing 
To enable efficient loading of MHC class I molecules with peptides of high affinity, tapasin is 
thought to catalyse the dissociation of low-affinity peptides loaded onto MHC class I, allowing 
their replacement with peptides of higher affinity. Two assays were developed to directly 
assess the ability of tapasin to edit peptides on MHC class I molecules. First, Chen and Bouvier 
have shown, by tethering recombinant versions of tapasin and MHC class I refolds via a leucine 
zipper, that tapasin directly facilitates dissociation of low-affinity peptides from class I 
molecules (Chen and Bouvier, 2007). Second, Wearsch and Cresswell showed that recombinant 
tapasin-ERp57 conjugates promote peptide binding to MHC class I molecules found 
intracellularly and also edited peptides on these molecules to maximize their affinity (Wearsch 
and Cresswell, 2007).  
In trying to characterize the mechanisms of tapasin-mediated peptide exchange, based on the 
proposed interaction site between tapasin with the α2-1 region of the MHC class I groove 
(Dong et al., 2009), multiple studies speculated that tapasin actively decreases the binding 
energy between the C-terminus of the sub-optimally loaded peptides and the MHC class I 
binding groove (Van Hateren et al., 2010). Moreover, tapasin was proposed to stabilize the 
empty F pocket of the MHC class I binding groove to facilitate a subsequent round of peptide 
loading (Sieker et al., 2007, Zacharias and Springer, 2004). Since tapasin was suggested to bind 
exclusively to peptide-receptive conformations of MHC class I molecules, it is believed that 
tapasin traps the open conformation of MHC class I molecules loaded with low-affinity 
peptides, conformations which are highly unstable and occur transiently during sporadic partial 
dissociation of the peptide (Elliott, 1997, Elliott and Williams, 2005, Yu et al., 1999, Wright et 
al., 2004). In doing so, tapasin shifts the equilibrium between the two conformations of the 
peptide-loaded MHC class I molecule towards the open/receptive state, promoting the 
dissociation of the bound low-affinity peptide and its subsequent exchange by high-affinity 
ones (Praveen et al., 2010, Wright et al., 2004).  
In accordance with these predictions, a more recent study relying on molecular dynamics 
simulation suggested that tapasin mediates peptide dissociation from MHC class I in a “tug-of-
war” manner, by actively pulling the α2-1 helix region of the binding groove away from the 
peptide (Fisette et al., 2016). This in turn would disrupt hydrogen bonds between the peptide 




addition, this model predicted that tapasin additionally stabilizes the F pocket of the class I 
binding groove, facilitating the access of the incoming peptide (Fisette et al., 2016). 
 
1.7.4. Allelic dependence of HLA class I on tapasin 
Despite the suggestive role of tapasin in the optimal loading of MHC class I molecules and 
hence in the expression of stable pMHC class I complexes at the cell surface, previous studies 
have shown that HLA class I molecules exhibit a wide spectrum of dependencies on tapasin for 
optimal surface expression and peptide presentation. In other words, some HLA class I 
allotypes seemed considerably more dependent on tapasin for efficient peptide presentation at 
the cell surface than others (Rizvi et al., 2014, Williams et al., 2002, Wright et al., 2004). These 
studies have addressed tapasin-dependency mainly as a read-out of surface expression levels 
or thermostability of MHC class I molecules, in the presence or absence of tapasin. 
Interestingly, while most HLA class I allotypes show a clear reduction in surface expression 
levels in the absence of tapasin, there are a few, such as HLA-B*44:05, -A*02:01 or -B*27:05, 
that remain largely unaffected (Park et al., 2003, Peh et al., 1998, Rizvi et al., 2014, Williams et 
al., 2002).    
Several studies have suggested that residue 116 in particular, which is highly polymorphic in 
MHC class I molecules, influences tapasin-dependence by affecting the overall plasticity of the 
MHC class I F pocket and hence the availability of open MHC class I conformations, accessible 
to tapasin (Sieker et al., 2007, Wright et al., 2004, van Hateren et al., 2015, Van Hateren et al., 
2010, Garstka et al., 2011). Interestingly however, residue 116 was also suggested to influence 
the specificity of the F pocket for peptide residues (Garrett et al., 1989), however the extent to 
which the MHC class I F pocket specificity influences tapasin-dependency remains largely 
unclear, given the lack of any clear correlation between the two.      
These studies, having mainly assessed tapasin-dependency across HLA-B molecules, have 
concluded that, generally, molecules belonging to the Bw4 group are more dependent on 
tapasin, in terms of efficient folding and peptide loading, as well as regarding their successful 
expression at the cell surface. However, there were multiple exceptions to this trend, with Bw6 
molecules, such as HLA-B*08:01 or HLA-B*15:03, displaying higher tapasin-dependence than 
many Bw4 allotypes (Rizvi et al., 2014). Moreover, Bw4 molecules such as B*44:05 displayed 




molecules belonging to the Bw6 group. Based on this work and the work of other groups 
interrogating allelic-dependence of HLA class I on tapasin (Park et al., 2003), there are currently 
no precise criteria on which tapasin-dependence of HLA class I molecules is based.  
  
1.8. Non-canonical MHC class I antigen presentation pathways 
 
1.8.1. TAP-independent peptide loading of MHC class I molecules 
While the canonical pathway is the main source of pMHC class I complexes expressed at the 
cell surface, the acquisition of antigenic pathways MHC class I molecules is possible via 
alternative pathways, all of which occur independently of TAP-mediated translocation of 
peptides into the ER lumen. This phenomenon was first observed in the human T2 cell line (a T 
cell X B cell line expressing HLA-A2, however lacking both TAP1 and TAP2) (Salter and Cresswell, 
1986, Salter et al., 1985). Despite the low surface expression levels of HLA-A2 in these cells, 
analysis of the immunopeptidome revealed that the most abundant peptides presented on 
HLA-A2 were derived from the signal sequences of both membrane and secreted proteins, 
sequences required for the translocation of these proteins into the ER lumen and which are 
then cleaved by the signal peptidase (Henderson et al., 1992, Wei and Cresswell, 1992). It was 
later shown that such peptides derived from protein signal sequences bound to HLA-A2 in T2 
cells can even induce CD8+ T cell-mediated recognition (Henderson et al., 1993). Moreover, 
presentation of signal sequence-derived peptides was also discovered in TAP-expressing cells, 
however, naturally, at much lower abundance (Huczko et al., 1993). The presentation of these 
peptides however was restricted to HLA class I molecules that typically accommodate 
hydrophobic amino acid residues present at the C-terminus of the peptide, such as HLA-A2 and 
HLA-B7, given the preferred cleavage site of the signal peptidase (Huczko et al., 1993, Wei and 
Cresswell, 1992).  
The importance of these alternative antigen presentation pathways has also been highlighted 
in vivo, as patients with the TAP-deficiency syndrome (Gadola et al., 2000), characterised by 
mutations in TAP1 or TAP2 (de la Salle et al., 2002), displayed CD8+ T cell-mediated immune 
responses against Epstein-Barr virus (EBV) infection (de la Salle et al., 2002, Lautscham et al., 




loaded onto MHC class I molecules independently of TAP. Strikingly, these TAP-deficient 
patients appear to control such viral infections rather efficiently.  
Having highlighted the importance of TAP-independent pathways in the generation of immune 
responses against intracellular pathogens, the exact mechanisms by which MHC class I 
molecules acquire peptides without the involvement of the PLC remain poorly understood. 
There have been numerous reports addressing the various pathways used to generate and load 
peptide epitopes onto MHC class I molecules, mainly focusing on the endovacuolar and 
endosomal compartments as cellular sites for this process (Oliveira and van Hall, 2013, Vyas et 
al., 2008).     
 
1.8.2. Cross-presentation 
One alternative MHC class I presentation pathway, specific to phagocytic immune cells, is 
known as cross-presentation. In order to alert the adaptive immune system of infections or 
tumours occurring in peripheral tissues, dendritic cells (DCs) need to sample the affected cells 
and migrate to the lymph nodes, where they present the foreign or abnormal peptides to T 
cells in order to generate appropriate adaptive immune responses. This means that DCs must 
first acquire the antigenic peptides either from intracellular sources of the infected cells or, in a 
vaccination setting, from extracellular sources. The process by which phagocytic antigen-
presenting cells (APCs) capture antigens from exogenous sources, load and present them on 
their own MHC class I molecules is known as cross-presentation. “Cross-priming” is another 
term used to describe this process, given that these cross-presented antigens are displayed by 
the DCs for the priming of T cells against specific peptides of foreign origin (Bevan, 1976b, 
Bevan, 1976a).  
Intense efforts have been made in the pursuit of unravelling the mechanisms and pathways 
governing cross-presentation. The fact that MHC class I molecules have been shown to be able 
to passively exchange peptides at pH values between 4.5 and 5.5 indicate that MHC class I 
molecules could acquire exogenous antigens in the endocytic compartments (Gromme et al., 
1999, Stryhn et al., 1996). Three main endocytic pathways for cross-presentations have been 
presented thus far, namely a cytosolic pathway, a vacuolar pathway and a phagosome-to-ER 
pathway. The cytosolic pathway (Kovacsovics-Bankowski and Rock, 1995) involves the 




the Sec61 transporter), point where they undertake the canonical antigen presentation 
pathway on MHC class I molecules. In the vacuolar pathway (Pfeifer et al., 1993, Schirmbeck et 
al., 1995, Song and Harding, 1996), exogenous antigens are directly processed in the early 
phagosome by resident cathepsins (Shen et al., 2004). The resulting antigenic peptides are then 
loaded onto MHC class I molecules (presumably by passively exchanging loaded self-peptides) 
which are recycled from the cell surface into the early phagosome via recycling endosomes. 
Following their loading with the pathogen-derived peptides, the mechanisms by which recycled 
MHC class I molecules are trafficked from the phagosome back to the plasma membrane 
remain poorly understood. Finally, in the phagosome-to-ER pathway, the phagosome fuses 
with the ER, enabling the transfer of both components of the canonical antigen presentation 
pathway and, potentially, components of the endoplasmic reticulum-associated protein 
degradation (ERAD) pathway from the ER to the phagosome (Guermonprez et al., 2003, Houde 
et al., 2003). Thus, misfolded soluble proteins internalized through the phagosome could get 
degraded in the phagosome, exported into the cytosol and then reacquired by the phagosome 
as peptides and loaded onto MHC class I molecules via the PLC. This pathway however is the 
most controversial among the three, having been subjected to consistent criticism (Gros and 
Amigorena, 2019, Rock and Shen, 2005, Touret et al., 2005).  
Despite the progress concerning the broad understanding of the potential routes of cross-
presentation, as well as of the cellular and molecular participants to this process, there is still a 
clear lack of understanding of the detailed molecular mechanisms by which exogenous antigens 
internalized by phagocytic cells gain access to and are loaded onto MHC class I molecules. The 
most interesting question in my opinion is regarding the means by which antigenic peptides 
resulted from the exogenous sources get physically loaded onto MHC class I molecules. It 
seems rather unlikely that exogenous antigens would simply replace self-peptides bound to 
MHC class I molecules, even in slightly acidic environments such as endocytic compartments, 
without a dedicated molecular chaperone to catalyse this exchange process. I base this 
speculation on the comparison with MHC class II molecules, which cannot exchange CLIP for 
antigenic peptides found in endosomes, even during prolonged time periods, in the absence of 
the corresponding peptide exchange catalyst HLA-DM or while the negative regulator of HLA-






1.9. Discovery of TAPBPR, a novel MHC class I-dedicated chaperone 
For over two decades, tapasin was considered to be the sole MHC class I-dedicated chaperone. 
However, several years ago, the Boyle lab has discovered another chaperone on this pathway, 
namely the tapasin-related protein TAPBPR (Boyle et al., 2013). Despite sharing 22% sequence 
identity and 33% domain homology with tapasin, the gene encoding for TAPBPR (tapbpl) is not 
located on the MHC locus, together with the other components of the pathway, but at 
chromosome position 12p13.3 (Teng et al., 2002), near a paralogous region of the MHC (Du 
Pasquier, 2000). However, similarly to the genes encoded in the MHC region, expression of 
TAPBPR is also IFN-γ-inducible (Landis et al., 2006). 
 
1.9.1. Binding to MHC class I molecules 
Similarly to tapasin, TAPBPR was also shown to form a direct interaction with MHC class I 
molecules (Boyle et al., 2013). Moreover, the two chaperones were suggested to bind in a 
similar orientation to the MHC class I molecules, given the same residues of the MHC class I 
molecule were essential for its interactions with both tapasin and TAPBPR (Hermann et al., 
2013). Namely, interaction studies upon performing site-directed mutagenesis revealed that 
essential for the interaction with MHC class I is a patch stretching over residues between 
positions 205 and 272 on neighbouring β-sheets of TAPBPR, residues completely conserved in 
tapasin (Hermann et al., 2013). Additionally, residues 331-337 on the IgC domain of TAPBPR, 
partially conserved in tapasin, however present at homologous positions within the protein 
structures, were shown to drive association with either the α3 domain of the MHC class I heavy 
chain, or with β2m. Consequently, TAPBPR and tapasin were shown to bind to MHC class I in a 
mutually exclusive manner (Hermann et al., 2013).  
Two recently discovered crystal structures of the TAPBPR-MHC class I complex confirmed the 
previously described interaction sites between MHC class I and TAPBPR, as well as the resulting 
orientation of TAPBPR onto MHC class I (Jiang et al., 2017, Thomas and Tampe, 2017). 
Moreover, these crystal structures, together with the one obtained for the PLC by cryogenic 
electron microscopy (cryo-EM), confirmed the similar orientations of tapasin and TAPBPR when 
bound to MHC class I (Hermann et al., 2013).  
However, in contrast to tapasin, which binds to MHC class I within the confines of the PLC, 




components of the PLC (Boyle et al., 2013). In fact, TAPBPR is not part of the PLC, nor does it 
bind to any component of the PLC (Boyle et al., 2013). Furthermore, TAPBPR also seems to 
have a higher intrinsic affinity for MHC class I compared to tapasin, given that TAPBPR on its 
own can form a stable interaction with MHC class I (Boyle et al., 2013, Hermann et al., 2015b), 
whereas tapasin requires either artificial tethering or the presence of the entire PLC for stably 
associating with MHC class I (Chen and Bouvier, 2007, Wearsch and Cresswell, 2007). Based on 
recent studies, it seems that the ability of TAPBPR to form stronger interactions with MHC class 
I than tapasin could be partially attributed to particular residues in its IgC domain, such as Q334 
or S335, which are not conserved in tapasin (Hermann et al., 2013) and were suggested to be 
involved in polar interactions with the α3 domain of MHC class I heavy chain (Jiang et al., 2017, 
Thomas and Tampe, 2017). Additionally, TAPBPR seems to have a higher degree of 
conformational plasticity than tapasin, which appears to be more rigid by comparison, allowing 
it to better mould onto the MHC class I molecule at individual interaction sites (Thomas and 
Tampe, 2017).   
Another difference in the binding to MHC class I between tapasin and TAPBPR is represented by 
their relative dependencies on the N-linked glycan on the MHC class I heavy chain. Given its 
dependence on the PLC for efficient association with MHC class I, tapasin relies on the prior 
recruitment of calreticulin on the MHC class I heavy chain. Therefore, mutation of the N-linked 
glycosylation motif on MHC class I was shown to impair tapasin binding (Neerincx and Boyle, 
2018, Rizvi et al., 2011). However, these non-glycosylated MHC class I molecules displayed an 
increased level of binding to TAPBPR (Neerincx and Boyle, 2018). These results are consistent 
with previous work from the Boyle lab, according to which MHC class I molecules show a higher 
accessibility to TAPBPR in the absence of tapasin (Hermann et al., 2013), suggesting that 
TAPBPR could potentially sever overlapping functions.   
 
1.9.2. Cellular trafficking 
Despite its high abundance in the ER, TAPBPR was shown to also traffic through the medial 
Golgi compartment (Figure 3)(Boyle et al., 2013). In constrast to tapasin, whose cellular 
localization is restricted to the ER, based on its ER-retrieval motif KKXX (Jackson et al., 1990, 
Lehner et al., 1998, Nilsson et al., 1989), the tail of TAPBPR does not contain any obvious motif 




different sub-compartments of the ER (Neerincx and Boyle, 2017, Boyle et al., 2013). Tapasin is 
associated with the TAP transporter, being present in the peptide-rich regions. Since TAPBPR 
does not bind TAP and can be exported through the medial Golgi, it was suggested to reside 
mainly in the peptide poor, outer layers of the ER (Neerincx and Boyle, 2017, Hermann et al., 
2015a, Kamhi-Nesher et al., 2001).  
 
1.9.3. Peptide editing 
Similarly to tapasin, TAPBPR was shown to directly mediate peptide editing on MHC class I 
molecules (Hermann et al., 2015b). More specifically, in a similar assay to the one used by Chen 
and Bouvier for tapasin (Chen and Bouvier, 2007), recombinant TAPBPR was shown to enhance 
the dissociation rate of fluorescently-labelled peptides from recombinant MHC class I refolds 
(Hermann et al., 2015b, Morozov et al., 2016). However, as opposed to tapasin, which requires 
artificial tethering to MHC class I to mediate peptide dissociation (Chen and Bouvier, 2007), 
TAPBPR was capable of catalysing this process without the need of any artificial modifications, 
partly due to its seemingly higher affinity for MHC class I compared to tapasin. This further 
suggested that TAPBPR alone is capable of editing peptides on MHC class I molecules.  
Regarding the molecular mechanisms used by TAPBPR in mediating peptide dissociation from 
MHC class I molecules, the two recently characterised crystal structures of TAPBPR in complex 
with MHC class I both revealed that, somehow similar to the tug-of-war model proposed for 
tapasin (Fisette et al., 2016), TAPBPR appears to pull the α2-1 region of the MHC class I peptide 
binding groove away from the C-terminus of the peptide, presumably to promote peptide 
dissociation (Jiang et al., 2017, Thomas and Tampe, 2017). In support of this idea is the finding 
described by both structures, namely that TAPBPR binding to MHC class I molecules induces a 
twist of the Y84 residue of MHC class I, involved in hydrogen bond formation with the C-
terminus carboxyl group of the bound peptide, towards the outside of the groove. This 
proposed mechanism of TAPBPR-mediated peptide dissociation was further confirmed by a 
recent study relying on nuclear magnetic resonance (NMR) analysis of the interactions between 
soluble TAPBPR and MHC class I refolds (McShan et al., 2018).  
In addition to the interactions with the α2-1 region of the MHC class I, Thomas and Tampe 
claim to have captured a floppy loop region of TAPBPR in the proximity of the MHC class I 




the C-terminus of bound peptides (Thomas and Tampe, 2017). However, this loop was poorly 
resolved based on the raw diffraction data, with several side chains of the resolved structure 
and even part of the peptide backbone falling outside of the electron density map. Moreover, 
this loop was not resolved on the crystal structure by Jiang and colleagues (Jiang et al., 2017). 
Therefore, alternative conformations of this loop regions are likely to occur and, moreover, the 
impact of this region on the catalytic function of TAPBPR remains to be determined.  
 
1.9.4. Interaction with UGT1 
A study conducted in the Boyle lab revealed that TAPBPR recruits UGT1 (Figure 3)(Neerincx et 
al., 2017), an enzyme previously shown to play a key role in the quality control machinery 
involved in MHC class I peptide presentation (Zhang et al., 2011, Wearsch et al., 2011). TAPBPR 
appears to associate with UGT1, involving the only free cysteine residue of TAPBPR, at position 
94. UGT1 was suggested to identify sub-optimally loaded peptide to send them back to the 
peptide loading complex for a subsequent round of peptide editing. Thus, the identification of 
TAPBPR interaction with UGT1 raised the question of whether TAPBPR, apart from directly 
dissociating sub-optimally loaded peptides from MHC class I, acts as an additional checkpoint 
on the pathway, by selecting peptides for presentation on MHC class I molecules. In support of 
the hypothesis that TAPBPR works in complex with UGT1 on selecting pMHC class I molecules 
for presentation is the finding that mutation of the C94 residue of TAPBPR, which abolished 
interaction with UGT1, triggers a significant change in the MHC class I-associated 
immunopeptidome (Neerincx et al., 2017). 
 
1.9.5. Shaping the peptide repertoire presented on MHC class I 
Naturally, given its ability to directly catalyse peptide dissociation from MHC class I molecules 
(Hermann et al., 2015b, Morozov et al., 2016) and to recruit UGT1 for recycling sub-optimally 
loaded MHC class I molecules back to the PLC (Figure 3)(Neerincx et al., 2017), TAPBPR was 
shown to significantly influence the repertoire of peptides presented at the cell surface 
(Hermann et al., 2015b). However, despite the similar peptide editing functions of tapasin and 
TAPBPR, their effects on peptide presentation on MHC class I differ considerably. In contrast to 
tapasin, which is crucial for the presentation of peptides stably bound to MHC class I molecules, 




Whereas the absence of tapasin leads to a severe impairment in the stability of pMHC class I 
complexes and consequently of the surface expression levels of MHC class I molecules 
(Howarth et al., 2004, Williams et al., 2002), in the absence of TAPBPR, the overall levels of 
MHC class I molecules at steady state are not significantly affected (Boyle et al., 2013, Hermann 
et al., 2015b). In fact, only a relatively small pool of normally retained pMHC class I complexes 
escape to the cell surface in TAPBPR-deficient cells. Moreover, the stability of individual pMHC 
class I complexes appears to be only marginally decreased in the absence of TAPBPR (Boyle et 
al., 2013, Hermann et al., 2015b). Based on these findings, it is currently unclear based on 
which criteria TAPBPR selects pMHC class I complexes for export to the cell surface.  
Our current understanding of the function of TAPBPR in antigen presentation is that TAPBPR 
acts as an additional quality control checkpoint on the MHC class I pathway, by selecting 
peptides for presentation on MHC class I molecules. TAPBPR appears to fulfil this role by 
directly dissociating sub-optimally loaded peptides from MHC class I molecules which have 
gone through tapasin-mediated peptide editing or/and by recruiting UGT1 to reglucosylate the 
resulting peptide-receptive MHC class I molecules back to the PLC for a subsequent round of 
editing. Upon facilitating the dissociation of bound peptides from MHC class I molecules, it is 
possible that TAPBPR subsequently enables the loading of incoming peptides, however this is 
rather unlikely given the suggested localization of TAPBPR away from the peptide-rich 






Figure 3: Proposed model of TAPBPR function in the MHC class I antigen presentation pathway, 
taken from Neerincx and Boyle (Neerincx and Boyle, 2017). TAPBPR is thought to bind sub-optimally 
loaded MHC class I molecules by the PLC and catalyse the dissociation of the bound peptide. 
Subsequently, TAPBPR either enables the association of high-affinity peptides or recruits UGT1, which 
reglucosylates the resulting peptide-receptive MHC class I molecules and recycles them to the PLC for 
a subsequent round of peptide editing. In contrast to tapasin, which solely localizes in the ER lumen, 
TAPBPR traffics through the medial Golgi and potentially through the endosomal compartment, in 








1.10.  Similarities between MHC class I and class II pathways  
In contrast to MHC class I molecules, which get loaded with peptides in the ER lumen, MHC 
class II molecules acquire their antigens in late endocytic compartments. Upon their folding and 
assembly in the ER lumen, MHC class II molecules recruit a transmembrane protein that 
associates with the peptide binding groove of MHC class II, known as MHC class II-associated 
invariant chain (Ii), in a similar fashion to antigenic peptides (Figure 4) (Kvist et al., 1982, 
Machamer and Cresswell, 1982, Sung and Jones, 1981). This chaperone guides the trafficking of 
MHC class II molecules from the ER lumen into late endosomes (Bakke and Dobberstein, 1990, 
Lotteau et al., 1990), while preventing their loading with peptide in the ER (Newcomb and 
Cresswell, 1993, Roche and Cresswell, 1990). The invariant chain is cleaved in a particular late 
endosomal compartment, referred to as the MHC class II compartment (MIIC), leaving only the 
short peptide associated with the MHC class II groove, known as CLIP (class II-associated 
invariant chain peptide) (Cresswell et al., 1987, Reyes et al., 1991, Roche and Cresswell, 1991).   
Similarly to MHC class I molecules, loading of antigenic peptides on MHC class II molecules is 
catalysed by a dedicated chaperone, HLA-DM, an MHC class II homologue (Cho et al., 1991, 
Denzin and Cresswell, 1995, Kelly et al., 1991b, Morris et al., 1994, Sloan et al., 1995). HLA-DM 
directly mediates the dissociation of CLIP from MHC class II, consequently facilitating the 
association of antigenic peptides (Figure 4) (Denzin and Cresswell, 1995, Sloan et al., 1995, 
Kropshofer et al., 1996, Vogt et al., 1996). Moreover, based on the discovery of the crystal 
structure of  HLA-DM in complex with HLA-DR1 (Pos et al., 2012), HLA-DM was suggested to use 
a similar molecular mechanism as tapasin in promoting peptide dissociation, with the mention 
that, in contrast to tapasin, HLA-DM destabilizes the interactions between the MHC class II 
groove at the N-terminus of the peptide, instead of at the C-terminus. Unlike the MHC class I 
pathway, in addition to a peptide editor, the MHC class II pathway comprises another 
chaperone, namely the MHC class II homologue HLA-DO, which functions as negative regulator 
of HLA-DM (Denzin et al., 1997, Kropshofer et al., 1998, Liljedahl et al., 1996). HLA-DO inhibits 
the HLA-DM-mediated release of CLIP and loading of antigenic peptides onto MHC class II 
molecules (Figure 4). Based on its ability to regulate the peptide editor in the pathway, HLA-DO 
has been proposed to shape the peptide repertoire presented on MHC class II for optimal 
effectiveness, acting as an additional checkpoint in the pathway. In terms of its overall effect on 





Figure 4: MHC class II presentation pathway, taken from Roche and Furuta (Roche and Furuta, 2015). 
Upon their folding and assembly in the ER lumen, MHC class II dimers, consisting of the 
transmembrane chains α and β bind to the invariant chain (Ii), which directs their trafficking from the 
ER through the Golgi and into early endosomes, via the cell surface. These endosomes are then fused 
with the antigen processing compartment, where the Ii bound to MHC class II molecules is cleaved, 
leaving only a small peptide (CLIP) attached to the peptide binding groove of MHC class II. In the same 
compartment, HLA-DM, whose activity is regulated by HLA-DO, catalyses the exchange of CLIP with 
exogenous peptide antigens internalized by pinocytosis. Once loaded with exogenous peptides, MHC 







Structural predictions generated in the lab, based on the previously characterised interaction 
sites between TAPBPR and MHC class I and based on domain homology between TAPBPR and 
tapasin, have identified a loop region of TAPBPR, comprising residues 22-35, at the interface 
with the peptide binding groove of MHC class I. These predictions were made prior to the 
discovery of the crystal structures of TAPBPR in complex with MHC class I (Jiang et al., 2017, 
Thomas and Tampe, 2017), only one of which claimed to capture the same TAPBPR loop in the 
proximity of the MHC class I groove (Thomas and Tampe, 2017). Based on our structural 
predictions, it was hypothesized that the 22-35 loop of TAPBPR could be a functional region 
involved in peptide editing on MHC class I (Figure 21). Moreover, based on the amino acid 
sequence of the loop, I speculated that TAPBPR potentially uses the loop to dissociate bound 
peptides from MHC class I molecules by competing with part of the peptide for binding to the 
groove of MHC class I.  
Therefore, the main objective of my PhD was to experimentally characterise the involvement of 
the loop in the peptide editing function of TAPBPR. In order to address this question, my first 
aim was to develop a high throughput cell-based assay which would allow me to directly 
measure the ability of TAPBPR to mediate peptide exchange on MHC class I molecules on a 
cellular membrane. Subsequently, I sought to use this high throughput system to screen various 
TAPBPR loop mutants for their ability to bind MHC class I molecules and to mediate peptide 
exchange. Finally, I aimed to assess how polymorphisms in MHC class I molecules influence 






2. Materials and Methods 
 
2.1. Constructs 
The cloning of full-length TAPBPRWT and TAPBPRTN5 in the lentiviral vector pHRSIN-C56W-
UbEM, which expresses the protein of interest under the control of the spleen focus-forming 
virus (SFFV) promoter and EGFP under the control of an ubiquitin promoter was previously 
described (Boyle et al., 2013). Tapasin was amplified from cDNA isolated from human foreskin 
fibroblasts using primers tapasinWT-BamHI-for and tapasinWT-NotI-rev (See Table 1 for primer 
sequences) and was then cloned into the pHRSIN-C56W-UbEM vector. The chimeric constructs 
TAPBPRPM and tapasinPM were generated using a two-step PCR procedure, where the 
ectodomain and transmembrane domains of either TAPBPR (amplified using primers 
TAPBPRWT-BamHI-for and TAPBPRPM-rev) or tapasin (amplified using primers tapasinWT-BamHI-
for and tapasinPM-rev) were fused to the cytoplasmic tail of CD8 (amplified with primers 
TAPBPRPM-for and CD8 tail-NotI-rev, or tapasinPM-for and CD8 tail-NotI-rev, respectively). 
TAPBPRER was produced using a similar procedure, in which the ectodomain of TAPBPR 
(amplified with primers TAPBPRWT-BamHI-for and TAPBPRER-rev) was fused to the 
transmembrane and cytoplasmic domains of tapasin (amplified using primers TAPBPRER-for and 
tapasinWT-NotI-rev). All TAPBPR constructs described in this study were variants of the α 
TAPBPR isoform, as this has been described as the only TAPBPR isoform present in a wide range 
of tissues and cell lines (Boyle et al., 2013). 
Table 1: Panel of primers used to generate the TAPBPR chimeric constructs 
Primer name Primer sequence (5’-3’) 
TAPBPRWT– EcoRV-for GCGCGATATCAGCAGCCTCCATGGGCA  
TAPBPRWT– NotI-rev GCGCGCGGCCGCTCAGCTGGGCTGGCTTACA  
TAPBPRPM – for GATGTTCCTGGGGCTTCAGAGACGAAGACGTGTTTGCAAATGTCC  
TAPBPRPM – rev GGACATTTGCAAACACGTCTTCGTCTCTGAAGCCCCAGGAACATC 
tapasinWT– BamHI-for GCGCGGATCCCGCAGCGCCATGAAGTCCCTGTCTCTGCTCC  
tapasinWT– NotI-rev GCGCGCGGCCGCTCACTCTGCTTTCTTCTTTGAATCCTTG  
tapasinPM– for CTTCAAGGCACTGGGCTGGCGAAGACGTGTTTGCAAATGTCC  
tapasinPM– rev GGACATTTGCAAACACGTCTTCGCCAGCCCAGTGCCTTGAAG 
TAPBPRER– for CCTGGAGGTAGCAGGTCTTTCAGCCTTGGGAGTCATCTTTGC  
TAPBPRER– rev GTTCTCAAGGGAGGGCCCTGTTCTCCGCTCTGGTGGG   
CD8 tail – NotI-rev GCGCGCGGCCGCTTAGACGTATCTCGCCGAAAGGC  
TAPBPR soluble – for GCGCGCTAGCCACCATGGGCACACAGGAGGGC  




TAPBPRØloop, in which amino acids 22–35 were replaced with glycine, alanine and serine 
residues, was generated based on the TAPBPRWT template, using the following procedure: first, 
amino acids 22–28 were mutated by quick-change PCR using primers M22-for and M22-rev 
(Table 2). Subsequently, amino acids 29–35 were mutated using a two-step PCR procedure. In 
the first step, the TAPBPR insert was amplified in two separate pieces, starting from each side 
of the mutation site (primers TAPBPRWT-BamHI-for and M29-rev for the N-terminus-containing 
side and primers M29-for and TAPBPRWT-NotI-rev for the C-terminus-containing side). In the 
second step, the two pieces bearing complementary regions over the mutated site were used 
in a second PCR reaction to amplify the entire TAPBPR mutated insert using primers TAPBPRWT-
BamHI-for and TAPBPRWT-NotI-rev. TAPBPRL30G and TAPBPRØG30L were generated from 
TAPBPRWT and from TAPBPRØloop respectively, using primers L30G-for and L30G-rev or ØG30L-
for and ØG30L-rev respectively (Table 2), by quick change PCR. All TAPBPR and tapasin mutants 
were cloned into the lentiviral vector pHRSIN-C56W-UbEM. 
Table 2: Panel of primers used to generate the TAPBPR loop mutants 







ØG30L-for  GGTGGAGGTCTGGGCGGCGGTGC 
ØG30L-rev GCACCGCCGCCCAGACCTCCACC 
 
The luminal domains of TAPBPRWT, TAPBPRTN5 and of all TAPBPR loop mutants were also cloned 
in a PiggyBac transposon vector, using primer TAPBPR-soluble-for and TAPBPR-soluble-rev 
(Table 1), to produce secreted versions of these proteins, containing a polyHis tag at the C-
terminus, in a mammalian expression system.  
cDNA templates for the panel of HLA class I alleles used in this study were obtained from Peter 
Parham (Stanford University), Elisabeth Chalmeau, (University Nantes, France), Jane Goodall 
(University of Cambridge, UK), Ashley Moffet (University of Cambridge, UK), Sebastian Springer 
(Jacobs University, Bremen, Germany), Rajiv Khanna (Queensland Institute of Medical 
Research, Australia), and Jim McCluskey (University of Melbourne, Australia). These were 




et al., 2013). The HLA-A*68:02WT construct was cloned by consecutive rounds of quick-change 
site-directed mutagenesis, using the HLA-A*68:01WT construct as a template (see Table 3 for 
primer sequences). Since residue 116 was mutated last in this process, the HLA-
A*68:02Y116D mutant was the final intermediate in this cloning process. The HLA-A*68:01D116Y, 
A*02:01Y116D, A*02:01V12M, A*02:01S105P, A*68:02M12V, A*68:02P105S, B*27:05D116Y, B*44:05D114H 
and C*01:02D114H were generated by quick-change PCR, using primers listed in Table 3. All HLA 
class I mutants were cloned into the pHRSINcPPT-SGW vector. Human cytomegalovirus (HCMV) 
pp65 was cloned into the lentiviral vector pHRSIN-C56W-UbEM. 
All the constructs used and generated in this work, namely each full-length TAPBPR, soluble 
TAPBPR and HLA construct, were sequence verified.  
Table 3: Panel of HLA class I mutants 
































2.2. Cell lines 
HeLaM, a variant of the HeLa cell line which is more responsive to IFNγ (a gift from Paul Lehner, 
University of Cambridge, UK), HEK 293T (from Paul Lehner, University of Cambridge, UK), MCF-
7 (human breast carcinoma), EL4 (mouse T cell lymphoma) cells and all derived cell lines were 
maintained in Dulbecco's Modified Eagle's medium (DMEM; Sigma-Aldrich, UK) supplemented 
with 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific), 100 U/ml penicillin and 
100 µg/ml streptomycin (Gibco, Thermo Fisher Scientific), at 37°C with 5% CO2. To induce 
expression of endogenously-expressed TAPBPR and up-regulate the surface expression of MHC 
class I molecules, cells were treated with 200 U/ml IFNγ (Peprotech, UK), of either human or 
mouse origin, depending on the cell line, for 48–72 h. All cells were confirmed to be 
mycoplasma negative (MycoAlert, Lonza, UK). 
 
2.3. Lentiviral transduction and transfections 
Lentivirus was produced in HEK-293T cells, by transfecting the cells with either the pHRSIN-
C56W-UbEM or pHRSINcPPT-SGW lentiviral vector, containing the insert of interest, along with 
the packaging vector pCMVΔR8.91 and the envelope vector pMD.G, in the presence of FuGENE 
(Promega, UK). Transductions were performed by collecting virus-containing supernatant at 48 
h and again at 72 h and adding it onto target cells, through a syringe filter, in the presence of 8 
μg/mL polybrene (Sigma-Aldrich, UK).  
HeLaM-TAPBPRKO cells (HeLaMKO) were transduced with each TAPBPR and tapasin full-length 
variant described in this study. HeLaM cell line deficient of the HLA-A, -B and -C (HeLaM-HLA-
ABCKO) was transduced with each specified HLA class I constructs to generate a panel of HeLaM 
cells expressing single individual HLA class I allotypes.  
 
2.4. Antibodies  
TAPBPR was detected using either PeTe-4, a mouse monoclonal antibody (mAb) specific for the 
native conformation of TAPBPR, raised against amino acids 22–406 of human TAPBPR (Boyle et 
al., 2013) that does not cross-react with tapasin (Hermann et al., 2013), or ab57411, a mouse 
mAb raised against amino acids 23–122 of TAPBPR that recognizes denatured TAPBPR (Abcam, 




tapasin (Dick et al., 2002), or with R.gp48N, a rabbit polyclonal antibody specific for the 
denatured form of tapasin (Sadasivan et al., 1996)(kind gifts from Peter Cresswell, Yale 
University School of Medicine). MHC class I heavy chains were detected using the mouse mAb 
HC10 (Stam et al., 1986) and mAb HCA2 (Stam et al., 1990). β2m was detected using a rabbit 
polyclonal antibody (Dako, UK). Folded MHC class I molecules present either at the cell surface 
or coupled to SABs were detected using W6/32, a pan-MHC class I mouse mAb that recognizes 
a conformational epitope of the α2 domain of MHC class I, only in the presence of β2m and 
peptide (Barnstable et al., 1978). OVA257-264 [SIINFEKL] peptide on H-2Kb was detected using the 
mAb 25D-1.16 (Thermofisher). The Epstein-Barr Virus derived peptide Latent Membrane 
Protein 1125–133 [YLLEMLWRL] in association with HLA-A*02:01 was detected using the TCR-
like mAb L1 (Sim et al., 2013) (a king gift from Paul MacAry, University of 
Singapore). Calnexin was detected via western blot analysis using the rabbit polyclonal 
antibody ADI-SPA-860 (Enzo Life Sciences, UK). A mouse IgG2a isotype control was also used as 
a control (Sigma-Aldrich).  
 
2.5. MHC class I-binding peptides 
Fluorescently-labelled peptides specific to individual HLA class I allotypes or to the mouse MHC 
class I molecule H-2Kb were derived from epitopes selected using SYFPEITHI database 
(Rammensee et al., 1999), the Immune Epitope Database and Analysis Resource or the HIV 
molecular immunology epitope database(www.hiv.lanl.gov)(Table 4). All peptides were 















Table 4: Fluorescently-labelled MHC class I-binding peptides used in this study 
Peptide sequence Original epitope Origin MHC class I allotype(s) specificity 
NLVPK*VATV NLVPMVATV HCMV HLA-A*02:01 
YLLEK*LWRL YLLEMLWRL EBV HLA-A*02:01 
IMDQK*PFSV IMDQVPFSV EBV HLA-A*02:01 
CLGGK*LTMV CLGGLLTMV EBV HLA-A*02:01 
LLGRK*SFEV LLGRNSFEV tumour-associated HLA-A*02:01 
ELAGK*GILTV ELAGIGILTV tumour-associated HLA-A*02:01 
RLLQK*TELV RLLQETELV tumour-associated HLA-A*02:01 
YVVPFVAK*V YVVPFVAKV self HLA-A*02:01; -A*68:02; -C*02:02 
ETVSK*QSNV ETVSEQSNV neoantigen HLA-A*68:02 
EGVSK*QSNG ETVSEQSNV neoantigen HLA-A*68:02 
KTGGPIYK*R  KTGGPIYKR influenza virus HLA-A*68:01 
PYLFK*LAAI  PYLFWLAAI EBV HLA-A*23:01 
RVLDK*VEKW  N/A artificial HLA-A*32:01 
SRYWK*IRTR SRYWAIRTR influenza virus HLA-B*27:05; -B*27:09 
SPAIK*QSSM SPAIFQSSM HIV HLA-B*07:02; -B35; -A30 
SHETK*IIEL  SHETVIIEL neoantigen HLA-B*38:01 
EEFGK*AFSF  EEFGRAFSF self HLA-B*44:05 
LNPSK*AATL LNPSVAATL HCV HLA-C*01:02 
SIINFEK*L SIINFEKL mouse ovalbumin H-2Kb 
• K* = lysine labelled with 5-carboxytetramethylrhodamine [TAMRA] 
 
 
2.6. Expression and purification of TAPBPR protein 
In order to produce secreted soluble forms of either the TAPBPR loop variants or the TN5 
mutant of TAPBPR, the lumenal domains of these proteins were cloned into a modified version 
of the PB-T-PAF vector where the N-terminal Protein A fusion was removed and a C-terminal 
His6 tag introduced. These soluble TAPBPR proteins were stably expressed in 293T cells using 
the PiggyBac expression system. 48 hr after transfection, cells were transferred for at least 5 
days into selection media (DMEM supplemented with 10% FBS, 1% pen/strep, 3 µg/mL 
puromycin (Invivogen, San Diego, CA) and 700 µg/mL geneticin (Thermo Fisher Scientific, UK). 
To induce protein expression, cells were harvested and transferred into DMEM supplemented 
with 5% FBS, 1% pen/strep and 2 µg/mL doxycycline (Sigma-Aldrich, UK). After 5–7 days, the 
media was collected and TAPBPR was purified using nickel-nitrilotriacetic acid (Ni-NTA) affinity 





2.7. Differential scanning fluorimetry (DSF) 
Thermofluor analysis was performed in 96-well low-profile clear PCR plates for Viia7 cyclers 
(Axygen). Reactions of 20 μl consisted of 5 μg protein, 1x protein Thermal Shift Dye (Life 
Technologies) in PBS at pH 7.4. The melting curve was performed using a Viia7 thermocycler 
between 20°C and 95°C in 1°C steps with 20 s equilibration time per step and fluorescence 
monitored on the ROX channel. 
 
2.8. Flow cytometry 
For analysis by flow cytometry, cells were first detached from the flasks by trypsinisation and 
then washed in 1% bovine serum albumin (BSA) dissolved in 1x phosphate-buffered saline (PBS) 
at 4°C. Cells were then stained for 30 min at 4°C in 1% BSA containing one of the following 
antibodies: W6/32, PeTe4, Pasta-1, TCR-like mAb L1, 25-D1.16 or an isotype control antibody. 
After washing the cells to remove excess unbound antibody, the primary antibodies bound to 
the cells were detected by incubation at 4°C for 25 min with goat anti-mouse Alexa-Fluor 647 
IgG (Invitrogen Molecular Probes, Thermo Fisher Scientific). Following three subsequent rounds 
of washing, the fluorescence levels were detected using a BD FACScan analyser with Cytek 
modifications and analysed using FlowJo (FlowJo, LLC, Ashland, OR).  
 
2.9. Single antigen bead screen 
3 μL of the LABScreen® single antigen HLA bead suspension (One Lambda, Inc., CA, USA) were 
added per well of a 96-well plate and incubated with either 100 nM or 1 μM soluble TAPBPRWT 
or TAPBPRTN5 at 22°C, with rotation, for 60 min. The beads were washed three times in wash 
buffer (One Lambda, Inc., CA, USA) to remove any excess of soluble TAPBPR. Subsequently, the 
beads were first incubated with PeTe4 antibody for 30 min, washed and then incubated with a 
PE-conjugated goat anti-mouse IgG (Abcam, UK) for another 30 min at 22°C. After a subsequent 
round of washing, cells were re-suspended in 1x PBS and the TAPBPR levels bound to the beads 
were measured by a using the Luminex Fluoroanalyser system (One Lambda, Inc., CA, USA) and 





2.10. BFA decay assays 
IFN-γ-stimulated HeLa-HLA-ABCKO cells, reconstituted with individual HLA class I allotypes were 
treated with 10 μg/mL BFA (Sigma-Aldrich), diluted in regular media, for different time periods. 
Cells were then harvested and the levels of MHC class I molecules present at the surface of 
each cell line, at each time point, were measured by flow cytometry, by staining with the 
W6/32 antibody. 
 
2.11. Immunoprecipitation, gel electrophoresis and western blotting 
For immuno-precipitation from the whole cell lysates, IFNγ-stimulated cells were harvested, 
washed in PBS and then snap-frozen in dry ice for >5 min. Cells were then lysed in 1% triton X-
100 (VWR, Radnor, PN), Tris-buffered saline (TBS) (20 mM Tris-HCl, 150 mM NaCl, 2.5 mM 
CaCl2), whenever TAPBPR was pulled down, or in 1% digitonin-TBS, whenever tapasin was 
pulled down, supplemented with 10 mM N-ethylmaleimide (NEM), 1 mM phenylmethylsulfonyl 
fluoride (PMSF) (Sigma-Aldrich), and protease inhibitor cocktail (Roche, UK) for 30 min at 4°C. 
Nuclei and cell debris were pelleted by centrifugation at 13,000 × g for 15 min and supernatants 
were collected. TAPBPR was then pulled down from the whole cell lysate using protein A 
sepharose beads conjugated to the PeTe4 antibody, at 4°C, over 90 min, with rotation. 
Following immunoprecipitation, beads were washed thoroughly in 0.1% detergent-TBS to 
remove unbound protein. For separation by gel electrophoresis, the samples were heated at 
94°C for 10 min in sample buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 0.04% 
bromophenol blue), supplemented with 100 mM β-mercaptoethanol. In order to detect the 
samples by western blotting, proteins were transferred onto an Immobilon transfer membrane 
(Merck Millipore). Membranes were blocked using 5% (w/v) dried milk and 0.05% (v/v) Tween 
20 in PBS for 30 min and subsequently incubated with the indicated primary antibody for 1–16 
h. After washing, membranes were incubated with species-specific HRP-conjugated secondary 
antibodies for 1-2 h at room temperature, washed and detected by enhanced 
chemiluminescence using Western Lightning (Perkin Elmer, UK) and Super RX film (Fujifilm, UK). 
Films were scanned on a CanoScan8800F using MX Navigator Software (Canon, UK).  
For immunoprecipitation of the TAPBPR fraction present at the plasma membrane, prior to 




rotation at 4°C. Excess antibody was removed by washing the cells 5 times in 1x PBS at 4°C. 
Subsequently, cells were lysed and the TAPBPR fraction originally present the plasma 
membrane, bound to the PeTe4 antibody, was then precipitated using protein A sepharose 
beads alone (GE Healthcare) for 2 h at 4°C with rotation. The intracellular fraction of TAPBPR 
was pulled-down from the resulting flow through using the same procedure as the one used to 
pull down TAPBPR from the whole cell lysate.  
For pulldown experiments using soluble TAPBPR proteins, protein A sepharose precleared 
lysates from IFNγ-stimulated HeLaM-TAPBPRKO cells were incubated with 2 µg of the soluble 
TAPBPR variant for 90 min at 4°C. Immunoprecipitation of soluble TAPBPR was performed using 
PeTe4 as above. Soluble TAPBPR variants were detected on western blots with the anti-poly His 
primary antibody. 
 
2.12. Peptide binding 
Target cell lines were seeded at 25,000-30,000 cells/well in 12-well plates and stimulated with 
IFNγ. Following the stimulation period, the cells were washed 3 times with 1x PBS and 
incubated with 300 μL opti-MEM at 37°C (Thermo Fisher Scientific, UK). In case the peptide 
binding was done in the presence of recombinant TAPBPR, the cells were treated with or 
without recombinant TAPBPR. After 15 min, the desired TAMRA-labelled peptide was added to 
the cells, at concentration dependent on the MHC class I molecule tested, and incubated at 
37°C for different time periods, dependent on the MHC class I molecule tested. In case the 
peptide binding was facilitated by over-expressed TAPBPR, the labelled peptide was directly 
added to the cells, without using recombinant TAPBPR. Following the peptide treatment, the 
cells were washed three times in 1x PBS and harvested. The level of bound peptide/cell was 
determined by flow cytometry, using the YelFL1 channel (Cytek).  
 
2.13. Peptide exchange 
HeLaM-TAPBPRKO cells, reconstituted with TAPBPR, were seeded at 25,000 cells/well and 
stimulated with IFNγ. The cells were then washed and treated with 10 nM TAMRA-labelled 




binding step, the peptide-containing media was removed, the cells were washed and then 
treated with media alone or with different concentrations of non-labelled peptide for another 
15 min at 37°C. The cells were then washed and harvested and the level of bound peptide per 
cell was determined by flow cytometry, using the YelFL1 channel (Cytek). 
 
2.14. FluoroSpot T cell assay 
 
2.14.1. Expansion of HCMV-specific CD8+ T cells 
CD8+ T cells were isolated from peripheral blood mononuclear cells (PBMC) by magnetic-
activated cell sorting (MACS), using anti-CD8 direct beads (Miltenyi Biotec, Bisley, United 
Kingdom) for magnetic separation and then resuspended in supplemented RPMI + 10% Fetal 
Bovine Serum (FBS) (Invitrogen) + 10% heat inactivated autologous donor serum. Cells were 
stimulated with peptide-pulsed irradiated autologous PBMC in the presence of 2.5 IU/ml 
human recombinant IL-2 (National Institute for Biological Standards and Control, Potters Bar, 
United Kingdom) in round bottom 96 well plates at 37°C and 5 % CO2 for 10 – 14 days. Fresh 
media was replenished every five days. The specificity of expanded CD8+ T cell cultures was 
tested using IFNγ FluoroSpot assays, upon stimulation with HeLaM cells over-expressing both 
HLA-A2 and pp65. The HLA-A2-restricted peptide from HCMV pp65 used in this study was 
NLVPMVATV (pp65495 -504). 
Ethical approval for this study was obtained from the Addenbrookes National Health Service 
Hospital Trust institutional review board (Cambridge Research Ethics Committee). Informed 
written consent was obtained from all recipients in accordance with the Declaration of Helsinki 
(LREC 97/092). 
2.14.2. Experimental set up 
Target cells (MCF-7 or HeLaM-HLA-ABCKO reconstituted with HLA-A*02:01 heavy chain) were 
seeded at 80,000 cells/well of a 6-well plate and stimulated with IFNγ for 72 h. Cells were then 
washed 3 times with 1x PBS and incubated with 600 μL pre-warmed opti-MEM, containing 
either soluble TAPBPRWT, TAPBPRTN5, or without TAPBPR. After 15 min, 100 pM NLVPMVATV 




treatment, cells were washed 3 times in 1x PBS and harvested. Each sample was then washed 
again twice in 1x PBS and resuspended in X-VIVO 15 media (Lonza, Slough, UK) at 1x106 
cells/mL. Target cells were then irradiated for 20 min, in order to cease proliferation 
throughout the experiment. Triplicate wells of NLVPMVATV-specific CD8+ T cells in X-VIVO 15 
media were incubated in coated Fluorospot plates (Human IFNγ FLUOROSPOT (Mabtech AB, 
Nacka Strand, Sweden)), either at 8,000 or at 4,000 cells/well, with target cells, at 50,000 
cells/well, at 37°C in a humidified CO2  atmosphere for 20 hours. The cells and medium were 
decanted from the plate and the assay was developed following the manufacturer's 
instructions.  Developed plates were read using an AID iSpot reader (Autoimmun Diagnostika 




OT-I RAG2-/- mice were a generous gift from Suzanne Turner (Dept. of Pathology, University of 
Cambridge) and were bred and housed in accordance with UK Home Office regulations. 
 
2.16. Cytotoxicity assay 
To generate OT-I cytotoxic T lymphocytes (CTL), spleens were extracted from OT-I RAG2-/- mice 
and single cell suspensions of splenocytes were obtained using a 70 μm cell strainer (Greiner 
Bio-one). Splenocytes were stimulated with 10 nM OVA257-264 (SIINFEKL) peptide (Peprotech, 
UK). After 3 days of culture, cells were washed, transferred into fresh T cell media on a daily 
basis and used 3-4 days later. T cells were cultured in RPMI 1640 medium with L-glutamine 
(Gibco, Thermo Fisher Scientific), 10% heat–inactivated FCS (Biosera), 50 μM of β-
mercaptoethanol, 1 mM sodium pyruvate (Gibco, Thermo Fisher Scientific), 10 mM Hepes 
(Sigma-Aldrich), 50 IU/ml recombinant murine IL-2 (Peprotech, UK) and 50 U/ml penicillin and 
streptomycin (Gibco, Thermo Fisher Scientific) (T cell media). 
The CytoTox96 Non-Radioactive Cytotoxicity Assay (Promega) was used to measure EL4 target 
cell death. Target H-2b EL4 cells were washed the day prior to the experiment and resuspended 
in fresh DMEM at 3x105 - 4x105 cells/ml. The following morning, the EL4 cells were washed 




1 μM soluble TAPBPR alone or with carrier alone for 10 min, after which either 1 nM OVA257-264 
(SIINFEKL) peptide or carrier alone was added to the cells for another 30 min. Cells were then 
washed 1x in Opti-MEM and 2x in killing assay media (RPMI medium minus phenol red, 2% FCS) 
and subsequently resuspended in killing assay media at 1x105 cells/ml in a round-bottom 96-
well plate. Effector OT-I T cells were washed in killing assay media once and then added to the 
plate at titrated effector to target cell (E:T) ratios. Plates were incubated at 37C and after 6-7 
hours. EL4 killing was assessed by release of lactate dehydrogenase in the supernatant. 
 
2.17. Isolation of HLA peptides 
HLA class I molecules were isolated from HeLaM-TAPBPRKO cells transduced with either 
TAPBPRWT, TAPBPRØloop or TAPBPRØG30L using standard immunoaffinity chromatography, using 
the pan-HLA class I-specific antibody W6/32 (produced in-house), as described previously 
(Kowalewski and Stevanovic, 2013). Tissue typing confirmed the HeLaM cells express HLA-
A*68:02, -B*15:03 and -C*12:03. These experiments were performed by Ana Marcu, from the 
lab of Prof. Stefan Stefanović (University of Tübingen, Germany). 
 
2.18. Analysis of HLA ligands by LC-MS/MS 
Peptides isolated from pulled-down MHC class I molecules were analysed in five technical 
replicates. Peptide samples were separated by nanoflow high-performance liquid 
chromatography (RSLCnano, Thermo Fisher Scientific, Waltham, MA) using a 50 μm × 25 cm 
PepMap rapid separation liquid chromatography column (Thermo Fisher Scientific) and a 
gradient ranging from 2.4% to 32.0% acetonitrile over the course of 90 min. The eluted 
peptides were analysed in an online-coupled LTQ Orbitrap XL mass spectrometer (Thermo 
Fisher Scientific) using a top five CID (collision-induced dissociation) fragmentation method. 
These experiments were performed by Ana Marcu, from the lab of Prof. Stefan Stefanović 







2.19. Database search and HLA annotation 
Spectra were annotated to corresponding peptide sequences by database search across the 
human proteome as included in the Swiss-Prot database (20,279 reviewed protein sequences, 
September 27th 2013), by using the SEQUEST HT search engine (Eng et al., 1994) integrated into 
ProteomeDiscoverer 1.4 (Thermo Fisher Scientific). Data processing was performed without 
enzyme specificity, with peptide length restricted to 8–12 amino acids, and methionine 
oxidation set as dynamic modification. The false discovery rate was computed using the 
Percolator algorithm (Kall et al., 2007) and set to 5%. HLA class I allotype annotation was 
performed using NetMHCpan-4.0, with a percentile rank threshold of 2%. These experiments 
were performed by Ana Marcu, from the lab of Prof. Stefan Stefanović (University of Tübingen, 
Germany) and by Dr. Clemens Hermann (University of Cape Town, RSA). 
 
2.20. Label-free quantitation 
Label-free quantitation (LFQ) was used as previously described (Nelde et al., 2018) to assess the 
relative peptide abundances between TAPBPRWT, TAPBPRØloop or TAPBPRØG30L-expressing cells. 
Relative quantitation of HLA peptides was performed by calculating the area under the curve of 
the respective precursor extracted ion chromatogram (XIC), using ProteomeDiscoverer 1.4 
(Thermo Fisher Scientific). For LFQ analysis, the total injected peptide amount of all samples 
was normalised prior to LC-MS/MS analysis. Volcano plots were generated using an in-house R 
script (v3.2) and display pairwise comparisons of the ratios of the mean areas for each 
individual ligand in the five LFQ-MS runs. Significant modulation was defined by an adjusted p-
value of < 0.01 and a fold change of ≥ log2 2-fold change, as calculated by two-tailed t-tests 
implementing Benjamini-Hochberg correction. These experiments were performed by Ana 
Marcu, from the lab of Prof. Stefan Stefanović (University of Tübingen, Germany). 
 
2.21. Statistics 
Throughout the study, statistics were performed as unpaired t tests using GraphPad Prism. 
Data was summarised mainly as mean ± SD, unless otherwise specified. Significance was 




3. Chapter 3: Designing an assay to identify functional regions of 




In order to explore the molecular mechanisms of TAPBPR-mediated peptide exchange on MHC 
class I and to identify key functional regions of TAPBPR essential for this process, I first needed 
to establish an appropriate peptide exchange assay for TAPBPR. Prior to this work, the only 
known assay to test the ability of TAPBPR to mediate peptide exchange on MHC class I 
molecules was the one established by the Elliott lab (University of Southampton, UK) in 
collaboration with the Boyle group (Hermann et al., 2015b), based on the pre-existing assay 
designed by Chen and Bouvier for tapasin (Chen and Bouvier, 2007). This assay, which was later 
reproduced by another group (Morozov et al., 2016), relies on assessing the effect of the 
luminal domain of TAPBPR alone on the dissociation of fluorescently-labelled peptides from 
recombinant MHC class I refolds, in solution, by fluorescence polarization (FP) measurements.  
However, this assay exhibited a number of important limitations which I believed would not 
allow for efficient screening of TAPBPR mutants for their ability to edit peptides. The two most 
concerning limitations of this assay were its low sensitivity and its extremely low throughput 
nature. Regarding its sensitivity, addition of TAPBPR in the range of 0.1 – 1.0 μM to 
recombinant MHC class I molecules, refolded with high-affinity fluorescently-labelled peptides 
in solution, induced an extremely low dissociation rate of the peptide (Hermann et al., 2015b). 
This would leave little space for any intermediate peptide exchange phenotypes, potentially 
corresponding to partially dysfunctional TAPBPR mutants. This could have been a result of 
refolding the HLA-A2 molecules only with individual high-affinity peptides of choice, instead of 
using a pool of peptides with different affinities for A2, which is what TAPBPR naturally 
encounters inside the cell. Regarding the throughput of the experimental procedure, each 
experiment requires manual generation of individual MHC class I refolds, with individual 
peptides of choice, process which generally takes between five and seven days. Moreover, 
once generating the refolds, the peptide exchange experiment spans over 4 – 6 hours.   
I thus decided to establish an alternative system that would allow for a higher sensitivity of the 




mediated peptide exchange in a high-throughput manner. Such an assay would subsequently 
allow me to explore the molecular mechanisms of TAPBPR-mediated peptide editing on MHC 




3.2.1. TAPBPR is present at the cell surface when over-expressed in HeLaM cells  
One interesting property of TAPBPR, previously described by the Boyle lab, is its ability to traffic 
to the cell surface upon over-expression (Boyle et al., 2013), property which was not observed 
for tapasin. It is important to mention that endogenously-expressed TAPBPR has only been 
detected intracellularly and that, only when over-expressed, gets trafficked to the cell surface. 
Since TAPBPR was shown to mediate peptide exchange on MHC class I alone, without the need 
of additional cellular factors or mutation of the protein (Hermann et al., 2015b, Morozov et al., 
2016), its observed presence at the cell surface upon over-expression raised the interesting 
question of whether TAPBPR retains its ability to function as a peptide exchange catalyst on 
MHC class I at this atypical location. If so, the presence of TAPBPR at the cell surface upon over-
expression could allow me to measure TAPBPR-mediated peptide exchange on MHC class I 
molecules on a cellular membrane. The plasma membrane is arguably the only cellular location 
where this process could be measured directly, as the luminal domains of the proteins are 
exposed to the extracellular space, enabling direct access of surface expressed MHC class I 
molecules to exogenously-added peptides (e.g. quantifiable by flow-cytometry).   
A HeLaM cell line over-expressing TAPBPRWT was created by reconstituting the TAPBPR knock-
out HeLaM cells (HeLaMKO )(generated by Dr. Andreas Neerincx, University of 
Cambridge)(Hermann et al., 2015b) with TAPBPRWT (HeLaMKOTAPBPRWT). TAPBPRWT was cloned 
in lentiviral vector, upstream of an eGFP reporter gene (Boyle et al., 2013), for assessing 
transduction efficiency (Figure 5a). I first tested HeLaMKOTAPBPRWT cells for surface expression 
levels of both TAPBPR and MHC class I, by flow cytometry (Figure 5b and 5c). Whereas 
endogenously expressed TAPBPR was undetectable at the cell surface in IFNγ-treated HeLaM 
cells, the cells over-expressing TAPBPRWT showed a clear presence of TAPBPR at the surface 
(Figure 5b). Second, TAPBPR over-expression led to a considerable down-regulation in MHC 




significantly alter the steady state level of MHC class I at the cell surface (Figure 5c), as 
previously described (Boyle et al., 2013). To understand whether HLA-A and HLA-B molecules 
were downregulated to a similar extent by over-expression of TAPBPR, I measured the levels of 
HLA-A (Figure 5d) and HLA-B molecules (Figure 5c) respectively, on cells over-expressing 
TAPBPR, and compared these levels to the ones detected on HeLaM and HeLaMKO cells. 
Interestingly, while HeLaMKOTAPBPRWT cells showed a clear reduction, of almost 90%, in the 
surface expression of HLA-A compared to HeLaM cells (Figure 5b), the levels of HLA-B were 
very similar between these two cell lines (Figure 5c). This suggests that TAPBPR preferentially 
decreases expression of HLA-A molecules at the cell surface in HeLaM cells. However, this 
phenomenon seems to be applicable solely for over-expressed TAPBPR, as knocking out 
endogenous TAPBPR did not trigger any difference in MHC class I surface expression         
(Figure 5c-e).   
 
Figure 5: Over-expressed TAPBPR is trafficked to the cell surface and down-regulates MHC class I 
surface expression. TAPBPR was cloned upstream of an eGFP reporter gene in a lentiviral vector and 
transduced into HeLaMKO cells for stable over-expression (HeLaMKOTAPBPRWT). Histograms show the 
levels of (a) eGFP expression or of (b) TAPBPR, (c) MHC class I molecules, recognized by the W6/32 
mAb, (d) HLA-A molecules, recognized by the αA2A28 mAb and (e) HLA-B molecules, recognized by 
the 4E mAb, at the surface of HeLaM, HeLaMKO and HeLaMKOTAPBPRWT cells. For each measurement, 
a sample stained with an isotype control antibody was chosen as a negative control (dashed grey 




To assess the effect of TAPBPR on peptide exchange on MHC class I, I tested whether TAPBPR 
over-expression could facilitate the binding of exogenously-added peptides to the surface of 
HeLaMKOTAPBPRWT cells. To this end, I decided to use fluorescently-labelled peptides with high 
affinity for MHC class I, which would permit quantifying the level of bound peptide per cell 
using flow cytometry. The first peptide I used was ETVSKTAMRAQSNV (ETVSK*QSNV), a 
fluorescently-labelled derivative of ETVSEQSNV, which was reported to be a carcinoma-specific 
peptide, presented on HLA-A*68:02, which is an allele expressed in HeLaM cells (Hogan et al., 
1998). I thus tested the binding of ETVSK*QSNV to HeLaMKOTAPBPRWT cells and compared it to 
the binding of the labelled peptide to HeLaM and HeLaMKO cells.  
 
3.2.2. TAPBPR over-expression significantly promotes peptide binding to cells  
In my initial experiment, I tested the binding of 10 µM ETVSK*QSNV (ETV*) to cells stimulated 
with IFNγ for 48 h at 37oC in opti-MEM (Figure 6). I used the peptide at 10 µM, as the peptide 
concentrations used for previously-reported peptide-pulsing experiments in human cells have 
varied between 10 and 50 μM (e.g. references (Wills et al., 1996, Zehn et al., 2006)). Also, I 
chose opti-MEM over regular DMEM due to the lack of protein that could potentially interfere 
with the peptide binding to cells. IFNγ stimulation was necessary in order to boost the MHC 
class I levels on HeLaMKOTAPBPRWT cells, since TAPBPR over-expression severely downregulates 
MHC class I surface expression in HeLaM cells in the absence of IFNγ (Figure 5)(Boyle et al., 
2013). Upon performing this experiment however, I observed a progressive increase in the 
fluorescence of the cells, which continued even after 3 hours (Figure 6a). Since even HeLaM 
and HeLaMKO cells showed a rapid and progressive increase in fluorescence, I concluded that at 
37oC, the fluorescence of these cells may reflect constant endocytosis of the exogenously 
added peptide, due to active trafficking at the plasma membrane, which may occur both by 
pinocytosis or via binding to MHC class I molecules at the cell surface. The rapid accumulation 
of peptide was also likely a result of using a high peptide concentration in the experiment.  
Nevertheless, the fluorescence signal observed for HeLaMKOTAPBPRWT cells was considerably 
higher than the one recorded for both HeLaMKO and HeLa cells (Figure 6b), despite the lower 
HLA-A*68:02 levels on the surface of HeLaMKOTAPBPRWT cells (Figure 5d). On the other hand, 
presence or absence of endogenously-expressed TAPBPR did not appear to influence the level 




over-expressed TAPBPR appeared to trigger an enhancement either in the binding of MHC class 
I-specific peptides to cells or in their internalisation.  
 
Figure 6: Progressive internalisation of peptides into cells at 37°C. (a) Following stimulation with 
IFNγ for 48 h, HeLaM cells (right), HeLaMKO cells (left) and HeLaMKOTAPBPRWT cells (right) were 
treated without peptide (dashed grey line) or with 10 µM ETV* for different time periods (black = 15 
min, teal = 60 min, orange = 180 min). (b) Comparison of the amount of peptide bound to each of the 
cell lines in panel a), upon incubation of the cells with ETV* for 15 min. Samples treated without 
peptide were chosen as negative controls (dashed grey line). The amount of peptide bound 
to/accumulated in the cells was measured by flow cytometry. These histograms are representative 
examples of three independent experiments.   
 
To overcome the high amount of peptide internalization, I progressively decreased both the 
peptide concentration and the exposure time of the cells to the fluorescent peptide. In 
addition, to understand how much of the observed fluorescence level was due to MHC class I-
independent peptide internalisation, I performed this analysis on HeLaM cells in which the 
heavy chains of HLA-A, -B and -C molecules had been knocked out (HeLaM-HLA-ABCKO)(cell line 
generated by Dr. Andreas Neerincx, University of Cambridge)(Neerincx and Boyle, 2018) and 
compared the bound levels of fluorescent peptide to the ones observed on HeLaM cells and 




When exploring the kinetics of the peptide binding to cells, in the presence or absence of 
TAPBPR at the cell surface, I observed that, even at extremely low peptide concentrations, of 1 
- 10 nM, HeLaMKOTAPBPRWT cells exhibited a high level of peptide binding, whereas HeLaM 
cells did not show a significant level of peptide binding until the peptide concentration was 
raised above 100 nM (Figure 7a). Moreover, HeLaMKOTAPBPRWT cells required ~100-fold less 
peptide than HeLaM cells to achieve an equivalent fluorescence level, suggesting a clear 
enhancement by TAPBPR in peptide binding to cells. Since MHC class I-deficient HeLaM-HLA-
ABCKO cells appeared to begin fluorescing only when the peptide concentration was increased 
to 10 μM, I concluded that the observed peptide binding to the MHC class I-positive cell lines at 
lower peptide concentrations was occurring strictly in an MHC class I-dependent manner.  
To understand how rapidly TAPBPR facilitates peptide binding to MHC class I molecules, I 
treated the cell lines with 10 nM peptide and measured the level of bound peptide after 
different treatment periods. Strikingly, presence of TAPBPR at the cell surface triggered a 
strong enhancement in peptide binding at the cell surface within only a few minutes (Figure 
7b). In fact, the level of peptide bound to HeLaMKOTAPBPRWT cells after 5 minutes was twice 
higher compared to the level observed onto HeLaM cells after 180 min. At such low peptide 
concentration, there did not appear to be any peptide binding occurring to HeLaM-HLA-ABCKO 
cells, even after 180 min of peptide treatment, indicating the lack of passive peptide 
internalization.  
These results demonstrate that TAPBPR mediates peptide loading onto cells extremely rapidly 
and at very low peptide concentrations, in an MHC-class I dependent manner. Based on these 
findings, I decided to use 10 nM fluorescent peptide and a treatment period of 15 min as a 






Figure 7: Over-expressed TAPBPR facilitates peptide binding onto cell surface MHC class I molecules 
rapidly and at low peptide concentrations. (a) Dose-response and (b) time course curves showing the 
level of exogenously-added ETVSK*QSNV bound to IFNγ–stimulated HeLaM, HeLaMKO, 
HeLaMKOTAPBPRWT or HeLaM-HLA-ABCKO cells, treated with (a) increasing concentration of 
ETVSK*QSNV for 15 min or with (b) 10 nM ETVSK*QSNV from 0 to 180 min at 37 °C. Line graphs show 
MFI ± SD from three independent experiments. Taken from Ilca et al. (Ilca et al., 2018a). 
 
 
3.2.3. Over-expressed TAPBPR mediates peptide loading onto MHC class I molecules 
present at the cell surface 
I was next interested in confirming that over-expressed TAPBPR was facilitating peptide loading 
onto the cell surface pool of MHC class I molecules instead of enabling this process in 
intracellular compartments (i.e. recycling endosomes). To this end, I performed a similar 
peptide binding experiment upon blocking cellular trafficking. In order to block both export and 
import from the cell surface, I decided to perform the peptide treatment at 4oC, a temperature 
at which all cellular trafficking ceases (Breuer et al., 1995, Klausner et al., 1983, Schmid and 
Carter, 1990). 
Consistent with the results from the experiment performed at 37oC with low peptide exposure, 
I observed a clear increase in the binding of ETVSK*QSNV to the HeLaMKOTAPBPRWT cells 
compared to HeLaMKO cells (Figure 8). Moreover, I found that peptide binding to 
HeLaMKOTAPBPRWT cells saturated after only 15 min (Figure 8a) and at very low concentrations 
(Figure 8b), suggesting that there was no progressive accumulation of the peptide into the cells 
and that the fluorescence level detected reflected exclusively the amount of peptide bound at 
the cell surface. However, the level of peptide binding to HeLaMKO cells considerably increased 
from the 15 min time point to the 60 min one (Figure 8a), as well as with increasing peptide 




enhanced by TAPBPR over-expression. I excluded the possibility that the observed increase in 
peptide binding to cells over-expressing TAPBPR could be due to a higher binding capacity at 
the cell surface, since cells over-expressing TAPBPR display a considerably lower amount of 
surface expressed HLA-A*68:02 molecules compared to HeLaMKO cells (Figure 5d). 
 
Figure 8: Over-expressed TAPBPR promotes rapid peptide loading onto cell surface MHC class I 
molecules at 4°C. (a) Time course and (b) dose-response histograms showing the level of 
ETVSK*QSNV bound to the surface of IFNγ-stimulated HeLaMKOTAPBPRWT (left panels) or HeLaMKO 
cells (right panels) treated with either (a) 1 μM ETVSK*QSNV for 5 – 120 min or with (b) 0.1 – 10 μM 
ETVSK*QSNV for 60 min at 4°C. These histograms are representative examples of three independent 
experiments. Adapted from Ilca et al. (Ilca et al., 2018b). 
 
Finally, to confirm that the observed TAPBPR-mediated peptide binding onto MHC class I 
molecules was occurring based on the affinity of the peptide for MHC class I, I tested whether 
TAPBPR was able to load peptides of low affinity for MHC class I molecules onto the cell 
surface. For this purpose, I designed a fluorescently-labelled peptide with low affinity for HLA-
A*68:02, namely EGVSK*QSNG (ETVΔ2/9*), obtained by replacing the anchor residues on 
positions 2 and 9 of the high-affinity peptide ETVSK*QSNV with glycine residues. In contrast to 




that TAPBPR mediates peptide binding to MHC class I molecules present at the cell surface in a 
peptide affinity-dependent manner. 
 
Figure 9: Over-expressed TAPBPR does not mediate loading of low-affinity peptides onto cell 
surface MHC class I molecules. Histograms depicting level of bound EGVSK*QSNG (ETVΔ2/9*) to 
IFNγ-stimulated HeLaMKOTAPBPRWT (blue) or HeLaMKO (black line) cells, upon treatment with 10 nM 
ETVΔ2/9* for 15 min at 37°. HeLaMKO cells treated without peptide were chosen as a negative control 
(dashed grey line). This is a representative example of three independent experiments. Taken from 
Ilca et al. (Ilca et al., 2018b).  
 
 
3.2.4. TAPBPR present at the cell surface facilitates peptide loading onto MHC class I 
molecules  
To provide evidence that the pool of TAPBPR present at the cell surface, rather than its over-
expression, is responsible for loading the surface MHC class I molecules with exogenously-
added peptide, we generated two chimeric TAPBPR constructs that deliver TAPBPR to different 
subcellular compartments. Plasma membrane-targeted TAPBPR (TAPBPRPM) was achieved by 
fusing the luminal and transmembrane domains of TAPBPR with the cytosolic tail of CD8 
(Nilsson et al., 1989) (construct generated by Dr. Andreas Neerincx, University of Cambridge), 
while an ER-retained TAPBPR variant (TAPBPRER) (Li et al., 1997, Ortmann et al., 1997) was 
achieved by fusing the luminal domain of TAPBPR with the transmembrane and cytosolic 
domains of tapasin. Whereas TAPBPRER was not detected at the cell surface upon over-
expression, TAPBPRPM showed a high surface expression level (Figure 10a and 10b).  
When testing the ability of these TAPBPR chimeric proteins to promote peptide binding onto 
MHC class I molecules present at the cell surface, only cells expressing TAPBPRPM showed 
enhanced binding of the HLA-A*68:02-specific high-affinity peptides ETVSK*QSNV and 
YVVPFVAK*V (YVV*). Moreover, the level of peptide binding facilitated by TAPBPRPM compared 




variants (Figure 10c, 10d and 10e). Consistent with previous observations (Figure 9), there was 
no binding of the low-affinity peptide EGVSK*QSNG to any of the cell lines tested (Figure 10e). 
Together, these findings confirm that TAPBPR present at the cell surface, rather than its 
overexpression, promotes exogenous peptide loading onto cell surface MHC class I molecules, 
in a peptide affinity-based manner. 
 
Figure 10: TAPBPR present at the cell surface enhances exogenous peptide binding onto surface 
expressed MHC class I molecules. (a and b) Surface expression profiles of TAPBPR on IFNγ–treated (a) 
HeLaM cells, HeLaMKO or HeLaMKOTAPBPRWT cells or on (b) HeLaMKO, HeLaMKOTAPBPRPM or 
HeLaMKOTAPBPRER cells. (c and d) Histograms show the typical peptide binding level detected when 
the cell lines depicted in either panel a) or b) respectively were incubated with ETVSK*QSNV at 10 
nM, for 15 min at 37 °C. (e) Bar charts summarizing the level of fluorescent peptide bound when cells 
were incubated with 10 nM of EGVSK*QSNG (grey), ETVSK*QSNV (blue), or YVVPFVAK*V (yellow) for 
15 min at 37 °C. Bars show mean fluorescence intensity (MFI) ± SD from three independent 
experiments. n/s not significant, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 using unpaired two-




For general reference, throughout this thesis, peptides were classified as high-affinity for a 
specific MHC class I molecule simply based on their previously reported ability to stably bind to 
the MHC class I molecule and based the compatibility between their anchor residues and the 
MHC class I binding motif. Peptides were classified as low-affinity for a specific MHC class I 
molecule, based on the obvious lack of compatibility between their anchor residues and the 
MHC class I binding motif. No precise kinetic parameters were measured in this work for any 
peptide-MHC class I interactions. 
 
3.2.5. TAPBPR present on the plasma membrane associates with MHC class I molecules 
at the cell surface 
Given that TAPBPR promotes peptide loading of MHC class I molecules at the cell surface, I 
wanted to confirm the physical association between TAPBPR and MHC class I at this subcellular 
location. For this purpose, I performed an immuno-precipitation experiment in which I 
sequentially pulled down the fraction of TAPBPR present at the cell surface and then the 
intracellular pool of TAPBPR. The levels of MHC class I bound to the each individual TAPBPR 
fraction were measured by western blot (Figure 11).  
As expected, TAPBPRPM and TAPBPRWT were present in high amounts in the cell surface pull-
down fraction, while TAPBPRER showed negligible levels at the cell surface despite its high 
abundance in the intracellular fraction. The cell surface TAPBPR pools from both TAPBPRPM- 
and TAPBPRWT-expressing cells confirmed the association of TAPBPR with MHC class I at the 
plasma membrane (Figure 11). However, as opposed to the intracellular fraction of TAPBPRWT, 
the extracellular fraction of TAPBPRWT showed no association with its known binding partner 
UGT1 (Neerincx et al., 2017), which is an ER-resident enzyme, further verifying the lack of cross-
contamination between the cell surface and the intracellular pull-down fractions (Figure 11). 
Intracellularly, each of the three TAPBPR variants showed significant levels of MHC class I 
bound. However, only TAPBPRWT and TAPBPRER showed binding to UGT1, confirming the 
predicted sub-cellular localization of the TAPBRPWT and TAPBPRER, mainly in the ER, while 
TAPBPRPM was expected to be present primarily through the secretory pathway.   
Taken together, all these findings indicate the active involvement of TAPBPR in facilitating the 





Figure 11: Surface-expressed TAPBPR interacts with MHC class I molecules at the cell surface. 
Western blot analysis of immunoprecipitation experiments, where either the surface or the 
intracellular pool of TAPBPR was pulled down from IFNγ-stimulated HeLaMKO cells over-expressing 
TAPBPRWT, TAPBPRPM or TAPBPRER. Membranes were stained for TAPBPR, MHC class I (using HC10), or 
UGT1 on pull-down samples and lysate fractions as indicated. The data shown here is representative 
of three independent experiments. Taken from Ilca et al. (Ilca et al., 2018b). 
 
 
3.2.6.  Surface-expressed tapasin does not promote substantial peptide loading of 
MHC class I molecules 
Since tapasin is also a peptide editor on MHC class I molecules, I next tested whether tapasin is 
also capable of retaining its peptide editing function on MHC class I molecules, when delivered 
to the cell surface. To target tapasin to the cell surface, we generated another chimeric 
construct, fusing the luminal and transmembrane domains of tapasin to the cytosolic tail of 
CD8 (tapasinPM) (construct generated by Dr. Andreas Neerincx, University of Cambridge). As 
expected, upon over-expression, I only detected tapasinPM at the cell surface, whereas 
tapasinWT was not (Figure 12a).  
When I measured the ability of the two tapasin variants to modulate exogenous peptide 
binding to cell surface MHC class I molecules, while tapasinWT did not show a significant 




higher level of bound peptide compared to the parental HeLaM cell line (Figure 12b and 12c). 
However, this difference was >10-fold lower than the one recorded for TAPBPRPM (Figure 10d 
and 10e), indicating that TAPBPR is a much more efficient peptide loading catalyst than tapasin 
at the cell surface. In fact, we speculate that the slight increase in peptide loading observed 
upon over-expression of tapasinPM is more likely due to the export of peptide-receptive MHC 
class I molecules together with tapasinPM to the cell surface, or to the disruption of the peptide 
loading complex by this abundant plasma membrane-targeted tapasin variant, rather than 
tapasin directly catalysing peptide exchange.  
 
Figure 12: Over-expressed tapasin present at the cell surface does not mediate efficient peptide 
loading onto surface expressed MHC class I molecules. (a) Surface expression profiles of tapasin, 
detected using the mAb Pasta1, on IFNγ–treated (a) HeLaM cells or on HeLaM cells transduced with 
either tapasinWT or with tapasinPM. (b) Histograms showing the typical peptide binding level detected 
when the cell lines depicted in panel a) were incubated with 10 nM ETVSK*QSNV for 15 min at 37 °C. 
(c) Bar charts summarizing the level of fluorescent peptide bound when cells were incubated with 10 
nM of the low-affinity peptide EGVSK*QSNG (grey) or with either of the high-affinity peptides 
ETVSK*QSNV (blue) or YVVPFVAK*V (yellow) for 15 min at 37 °C. Bars show mean fluorescence 
intensity (MFI) ± SD from three independent experiments. n/s not significant, **P ≤ 0.01, ***P ≤ 




My results are consistent with the previous differences reported between TAPBPR and tapasin 
in modulating peptide exchange on recombinant MHC class I refolds, in which TAPBPR alone 
efficiently mediates peptide dissociation (Hermann et al., 2015b, Morozov et al., 2016). In 
contrast, tapasin requires artificial tethering to MHC class I or other co-factors in order to 
promote peptide exchange (Chen and Bouvier, 2007, Wearsch and Cresswell, 2007).  
 
3.2.7. TAPBPR functions as a peptide exchange catalyst on MHC class I molecules at 
the cell surface 
There are two conceivable mechanisms by which TAPBPR mediates peptide loading on cell 
surface MHC class I molecules: it could either drag peptide-receptive MHC class I molecules 
along with it through the secretory pathway to the cell surface or it could actively exchange the 
endogenous peptides presented on MHC class I for the exogenously-added ones.  
To address this question, I designed an assay to directly test whether TAPBPR was capable of 
actively mediating peptide dissociation from cell surface-expressed MHC class I molecules. First, 
cells were treated with 10 nM of fluorescently labelled peptide to prime the peptide-receptive 
MHC class I molecules present at the cell surface. Subsequently, the cells were washed 
thoroughly to remove any excess of unbound fluorescent peptide. Finally, I tested the ability of 
cells over-expressing TAPBPR to dissociate the bound fluorescent peptide in the presence of an 
excess of unlabelled competitor peptides with different affinities for HLA-A*68:02 (Figure 13a). 
The level of peptide dissociation was measured by the decrease in fluorescence levels of the 
cells, upon applying the unlabelled competitor. The treatment periods with both the 
fluorescent peptide and the non-fluorescent competitor were 15 min, in order to diminish 
peptide internalisation and to quantify binding and dissociation of the peptides strictly to cell 
surface MHC class I molecules. Using this technique, I observed a high dissociation of both 
ETVSK*QSNV (Figure 13c and 13e) and YVVPFVAK*V (Figure 13b and 13d), in the presence of 
high-affinity competitor peptides (either ETVSEQSNV or YVVPFVAKV), but not in the presence 





Figure 13: TAPBPR present at the cell surface actively mediates peptide exchange on surface-
expressed MHC class I molecules. (a) Schematic depiction of the experimental set-up used to 
measure peptide dissociation by plasma membrane-bound TAPBPR. (b-e) IFNγ–stimulated 
HeLaMKOTAPBPRWT cells were incubated with 10 nM of either (b and c) YVVPKVAK*V or (d and e) 
ETVSK*QSNV for 15 min at 37 °C, then washed thoroughly to remove unbound peptide. The 
dissociation level of the fluorescent peptides was subsequently measured in the presence or absence 
of increasing concentrations of the non-labelled competitor peptides YVVPFVAKV (YVV), ETVSEQSNV 
(ETV), or EGVSEQSNG (ETVΔ2/9), which were added to cells for 15 min at 37 °C. (b and d) Histograms 
showing the typical dissociation levels of the bound fluorescent peptide observed following 
incubation with 100 nM competitor peptide. (c and e) Line graphs showing the percentage of 
fluorescent peptide remaining on the cell surface ±SD following treatment with increasing 
concentrations of the non-labelled peptides from three independent experiments. Adapted from Ilca 





These results suggest that plasma membrane-expressed TAPBPR directly promotes peptide 
exchange on MHC class I molecules based on the affinity of the incoming peptide. Remarkably, 
within only 15 min of exposure to the non-labelled competitor, roughly 80% of both 
ETVSK*QSNV (Figure 13c and 13e) and YVVPFVAK*V (Figure 13b and 13d) dissociated from 
MHC class I in the presence of their respective non-labelled equivalents. This again highlights 
the high efficiency of TAPBPR-mediated peptide dissociation from cell surface-expressed MHC 
class I, especially given the relatively high-affinity of the dissociated fluorescent peptides.  
It is important to point out that although the binding of YVVPFVAK*V (Figure 13b) to cells over-
expressing TAPBPR appeared as a single sharp fluorescence peak, the binding of ETVSK*QSNV 
appeared bimodal in comparison (Figure 10b and 13d). We believed that this is due to the 
higher affinity of YVVPFVAK*V compared to ETVSK*QSNV, which allows it to reach saturation in 
its binding to the surface pool of MHC class I molecules even at such low concentrations and 
short exposure times as the one used in the experiment. To test this hypothesis, I assessed the 
binding patter of ETVSK*QSNV across the entire cell population over-expressing TAPBPR, when 
peptide was added for different time periods (Figure 14a) and at different concentrations 
(Figure 14b). As expected, once the peptide exposure was either increased over 60 min (Figure 
14a) or added at concentrations ≥100 nM (Figure 14b), the binding of ETVSK*QSNV was 
brought up to comparable levels and distribution as the binding of YVVPFVAK*V, added to cells 
at 10 nM for 15 min (Figure 13b). The higher affinity of YVVPFVAK*V compared to ETVSK*QSNV 
is also backed up by the higher dissociation rates of both fluorescent peptides used in the 
peptide exchange assays, in the presence of YVVPFVAKV than in the presence of ETVSEQSNV 







Figure 14: Peptide loading by over-expressed TAPBPR with varying peptide exposure. IFNγ–
stimulated HeLaMKOTAPBPRWT cells were treated with ETV* at 37°C, (a) at 10 nM for different time 
periods or (b) at different peptide concentrations for 15 min. Histograms are representative examples 
of three independent experiments. A cell sample treated without fluorescent peptide was included as 
a negative control (grey dashed line). Taken from Ilca et al. (Ilca et al., 2018b). 
 
To further confirm that the peptide exchange observed on cell surface MHC class I in the assay 
performed at physiological temperature occurs exclusively at the cell surface and that the 
fluorescent peptide is not exchange in endosomal compartments, I again performed the 
peptide exchange assay at 4°C, to block cellular trafficking (Breuer et al., 1995, Klausner et al., 
1983, Schmid and Carter, 1990) (Figure 15). Surprisingly, TAPBPR retains its ability to mediate 
peptide dissociation (Figure 15a and 15b) from MHC class I molecules at low temperatures, 





Figure 15: Cell surface TAPBPR mediates peptide exchange on surface-expressed MHC class I 
molecules even at 4°. (a and b) IFNγ–stimulated HeLaMKOTAPBPRWT cells were incubated with 1 μM 
ETVSK*QSNV for 60 min at 4°C, then washed thoroughly to remove unbound peptide. The 
dissociation of ETVSK*QSNV was subsequently measured in the presence of the non-labelled 
competitor peptides ETVSEQSNV (ETV) or EGVSEQSNG (ETVΔ2/9). (a) Histograms showing the typical 
dissociation levels of ETVSK*QSNV observed following incubation with 1 μM competitor peptides. (b) 
Line graphs showing the percentage of ETVSK*QSNV remaining on the cell surface ±SD following 
treatment with increasing concentrations of the non-labelled peptide ETVSEQSNV, added for either 
15 min (light blue) or 60 min (dark blue), from three independent experiments. Taken from Ilca et al. 
(Ilca et al., 2018b). 
 
When comparing the efficiencies of TAPBPR-mediated peptide dissociation between my cellular 
system here and the already established soluble system (Hermann et al., 2015b), where the 
luminal domain of TAPBPR alone was shown to enhance peptide dissociation from HLA-A*02:01 
refolds, the difference is striking; in the soluble system, the dissociation reaction does not reach 
equilibrium even after 6 h (Hermann et al., 2015b), whereas in my cellular system, more than 
80% of the peptide is dissociated after only 15 min of applying an excess of unlabelled peptide. 
This suggest that TAPBPR-mediated peptide dissociation is occurring at a much higher rate on a 
cellular membrane compared to in solution. Moreover, it is important to consider that, in 




occurring conformations, namely membrane-bound and comprising their corresponding post-
translational modifications.   
 
3.2.8. Soluble TAPBPR binds to cell surface HLA-A*68:02 class I molecules 
Given that I have shown that full-length TAPBPR delivered to the cell surface is capable of 
actively promoting peptide dissociation from MHC class I molecules, I asked whether the 
luminal domain of TAPBPR alone (soluble TAPBPR), added exogenously to cells, could also 
function as a peptide exchange catalyst on MHC class I molecules. This assay would thus serve 
as an additional system to test TAPBPR-mediated peptide exchange on MHC class I molecules. 
Unlike over-expressing full-length TAPBPR, which clearly altered the surface pool of MHC class I 
molecules (Figure 5d and Figure 7), adding soluble TAPBPR exogenously onto the cell surface 
allowed me to assess the peptide exchange ability of TAPBPR onto a pool of MHC class I 
molecules present at steady state, presenting a naturally-occurring peptide repertoire.  
I thus expressed soluble TAPBPRWT containing a C-terminal polyHis tag in 293T cells, using the 
Piggy-Bac inducible expression system set up in the lab by Dr. Andreas Neerincx (University of 
Cambridge), and purified it by Ni-NTA affinity chromatography. Using this system, soluble 
TAPBPR protein was obtained in high yields (7-10 mg/L of media) and at relatively high purity, 
which was assessed by SDS-PAGE followed by coomassie staining (Figure 16a).  
Upon incubating HeLaM cells with 100 nM soluble TAPBPRWT for only 15 min, I detected high 
levels of TAPBPRWT bound to the cell surface. This binding was dependent on the ability of 
TAPBPR to associate with MHC class I molecules present at the cell surface, as the TN5 TAPBPR 
mutant (TAPBPRTN5), which cannot bind to MHC class I (Hermann et al., 2013), was not 
detected bound to HeLaM cells (Figure 16b). Moreover, TAPBPR did not show any binding to 
HeLaM-HLA-ABCKO cells (Figure 16b), which are deficient of MHC class I, however the binding 
was restored once HeLaM-HLA-ABCKO cells were reconstituted with HLA-A*68:02 (Figure 16c). 
These findings confirmed that soluble TAPBPR was exclusively binding to MHC class I molecules 





Figure 16: Soluble TAPBPR associates with MHC class I molecules present at the cell surface.  
(a) Expression and purity of the luminal domain of TAPBPRWT (soluble TAPBPR), assessed by 
coomassie staining of an SDS/PAGE, after the protein was purified from the culture supernatant using 
Ni-NTA affinity chromatography. E1-E4 represent the elution fractions collected. (b) Histograms 
showing the binding of the soluble versions of either TAPBPRWT to either HeLaM (blue line) or HeLa-
HLA-ABCKO (dashed blue line) cells or of TAPBPRTN5 to HeLaM cells (red line), when TAPBPR was added 
at 100 nM for 30 min at 37°. (c) Histograms showing the binding of either soluble TAPBPRWT (blue) or 
soluble TAPBPRTN5 (red) to HeLa-HLA-ABCKO cells reconstituted with HLA-A*68:02. Cells treated with 
no TAPBPR were chosen as a negative control (black line). These are representative examples of three 
independent experiments. Taken from Ilca et al. (Ilca et al., 2018b).   
 
 
3.2.9. Soluble TAPBPR facilitates peptide exchange onto surface-expressed               
HLA-A*68:02 
I next explored the capacity of soluble TAPBPR to facilitate peptide exchange on cell surface 
MHC class I molecules, by testing its ability to replace endogenously-presented peptides on 
MHC class I molecules with exogenously-added fluorescently labelled peptides (Figure 17). To 
this end, cells were first incubated with 100 nM TAPBPR alone for 15 min, followed by 
incubation with varying concentrations of fluorescent peptides with different affinities for 
another 15 min. The amount of bound fluorescent peptide was measured by flow cytometry, in 




that soluble TAPBPR promoted the loading of both high-affinity peptides ETVSK*QSNV and 
YVVPFVAK*V, but not of the low-affinity peptide EGVSK*QSNG to both HeLaM cells (Figure 17b 
and 17c) and to HeLaM-HLA-ABCKO cells reconstituted with HLA-A*68:02 (Figure 17d). 
Negligible peptide binding was observed to HeLaM-HLA-ABCKO cells in the presence of 
TAPBPRWT (Figure 17e) or to HeLaM cells in the presence of TAPBPRTN5 (Figure 17b, 17c and 
17e), indicating that the peptide binding was occurring in an MHC class I-dependent manner. 
Remarkably, presence of soluble TAPBPR allowed for a high level of exogenous peptide binding 
at extremely low peptide concentrations, requiring ~1000-fold less peptide than in the absence 
of TAPBPR to achieve similar levels of loaded peptide (Figure 17e). These results demonstrate 
that the luminal domain of TAPBPR alone is capable of catalysing peptide exchange on HLA-







Figure 17: Soluble TAPBPR added exogenously enhances exogenous peptide association onto 
surface-expressed MHC class I molecules. (a) Schematic representation of the experimental set-up 
used to assess peptide exchange on surface-expressed MHC class I by soluble TAPBPR. IFNγ–treated 
(b and c) HeLaM or (d)  HeLaM-HLA-ABCKO cells reconstituted with HLA-A*68:02 were incubated with 
or without 100 nM soluble TAPBPRWT or TAPBPRTN5 for 15 min at 37 °C, followed by incubation with or 
without 10 nM of ETVSK*QSNV (ETV*), YVVPFVAK*V (YVV*), or EGVSK*QSNG (ETVΔ2/9) for 15 min at 
37°C. (b) Histograms showing the typical binding levels of ETVSK*QSNV or YVVPFVAK*V to the cell 
surface. (c) Bars graphs showing the MFI of fluorescent peptide binding ±SD from three independent 
experiments. (e) Dose–response curves exhibiting ETVSK*QSNV binding to IFNγ-treated HeLaM and 
HeLaM-HLA-ABCKO cells, treated with or without 100 nM of either soluble TAPBPRWT or soluble 
TAPBPRTN5 and with increasing concentrations of peptide, for 15 min at 37 °C ±SD, from three 








3.2.10. Soluble TAPBPR dissociates from HLA-A*68:02 upon loading high-affinity 
peptides 
Binding of TAPBPR and peptides to recombinant MHC class I refolds was shown to occur in a 
competitive manner, as loading of high-affinity peptides onto MHC class I molecules was shown 
to lead to the dissociation of soluble TAPBPR (Hermann et al., 2015b, Morozov et al., 2016). I 
was thus interested to test whether upon facilitating the loading of exogenously-added high-
affinity peptides onto cell surface MHC class I molecules, TAPBPR would dissociate from MHC 
class I. To this end, I measured the level of soluble TAPBPR bound to the surface of HeLaM cells, 
upon treatment with or without peptide. The results showed that, indeed, binding of 
ETVSK*QSNV and YVVPFVAK*V, but not of the low-affinity peptide EGVSK*QSNG, triggered 
significant dissociation of soluble TAPBPR from cell surface MHC class I molecules on HeLaM 
cells (Figure 18a). The same results were obtained when running these experiments on HeLaM-
HLA-ABCKO cells reconstituted with HLA-A*68:02 (Figure 18a). Treatment with YVVPFVAK*V 
triggered a higher dissociation level of soluble TAPBPR from cell surface MHC class I than 
treatment with ETVSK*QSNV, which was consistent with the relative abilities of the two 
peptides to bind to HLA-A*68:02 (Figure 18a). Moreover, increasing concentrations of the high 
affinity peptides ETVSK*QSNV and YVVPFVAK*V, but not of the low-affinity peptide 
EGVSK*QSNG, led to an increasing level of TAPBPR dissociation from the cell surface (Figure 
18b and 18c). Together, this data clearly supports the competitive binding model between 
TAPBPR and peptide to MHC class I. In other words, soluble TAPBPR dissociates endogenously-
presented peptides from cell surface MHC class I molecules, consequently attaching to MHC 
class I, however it detaches from MHC class I once the bound MHC class I molecule acquires a 





Figure 18: Soluble TAPBPR dissociates from surface-expressed MHC class I molecules upon binding 
of high-affinity peptides. IFNγ-stimulated HeLaM cells and HeLaM-HLA-ABCKO cells reconstituted with 
HLA-A*68:02 (HeLa-A*68:02) were incubated with or without 100 nM soluble TAPBPRWT for 15 min at 
37°C, followed by incubation with or without different concentrations of EGVSK*QSNG, ETVSK*QSNV 
or YVVPFVAK*V for 15 min at 37°C. Subsequently, the amount of TAPBPR remaining on the cell 
surface was detected by staining with the TAPBPR specific mAb PeTe4. (a) Histograms showing 
TAPBPR binding to either HeLaM cells (left) or HeLa-A*68:02 cells (right), in the presence or absence 
of 10 nM EGVSK*QSNG, ETVSK*QSNV or YVVPFVAK*V. (b) Histograms showing TAPBPR binding to 
HeLa-A*68:02 cells in the presence of increasing concentrations of either ETVSK*QSNV (top) or 
EGVSK*QSNG (bottom). (c) Line graphs showing the remaining percentage of TAPBPR bound to the 
cell surface in the presence of increasing concentrations of EGVSK*QSNG, ETVSK*QSNV or 








3.2.11. Soluble TAPBPR mediates peptide exchange on MHC class I molecules in a 
peptide affinity-based manner 
To assess whether the observed enhancement in peptide loading by TAPBPR was restricted to 
HLA-A*68:02 or whether TAPBPR can function as a peptide exchange catalyst on other human 
MHC class I molecules, I extended my analysis by exploring the ability of TAPBPR to load various 
peptides onto HLA-A*02:01 (Figure 19). To this end, I reconstituted HeLaM-HLA-ABCKO cells 
with HLA-A*02:01 and performed a similar peptide binding experiment as the one described 
above, this time however using HLA-A*02:01-specific peptides. Satisfyingly, TAPBPR was 
capable of efficiently loading peptides on HLA-A*02:01 as well (Figure 19a and 19b). However, 
it proved to function considerably less efficiently on HLA-A*02:01 compared to HLA-A*68:02, 
requiring a 10-fold higher TAPBPR concentration in order to provide a comparable level of 
peptide loading. As expected, TAPBPR only facilitated the loading of peptide reported to bind 
to HLA-A*02:01 onto HeLaM-HLA-ABCKO cells over-expressing HLA-A*02:01, namely 
NLVPK*VATV (HCMV-derived), YVVPFVAK*V (self-peptide) and YLLEK*LWRL (EBV-derived) 
(Figure 19a and 19b). Correspondingly, TAPBPR was not able to load peptides specific for other 
HLA class I allotypes, namely for HLA-A*68:02 (ETVSK*QSNV) or HLA-B*27:05 (SRYWK*IRTR), 
onto HLA-A*02:01. Surprisingly however, the loading of the other EBV-derived peptide tested, 
CLGGK*LTMV, specific for HLA-A*02:01, was not significantly enhanced in the presence of 
soluble TAPBPR (Figure 19a and 19b). This could be a result of the potentially lower affinity of 
this peptide for HLA-A*02:01, compared to the other peptide tested, which would not allow it 
to outcompete the bound soluble TAPBPR from the resulted peptide-receptive HLA-A*02:01 
molecules. Taken together, these results show that TAPBPR can function as a peptide exchange 
catalyst on different MHC class I molecules at the cell surface, based on the affinity of the 





Figure 19: Soluble TAPBPR facilitates efficient peptide loading onto surface-expressed HLA-A*02:01 
molecules, in an affinity-based manner. (a) Histograms showing the binding levels of different 
fluorescent peptides to IFNγ–treated HeLaM-HLA-ABCKO cells reconstituted with HLA-A*02:01 (HeLa-
A2), in the presence or absence of either soluble TAPBPRWT or TAPBPRTN5. Cells were incubated with 
or without 1 µM soluble TAPBPRWT or TAPBPRTN5 for 15 min, followed by treatment with 10 nM of 
NLVPK*VATV (NLV*), YVVPFVAK*V (YVV*), YLLEK*LWRL (YLL*), CLGGK*LTMV (CLG*), ETVSK*QSNV 
(ETV*) or SRYWK*IRTR (SRY*) for 60 min. (b) Bar graphs show the MFI of fluorescent peptide binding 
to HeLaM-A2 cells from two independent experiments with duplicates. ***P ≤ 0.001, ****P ≤ 0.0001, 








3.3. Discussion  
 
Although TAPBPR naturally functions as an intracellular peptide exchange catalyst on MHC class 
I molecules, I have demonstrated that, when artificially given access to the MHC class I 
molecules present strictly at the cell surface, TAPBPR retains its ability to mediate peptide 
exchange. Moreover, both the soluble and the full-length versions of TAPBPR were capable of 
efficiently catalysing peptide exchange on surface-expressed MHC class I molecules. I have 
therefore developed two novel assays to assess TAPBPR-mediated peptide exchange on MHC 
class I molecules in a cellular system, which complements the previously established technique 
using soluble MHC class I refolds (Hermann et al., 2015b, Morozov et al., 2016). I show that 
human TAPBPR promotes peptide exchange on different MHC class I molecule and that the 
efficiency of TAPBPR-mediated peptide exchange is dependent on the MHC class I allotype and 
on the affinity of the incoming peptide for the corresponding MHC class I molecule.  
However, there were a few challenges encountered throughout the development of these 
assays, mostly due to active trafficking at the plasma membrane. Most notably, the continuous 
export of new pMHC class I molecules made it difficult to perform kinetic measurements of 
TAPBPR-mediated peptide dissociation at physiological temperature. Moreover, due to the 
significant level of peptide internalization, either via MHC class I or by pinocytosis (Figure 7), 
low peptide exposures were used to best highlight the level of TAPBPR-mediated peptide 
exchange on MHC class I molecules occurring strictly at the cell surface (Figures 10, 17 and 19). 
To cease cellular trafficking, I performed the same assays on cells incubated at 4°C and still 
observed a high enhancement in peptide binding on cell surface MHC class I by TAPBPR (Figure 
8). However, the magnitude of the effect of TAPBPR on peptide editing at 4°C was significantly 
reduced compared to the one recorded at physiological temperatures, most likely due to the 
reduced protein dynamics at lower temperatures. To inhibit cellular trafficking at physiological 
temperatures, one would need to treat the cells with a mixture of inhibitors, to block both 
cellular export (e.g. brefeldin A)(Fujiwara et al., 1988) and import (e.g. dynasore)(Macia et al., 
2006), which I have not attempted in my peptide exchange assays due to the high likelihood of 
this causing high toxicity levels to the cells.       
Nonetheless, despite these mild shortcomings, these novel cell-based peptide exchange assays, 
specific for TAPBPR, offer a number of advantages over the previously established cell-free 




(Hermann et al., 2015b, Morozov et al., 2016). First, in contrast to the cell-free system, my 
assays test the interactions between TAPBPR and MHC class I molecules in their naturally-
occurring transmembrane conformations, either for both TAPBPR and MHC class I, or for MHC 
class I alone, thus taking into account the restrictions imposed on the proteins by a cellular 
membrane. Second, in contrast to the bacterial MHC class I refolds, which are refolded using 
individual peptides of choice, MHC class I molecules present at the cell surface are loaded with 
a pool of different peptides, spanning a relatively wide affinity spectrum, creating less bias and 
broader range of ligands for TAPBPR. I believe that this is the main reason why the cellular 
assays show a much higher efficiency of TAPBPR-mediated peptide exchange compared to the 
cell-free assay, with the exchange reaction saturating within minutes at the cell surface, which 
is many-fold quicker than the one observed in solution.  
Given the higher sensitivity of the cellular system over the cell-free one for assessing TAPBPR-
mediated peptide exchange on MHC class I molecules, as well as its consistent results across 
different MHC class I molecules, I decided to use these assays as functional read-out for 
investigating the catalytic mechanism of peptide exchange by TAPBPR.  




4. Chapter 4: Characterising the involvement of the K22-D35 loop of 





Prior to the recent publications of the crystal structure of TAPBPR in complex with MHC class I, 
previous members of the Boyle lab, in collaboration with Dr. Janet Deane (CIMR, University of 
Cambridge), docked the structure of TAPBPR, obtained via homology modelling based on the 
known tapasin structure (PDB ID 3F8U)(Dong et al., 2009) and on mutagenesis data which 
revealed critical regions for the TAPBPR-MHC class I interaction (Hermann et al., 2013), onto 
the structure of HLA-A*02:01 (PDB ID 3HLA) (Figure 20a). This docking model revealed a region 
of TAPBPR, stretching from residues 22 to 35, to be in close vicinity to the peptide binding 
groove of MHC class I, more specifically near the F pocket of the groove (Figure 20b). This 
region contains a loop, which appears to be different from the homologous loop of tapasin. The 
tapasin loop is significantly shorter and was not captured in the crystal structure (Figure 
20b)(Dong et al., 2009).  
 
Figure 20: Predicted interaction of the TAPBPR loop with the peptide binding groove of MHC class I. 
(a) Docking model of TAPBPR (pink) onto HLA-A*02:01 (heavy chain in blue and β2m in cyan) (PDB ID 
3HLA), based on interaction studies. (b) Top panel, depiction of the predicted proximity of the K22-
D35 loop of TAPBPR to the peptide binding groove, based on the positions of residues K22 and D35 
(viewed from the top of complex shown in panel a); lower panel, schematic representations of the 
amino acid sequences of the TAPBPR loop and of the homologous loop of tapasin (PDB ID 3F8U), 




The two recently published crystal structures of TAPBPR in complex with MHC class I molecules 
(Jiang et al., 2017, Thomas and Tampe, 2017) support our model, showing a similar orientation 
of TAPBPR onto MHC class I (Figure 21a). Moreover, the structure from Thomas and Tampe 
confirms the localization of the TAPBPR loop in the proximity of the MHC class I F pocket 
(Thomas and Tampe, 2017). However, the positioning and orientation of the loop in the two 
structures is poorly described. In the structure by Jiang et al, the loop was not sufficiently well 
ordered and is thus missing from the resolved crystal structure. The loop does appear in the 
structure by Thomas and Tampe, however it was poorly modelled, with multiple atoms, not 
only of the side chains but also belonging to the backbone of the loop, falling outside of the 
electron density of the structure (Figure 21b). This indicates that multiple conformations of the 
loop are possible and casts doubt on the presence of the unconventional short helix in the 
middle of the loop, as described in the structure.  
 
Figure 21: The loop of TAPBPR was poorly modelled in the crystal structure of TAPBPR:MHC class I 
complex. (a) Overlay of two recent X-ray structures of TAPBPR in complex with MHC class I (PDB ID 
5WER and 5OPI) coloured similarity to our TAPBPR:MHC class I docking model (Figure 20, panel a). 
The position of the TAPBPR loop is circled (black dashed line). (b) The electron density map (2Fo-Fc, 
green mesh) and the resolved model (brown sticks, residues D23-E34) of the TAPBPR loop (PDB ID 
5OPI). The two views of the loop and electron density shown are rotated by 90 degrees. Taken from 
Ilca et al. (Ilca et al., 2018a). 
 
Although the two crystal structures clearly highlight the conformational changes undergone by 
MHC class I molecules, upon binding to TAPBPR, which offer insight into how TAPBPR could 
potentially mediate the dissociation of peptides from MHC class I, they only show the starting 




behind TAPBPR-mediated peptide dissociation from MHC class I and whether this loop of 
TAPBPR indeed serves a catalytic function.  
Using my novel cellular peptide exchange assays specific for TAPBPR (Chapter 3), I could now 
attempt to design and screen TAPBPR loop mutants for their ability to edit peptides on cell 





4.2.1.  Designing and expressing TAPBPR loop mutants  
First, to test whether the presence of the loop was important for the peptide exchange 
function of TAPBPR, I designed a mutant in which I replaced all 14 residues of the loop with 
either glycine, alanine and serine residues, in order to generate a potentially functionless loop 
mutant (Øloop) (Table 5). Second, based on the work by Springer and colleagues, who showed 
that dipeptides, specifically carrying long hydrophobic residues on position 2, are able to bind 
into the F pocket of the MHC class I peptide binding groove (Saini et al., 2013, Saini et al., 
2015), I decided to target the leucine residue on position 30 of TAPBPR, the only long 
hydrophobic residue of the loop. I thus generated two additional TAPBPR mutants, one by 
replacing the L30 residue alone with a glycine (L30G) and the other by reconstituting the L30 
residue alone onto the empty loop mentioned above (ØG30L) (Table 5). This would inform on 
whether L30 is either necessary and/or sufficient for the ability of TAPBPR to mediate peptide 
dissociation from MHC class I. 
 
Table 5: Panel of TAPBPR loop mutants generated on both full-length and soluble TAPBPR 









I first tested whether the changes made to the loop affected the overall stability or 
conformation of TAPBPR. Upon over-expression in HeLaMKO cells, all three full-length TAPBPR 
mutants showed similar expression levels as TAPBPRWT (Figure 22). Moreover, the levels of 
MHC class I and UGT1 pulled down on each TAPBPR variant via immunoprecipitation were very 
similar to one another, suggesting that mutating the loop did not alter the stability of TAPBPR 
or its ability to interact with its known binding partners (Figure 22).  
 
Figure 22: Mutation of the loop does not alter expression levels of TAPBPR, nor its ability to 
interact with MHC class I and UGT1. TAPBPR loop variants listed in Table 5, over-expressed in 
HeLaMKO cells, were immunoprecipitated, using the TAPBPR-specific mAb PeTe-4, from the 
corresponding whole cell lysates. Western blot analysis was done on the pull-down samples to 
measure relative levels of MHC class I and UGT1 bound. The lysates were also stained for TAPBPR to 
highlight the relative expression levels of the loop mutants. The lysates were blotted for calnexin, as a 
loading control. This is a representative example of three independent experiments. Taken from Ilca 













4.2.2.  The K22-D35 loop of TAPBPR is an essential region for mediating peptide 
dissociation from HLA-A*68:02 
I next tested the ability of the TAPBPR loop mutants to mediate peptide exchange on MHC class 
I molecules, using the novel cellular peptide exchange assays which I developed. First, I 
assessed whether the over-expressed loop mutants, present at the cell surface, facilitate 
peptide dissociation from MHC class I molecules, using an identical experimental set-up as the 
one previously described in Figure 15.  
Upon treating the cell lines over-expressing each TAPBPR variant with the fluorescent peptide 
YVVPFVAK*V that has high affinity for HLA-A*68:02, surprisingly, all TAPBPR variants showed a 
similar increase in peptide loading onto the cell surface (Figure 23a). As previously mentioned, 
this could have been a result of the high number of peptide-receptive MHC class I molecules 
brought along to the cell surface by TAPBPR through the secretory pathway. However, when I 
then tested the ability of the TAPBPR loop variants to actively dissociate the fluorescent 
peptide from HLA-A*68:02 in the presence of an excess of the equivalent non-labelled 
competitor peptide YVVPFVAKV (Figure 23b), in contrast to the efficient peptide dissociation 
(associated with the decrease in fluorescence of the cells) observed with TAPBPRWT, 
TAPBPRØloop-expressing cells showed very little dissociation of the fluorescent peptide (Figure 
23c, 23d and 23e). These results indicate that the K22-D35 loop is indeed essential for the 





Figure 23: The K22-D35 loop of TAPBPR is essential for mediating peptide dissociation. 
(a) Histograms showing typical peptide binding to the surface of IFNγ-treated cells over-expressing 
each of the TAPBPR loop variants, after cells were incubated with 10 nM YVVPFVAK*V peptide for 15 
min at 37°C. (b) Schematic depiction of the experimental set-up used to compare the efficiency of 
peptide dissociation activity by plasma membrane-bound TAPBPRWT with the plasma membrane-
bound TAPBPR loop mutants. (c) Histograms depicting the level of dissociation of YVVPFVAK*V (YVV*) 
in the absence (blue line) and presence of 100 nM non-labelled competitor peptide YVVPFVAKV 
(YVV)(orange line) or EGVSKQSNG (ETVΔ2/9) (black line). (d-e) Graphs show the percentage of 
fluorescent peptide YVVPFVAK*V (YVV*) remaining, after the addition of (d) 100 nM or (e) increasing 
concentrations of the non-labelled competitor peptide YVVPFVAKV, as a percentage of the bound 
level of YVVPFVAK*V observed in the absence of a competitor peptide. Error bars show -
/+SD.****p≤0.0001, ***p≤0.001 using unpaired two-tailed t-tests, based on four independent 








4.2.3. L30 is a crucial residue for the peptide exchange function of TAPBPR on          
HLA-A*68:02 
Next, to assess the involvement of the L30 residue of the loop in the peptide exchange function 
of TAPBPR, I used the same assay to test the ability of TAPBPRL30G and TAPBPRØG30L to mediate 
peptide dissociation from surface-expressed HLA-A*68:02 molecules. As observed above with 
TAPBPRWT and with TAPBPRØloop, both TAPBPRL30G and TAPBPRØG30L were shown to facilitate 
loading of exogenously-added peptides onto cell surface HLA-A*68:02 (Figure 23a). However, 
TAPBPRL30G was completely incapable of dissociating the bound fluorescent peptide, even in 
the presence of 1 μM unlabelled competitor peptide (Figure 23c, 23d and 23e). Strikingly, 
mutating L30 residue alone led to the same impairment in the ability of TAPBPR to dissociate 
peptide, as mutating the entire loop. Moreover, the crucial role of the L30 residue in peptide 
exchange was confirmed by the fact that TAPBPRØG30L, on which residue L30 alone was 
reconstituted on a fully dysfunctional loop, was restored to a functional peptide exchange 
catalyst on HLA-A*68:02, albeit with a reduced efficiency compared to TAPBPRWT (Figure 23c, 
23d and 23e). More exactly, the presence of TAPBPRWT at the cell surface led to a dissociation 
level of about 75% of the fluorescent peptide form the cell surface, in the presence of 100 nM 
unlabelled competitor, while in the presence of TAPBPRØG30L, about 55% of the fluorescent 
peptide was dissociated. For the same concentration of unlabelled competitor used, the 
dysfunctional TAPBPR loop mutants, TAPBPRØloop and TAPBPRL30G, both showed very slight 
dissociation levels of florescent peptide, which could be attributed to TAPBPR-independent 
exchange of the labelled peptide by the non-labelled peptide, which was added in high excess 
(Figure 23d and 23e). To further highlight the impact of the loop and of the L30 residue on the 
peptide exchange function of TAPBPR, while TAPBPRWT and TAPBPRØG30L promoted rapid and 
highly efficient peptide dissociation even at competitor concentrations as low as 10 nM, 
TAPBPRØloop and TAPBPRL30G were extremely inefficient at exchanging the fluorescent peptide 
for the non-labelled peptide, even when 1 μM of competitor peptide was used (Figure 23e). 
Taken together, these results clearly indicate that residue L30 of the TAPBPR loop is both 







4.2.4. Mutation of L30 residue severely impairs the peptide exchange ability of soluble 
TAPBPR on HLA-A*68:02 
Having shown that soluble TAPBPRWT is capable of promoting efficient peptide exchange on a 
cell surface MHC class I molecules (Chapter 3), I used soluble TAPBPR loop mutants as a second 
mean to assess the importance of the loop for peptide exchange. In contrast to over-expression 
of TAPBPR, which appears to be dragging peptide-receptive MHC class I molecules along with it 
to the cell surface through the secretory pathway, the use of soluble TAPBPR allows us to 
overcome this problem, by simply adding TAPBPR exogenously to non-modified cell lines. This 
way, TAPBPR will only have access to cell surface MHC class I molecules folded with peptides of 
relatively high affinities.  
The soluble versions of the TAPBPR loop mutants were produced by cloning the luminal 
domains of TAPBPR mutants upstream of a polyHis tag, expressing the proteins in a HEK 293T 
cells and finally purifying them from tissue culture supernatant by Ni-NTA affinity 
chromatography. All mutants showed high purity levels, as assessed by coomassie staining 
(Figure 24a). Differential scanning fluorimetry revealed that all TAPBPR loop variants had a 
highly similar melting temperature, of approximately 55°C, suggesting that mutations made to 
the loop had not altered the overall stability of TAPBPR (Figure 24b).  
 
Figure 24: The soluble versions of the TAPBPR loop variants show equivalent thermostability to 
TAPBPRWT. (a) Relative expression and purity levels of soluble variants of WT, L30G, ØG30L, and 
Øloop TAPBPR, after their purification from the culture supernatant using Ni-NTA affinity 
chromatography. (b) Differential scanning fluorimetry showing that the three TAPBPR loop mutants 
have equivalent melting points and thermal denaturation profiles as TAPBPRWT. These graphs are 
representative examples of two independent experiments, ran with triplicate samples each. Taken 






Remarkably, when assessing the ability of the TAPBPR loop mutants to mediate peptide 
exchange on HLA-A*68:02 expressed on HeLaM cells, the results using the soluble proteins 
were highly consistent with the results obtained using the over-expressed the full-length 
TAPBPR mutants (Figure 25). Namely, when measuring the loading of ETVSK*QSNV onto the 
surface of HeLaM cells, TAPBPRWT was the most efficient peptide exchange catalyst, followed 
by TAPBPRØG30L, which exhibited ~33% of the peptide exchange activity observed for TAPBPRWT 
(Figure 25a and 25b). Again, both TAPBPRØloop and TAPBPRL30G were highly inefficient at 
catalysing peptide exchange on HLA-A*68:02, both showing only ~3% of the catalytic activity of 
TAPBPRWT. The same hierarchy in the peptide exchange ability across the TAPBPR loop variants 
(WT>ØG30L>L30G>TN5) was maintained over a wide range of TAPBPR concentrations (Figure 













Figure 25: Soluble TAPBPR loop mutants exhibit severe impairment in their ability to mediate 
peptide exchange on surface-expressed HLA-A*68:02 molecules. (a) Histograms showing the typical 
fluorescent peptide binding levels to IFNγ-treated HeLaM cells incubated with or without 100 nM of 
each exogenously-added soluble TAPBPR variant for 15 min at 37°C, followed by treatment with 10 
nM of either ETVSK*QSNV (left) or YVVPFVAK*V (right) for an additional 15 min. Soluble TAPBPRTN5, a 
TAPBPR variant which cannot bind to MHC class I (Hermann et al., 2013), is included as a negative 
control. (b) Bar graphs summarising the results in panel a). (c) Dose-response curves of ETVSK*QSNV 
binding to IFNγ-treated HeLaM cells, upon incubation with increasing concentrations of each soluble 
TAPBPR variant prior to the addition of 10 nM ETVSK*QSNV. Error bars represent MFI -/+SD from four 
independent experiments. ****p≤0.0001 using unpaired two-tailed t-tests. Taken from Ilca et al. (Ilca 
et al., 2018a). 
 
 
4.2.5. L30 residue is essential for the stable association of soluble TAPBPR with 
peptide-loaded MHC class I molecules 
I have thus far shown that stable association of soluble TAPBPR with surface-expressed MHC 
class I molecules leads to a high level of peptide dissociation from MHC class I. In turn, TAPBPR 
dissociates from surface-expressed MHC class I molecules upon loading exogenously-added 
high-affinity peptides (Figure 20). These observations confirmed the previous studies which 
suggested that binding of TAPBPR and peptides to MHC class I occurs in a competitive manner 
(McShan et al., 2018, Morozov et al., 2016). Thus, I hypothesized that TAPBPR can only bind 




peptides presented on then. To test this hypothesis, I measured the ability of the loop mutants 
to bind to HeLaM-HLA-ABCKO cells reconstituted with HLA-A*68:02 (Figure 26). Satisfyingly, 
upon incubating the cells with 100 nM of each TAPBPR loop variants, the TAPBPR binding 
hierarchy was the same as that observed for peptide exchange ability 
(WT>ØG30L>L30G/Øloop>TN5) (Figure 26a). This result suggests that, indeed, TAPBPR with an 
impaired ability to mediate peptide exchange cannot access MHC class I molecules loaded with 
peptides of relatively high affinity, such as the ones expressed on the surface of cells.   
As I had previously shown that the full-length TAPBPR loop mutants were capable of associating 
with MHC class I molecules intracellularly upon over-expression (Figure 22), I tested the ability 
of the soluble versions of the loop mutants to associate with the total pool of MHC class I 
molecules from cell lysates, by immunoprecipitation experiments (Figure 26b). In contrast to 
their ability to bind to MHC class I molecules present exclusively at the cell surface, all soluble 
loop mutants were shown capable of binding to MHC class I from the whole-cell lysates of 
HeLaMKO cells (Figure 26b). This confirmed that mutating the loop of soluble TAPBPR did not 
impair its intrinsic ability to associate with MHC class I, but only impacted its peptide editing 
function. Nonetheless, there were slightly lower amounts of MHC class I pulled down on 
TAPBPRØloop and TAPBPRL30G, compared to TAPBPRWT. A major difference between the cell 
surface pool and the total cellular pool of MHC class I is the intracellular availability of peptide-
receptive conformations. Based on my results, I speculated that TAPBPR variants with an 
impaired ability to edit peptides are still capable of binding to peptide-receptive MHC class I 
molecules, however, in contrast to functional TAPBPR molecules, they cannot access peptide-
loaded MHC class I, due to their inability to dissociate the peptide. This is consistent with 
previous findings according to which binding of TAPBPR and peptide to MHC class I occurs in a 
mutually exclusive manner (Hermann et al., 2015b, McShan et al., 2018, Morozov et al., 2016).  
To further support this hypothesis, I tested the relative ability of the TAPBPR loop mutants to 
bind to cell surface MHC class I molecules, following pre-incubation of HeLaM cells at 26°C, a 
condition which increases the expression of peptide-receptive MHC class I molecules at the cell 
surface (Ljunggren and Karre, 1990, Schumacher et al., 1990). All TAPBPR loop mutants, but not 
TAPBPRWT, showed a considerably increased binding to surface MHC class I at 26°C compared 
to at 37°C (Figure 26c and 26d). In fact, the defective TAPBPR mutants, TAPBPRØloop and 
TAPBPRL30G, showed the highest increase in binding to surface MHC class I, of ~7-fold. 




was not significantly changed (Figure 26d). Consistent with this result was the corresponding 
increase in ability of the loop mutants to promote loading of the high affinity peptide 
ETVSK*QSNV at 26°C compared to 37°C (Figure 26e and 26f).  
Moreover, incubation of cells cultured at 26°C with YVVPFVAK*V, to prime the MHC class I 
molecules with high affinity peptide prior to testing TAPBPR binding (Figure 27a), resulted in a 
strong reduction in the binding of TAPBPRØloop to the cell surface, while the binding of 
TAPBPRWT was unaffected (Figure 27b and 27c). This provides further confirmation that the 
observed association of TAPBPR with cell surface MHC class I molecules is dictated by the 
ability of TAPBPR to dissociate the endogenous peptide presented on MHC class I at steady 









Figure 26: Residues K22-D35 are essential for the ability of soluble TAPBPR to associate with 
peptide-loaded MHC class I molecules. (a and c) Histograms showing the binding of each soluble 
TAPBPR loop variant to HeLaM-HLA-ABCKO cells over-expressing HLA-A*68:02, upon incubation with 
100 nM TAPBPR (a) at 37°C or (c) at 26°C for 30 min. TAPBPRTN5 is included as a negative control. (b) 
TAPBPR pull-downs on IFNγ-treated HeLaMKO cells incubated with soluble TAPBPR loop mutants. 
TAPBPRTN5 is included as a non-MHC class I binding control. This data is representative of three 
independent experiments. Membranes were stained for TAPBPR, using an anti-polyHis mAb, for MHC 
class I heavy chain and for UGT1. (d) Bar graph summarising the TAPBPR binding to HeLaM-HLA-
ABCKO+A*68:02 cells at 37°C with 26°C from three independent experiments. Error bars represent -
/+SD. (e) Histograms showing typical levels of bound fluorescent peptide to IFNγ-stimulated HeLaM 
cells treated with or without 100 nM soluble TAPBPR variants for 15 min at 26°C, followed by 
incubation with 10 nM ETVSK*QSNV for another 15 min at 26°C. (f) Bar graph comparing 
ETVSK*QSNV binding to HeLaM cells treated with or without soluble TAPBPR variants at 37°C with 
treatment at 26°C, based on three independent experiments. Error bars represent -/+SD. n/s = not 
significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, using unpaired two-tailed t-tests. Taken 






Figure 27: Peptide priming to cell surface MHC class I inhibits the binding of TAPBPR with a mutated 
loop. IFNγ-stimulated HeLaM-HLA-ABCKO cells reconstituted with HLA-A*68:02 were treated with or 
without 10 nM YVVPFVAK*V for 15 min at 26°C. Excess peptide was then washed off and cells were 
incubated with 100 nM of either soluble TAPBPRWT or TAPBPRØloop. (a) Histograms showing the level 
of YVVPFVAK*V peptide bound to HeLaM cells, prior to the addition of soluble TAPBPR. (b) 
Histograms showing the level of bound TAPBPRWT (left) or TAPBPRØloop (right) on cell treated with or 
without peptide. (c) Bar graphs summarise the results in panel b). Error bars show -/+SD. n/s = not 
significant, ***p≤0.001 using unpaired two-tailed t-tests, based on four independent experiments. 








4.2.6. Mutation of the K22-D35 loop of TAPBPR alters the peptide repertoire 
presented on MHC class I 
Having shown that the K22-D25 loop of TAPBPR is essential for mediating efficient peptide 
dissociation from MHC class I molecules, we were interested in assessing whether mutation of 
the TAPBPR loop alters the peptide repertoire presented on MHC class I on cells. To this end, 
we thus compared the immunopeptidomes of IFNγ-stimulated HeLaMKO cells reconstituted 
with either TAPBPRWT, TAPBPRØloop or TAPBPRØG30L, in collaboration with Ana Marcu from Prof. 
Stefan Stefanovic’s lab (University of Tubingen, Germany) and with Dr. Clemens Hermann 
(University of Cape Town, RSA) (Figure 28). We found considerable changes in the peptides 
presented on MHC class I between cells expressing TAPBPRWT and TAPBPRØloop. Namely, while 
1276 peptides were found in both cell lines, 461 peptides were only found in cells expressing 
TAPBPRWT and 550 peptides were only present in cells expressing TAPBPRØloop (Figure 28a). 
Label-free quantitation by mass spectrometry revealed changes in the abundance of a high 
number of peptides between TAPBPRWT and TAPBPRØloop; among the peptides found in both cell 
lines, 193 exhibited increased abundance in TAPBPRWT-expressing cells, while 222 exhibited 
increased abundance in TAPBPRØloop-expressing cells (Figure 28b). These results demonstrate 
that mutation of the K22-D35 loop of TAPBPR triggers significant changes in the peptide 
repertoire presented on MHC class I molecules. We then compared the peptides presented on 
MHC class I between cells expressing either or TAPBPRWT and TAPBPRØG30L, to assess the impact 
of the L30 residue of TAPBPR on its ability to mediate peptide editing. Although there were still 
significant differences in the peptide repertoires between the two cell lines, reconstitution of 
L30 residue alone on the empty TAPBPR loop appeared to reduce some of the changes in 
peptide abundance observed upon mutating the entire TAPBPR loop (Figure 28a and 28b). 
Finally, upon assignment of the peptides presented on MHC class I molecules to the different 
MHC class I protein products found in HeLaM cells, namely HLA-A*68:02, HLA-B*15:03 and 
HLA-C*12:03, a very similar distribution was observed for all three TAPBPR loop variants (Figure 
28c and 28d).  
However, in the experiments presented above (Figure 28a-d), the peptides were eluted for 
analysis straight after harvesting the cells. In other words, we think that the cells may not have 
been allowed to recover their steady state surface levels of either MHC class I or TAPBPR 
following the use of trypsin, which could have potentially diminished the ability of TAPBPR to 




cells which were allowed to recover at 37°C following trypsinisation (Figure 28e-h). We 
anticipated that this additional recovery period would also enable over-expressed TAPBPRWT 
and TAPBPRØG30L, but not TAPBPRØloop, to actively dissociate a fraction of the peptides 
presented on MHC class I and thus further highlight the effect of this catalytic region of TAPBPR 
on peptide editing. First, the results of this experimental set-up confirmed the changes in the 
peptide repertoire presented on MHC class I upon mutation of the TAPBPR loop (Figure 28e 
and 28f). However, this time, there was a significant difference in peptide distribution across 
the different HLA class I allotypes found in HeLaM cells between cells expressing TAPBPRWT and 
TAPBPRØloop (Figure 28g and 28h). Namely, based on a presence/absence approach, only 29% of 
the peptides analysed were now assignable to HLA-A*68:02 in TAPBPRWT-expressing cells, 
compared to 37% in cells expressing TAPBPRØloop. Interestingly, compared to when assigning 
the peptides immediately following cell harvesting, the percentage of HLA-A*68:02-assignable 
peptides remained the same in cells expressing TAPBPRØloop, but decreased considerably for 
TAPBPRWT (Figure 28g). Consistent with this, when assigning only the upregulated peptides 
recorded for each cell line, remarkably, more than 80% of the peptides up-regulated in 
TAPBPRØloop-expressing cells were assignable to HLA-A*68:02, compared to only ~20% for 
TAPBPRWT (Figure 28h). In keeping with these findings, we observed similar changes in the 
peptide repertoire assigned to HLA-A*68:02 upon reconstitution of L30 alone onto the 
dysfunctional loop, as the ones observed for TAPBPRWT (Figure 28g and 28h). To highlight the 
reproducibility of these results, the comparison across the five technical replicates within this 
dataset are shown in Figure 29. These findings indicate that TAPBPR, containing a functional 
loop, dissociates a proportion of the peptides loaded onto HLA-A*68:02 in cells, but this effect 
is much less pronounced on HLA-B*15:03 and HLA-C*12:03. Moreover, it appears that 
mutation of the L30 residue of the TAPBPR loop leads to a less stringent peptide selection on 
this HLA class I allotype and thus further supports the involvement of this residue in the 






Figure 28: Mutation of the TAPBPR loop alters the peptide repertoire presented on MHC class I in 
cells. Peptide sets were eluted from MHC class I complexes isolated via immunoprecipitation on the 
W6/32 mAb from IFNγ-induced HeLaMKO cells over-expressing TAPBPRWT, TAPBPRØloop or TAPBPRØG30L. 
Peptides were then analysed using LC-MS/MS. (a–d) Cells were frozen immediately following harvest 
using trypsin, while in (e–h), cells were given a recovery period of 30 min at 37°C, in media, after 
harvesting and prior to freezing. The sequences of the identified peptides are available in the Dryad 
Digital Repository (DOI: https://doi.org/10.5061/dryad.p5k0156). (a and e) Venn diagrams comparing 
all the identified peptides between TAPBPRWT and either TAPBPRØloop (left) or TAPBPRØG30L (right), by a 
presence/absence approach. (b and f) Volcano plots summarising label-free quantitation display the 
relative abundance of each shared peptide between two cells lines, paired similarly as in a) and e). 
Coloured dots indicate the peptides which are significantly either up- or down- modulated between 
two cell lines, after applying an adjusted p-value of <0.01. n = number of significantly up- or down-
modulated peptides, % = the fraction of significantly modulated peptides in a specific cell line of the 
total pool of shared peptides. (c and g) Bar graphs depicting the assignment of the shared peptides 
identified in a) and e) to each individual MHC class I allotype found in HeLaM cells (HLA-A*68:02, -
B*15:03 or -C*12:03); unassigned peptides appear in orange (rest). (d and h) Bar graphs depicting the 
significantly modulated peptides in b) and f) matched to each individual MHC class I allotype, using 
the NetMHCpan-4.0. Taken from Ilca et al. (Ilca et al., 2018a). This data was generated and analysed 






Figure 29: Technical reproducibility of the immunopeptidome analysis by LC-MS/MS. The peptide 
elution and immunopeptidome analysis were performed in 5 technical replicates for each dataset. (a) 
Venn diagrams showing the peptidome overlaps among the 5 replicates within one experiment. (b) 
Bar graphs display the percentage of peptides found in 1-5 out of the 5 replicates for each of the 
TAPBPR loop variant-expressing cell lines. The sequences of the identified peptides are available 
in the Dryad Digital Repository (DOI: https://doi.org/10.5061/dryad.p5k0156). Taken from Ilca et al. 
(Ilca et al., 2018a). These data were generated and analysed by Ana Marcu, from the lab of Prof. 
Stefan Stefanović (University of Tübingen, Germany). 
 
To further explore this observed preference of TAPBPR for HLA-A*68:02 over HLA-B*15:03 and 
HLA-C*12:03, I assessed the ability of soluble TAPBPR to bind to each HLA class I allotype, 
chemically coupled to beads (Table 6). To this end, I incubated the beads with soluble TAPBPR 
at room temperature, washed the beads thoroughly and measured the level of TAPBPR on each 
bead set by flow cytometry. This binding experiment revealed a strong interaction between 
TAPBPRWT and HLA-A*68:02, but a lack of stable association with either HLA-B*15:03 and HLA-




expressed in HeLaM cells likely explains the observed reduction only in the peptides assignable 
to HLA-A*68:02 by TAPBPR carrying a functional loop. Consistent with this hypothesis, soluble 
TAPBPRØloop showed considerably weaker binding to HLA-A*68:02, compared to TAPBPRWT. 
Together, these findings demonstrate that the loop, and especially the L30 residue, is 
important for the ability of TAPBPR to shape the peptide repertoire presented on MHC class I 
molecules in cells, particularly on HLA-A*68:02 (Table 6).       
Table 6: Binding of TAPBPR variants to each HLA class I allotype found in HeLaM cells 
HLA class I allotype TAPBPRWT no TAPBPR TAPBPRØloop W6/32 
A*68:02 14461 ±(139) 418.3 (± 31.1) 2576.3 ±(19.6) 23344 
B*15:03 21.7 ±(2.3) 6 (± 10.4) 17.3 ±(1.5) 23670 
C*12:03 249 ±(12) 146 (±16.8) 175 ±(14.8) 23814 
- values are displayed in normalized MFI units 
 
 
4.2.7. L30 enables TAPBPR to mediate efficient peptide exchange on MHC class I 
molecules that accommodate hydrophobic residues in their F pocket 
Given the proximity of the TAPBPR loop to the F pocket region of MHC class I (Figure 5) 
(Thomas and Tampe, 2017), as well as the crucial role played by the L30 residue the TAPBPR 
loop in the ability of TAPBPR to mediate peptide exchange (Figures 23 and 25), I hypothesized 
that the TAPBPR loop facilitates peptide dissociation from MHC class I, by inserting its L30 
residue into the MHC class I F pocket, thus competing with the C-terminus of the peptide. If 
correct, this competitive binding would only be possible for MHC class I molecules that can 
accommodate a leucine or similar hydrophobic residues in their F pocket.  
To test this hypothesis, I assessed the involvement of the TAPBPR loop in peptide exchange on 
two other MHC class I molecules, HLA-A*02:01 and H-2Kb, to which TAPBPR has been 
previously shown to bind (Boyle et al., 2013, Morozov et al., 2016) and which, similarly to HLA-
A*68:02, have F pocket specificities for hydrophobic residues (Rammensee et al., 1999). 
Compared to HLA-A*68:02, HLA-A*02:01 binds similar residues in both B and F pocket, whereas 
H-2Kb has an entirely different peptide binding motif, the only similarity being that it also 
accommodates hydrophobic residues in its F pocket (Figure 30a). Given the ability of both HLA-
A*02:01 and H-2Kb to accommodate a leucine residue in their F pocket, I predicted that the 





To this end, I designed fluorescently-labelled peptides of high affinity for both HLA-A*02:01 
(NLVPK*VATV, used previously in Chapter 3) and H-2Kb (SIINFEK*L)(Saini et al., 2015) and 
tested their binding to the surface of either HeLaM-HLA-ABCKO cells reconstituted with HLA-
A*02:01, or to the mouse cell line EL4 which expresses H-2Kb, respectively, in the presence of 
the different TAPBPR loop mutants (Figure 30b and 30c). As expected, I observed a similar 
hierarchy in the ability of the TAPBPR loop variants to mediate peptide exchange as the one 
obtained for HLA-A*68:02 (Figure 25), with TAPBPRWT being the most efficient, followed by 
TAPBPRØG30L, while TAPBPRØloop and TAPBPRL30G were both highly inefficient (Figure 30c). For 
instance, when measuring the binding of NLVPK*VATV to HLA-A*02:01-expressing cells, 
TAPBPRØG30L, TAPBPRØloop and TAPBPR exhibited ~54%, ~23% and ~32% of the catalytic activity 
























Figure 30: TAPBPR edits peptides in a loop-dependent manner only on MHC class I molecules with F 
pocket specificities for hydrophobic peptide residues. (a) Comparison of the A-F pocket specificities 
among the peptide binding grooves of HLA-A*68:02, HLA-A*02:01, H-2Kb and HLA-A*68:01.               
(b) Binding of the appropriate fluorescent peptide to IFNγ-treated HeLaM-HLA-ABCKO transduced 
either with HLA-A*02:01 or with HLA-A*68:01 or to mouse EL4 cells (which express H-2Kb), in the 
presence or absence of 1 µM soluble TAPBPR variant for 15 min at 37°C, followed by incubation with 
10 nM NLVPK*VATV (for HLA-A*02:01) for 60 min, 1 nM SIINFEK*L (for H-2Kb)  for 30 min or 100 nM 
KTGGPIYK*R (for HLA-A*68:01) for 60 min at 37°C. (c) Bar graph summarising the peptide loading 
levels mediated by the soluble TAPBPR variants, as described in b). Error bars represent MFI -/+ SD 
based on four independent experiments. ****p ≤ 0.0001, ***p ≤ 0.001, *p ≤ 0.05, using unpaired 
two-tailed t-tests. (d) Structure of MHC class I seen from above the binding groove (PDB ID 4HWZ) 
and the different amino acids between HLA-A*68:02 and –A*68:01 highlighted in red. Taken from Ilca 
et al. (Ilca et al., 2018a). 
 
We observed a similar trend in the ability of the TAPBPR mutants to load another HLA-A2-
specific peptide, YLLEK*LWRL, as well as when testing peptide binding to HLA-A2 expressed on 




2Kb-specific peptide SIINFEK*L to EL4 cells, the ØG30L, Øloop and L30G variants exhibited ~ 
85%, 30% and 31% of the catalytic activity of TAPBPRWT, respectively (Figure 30b and 30c). 
Together, these results clearly highlight the crucial role of the L30 residue of TAPBPR in 
mediating efficient peptide exchange on HLA-A2 and on H-2Kb, despite TAPBPR still being able 
to exchange peptide on these MHC class I molecules to some degree. Remarkably, TAPBPR 
shows a similar functional dependency on L30 across HLA-A*68:02, HLA-A*02:01 and H-2Kb, 
despite the low degree of similarity between murine and human MHC class I molecules, both in 
their amino acid sequences and in their peptide binding motifs. However, the key shared 
feature between all three MHC class I molecules tested is their F pocket specificity for 
hydrophobic residues.    
 
Figure 31: Soluble TAPBPR-mediated peptide loading onto HLA-A*02:01 molecules. (a) Bar graphs 
displaying binding of fluorescent peptide to IFNγ-stimulated HeLaM-HLA-ABCKO reconstituted with 
HLA-A2, upon incubation with or without 1 µM of each soluble TAPBPR variant for 15 min at 37°C, 
followed by incubation with 10 nM YLLEK*LWRL (HLA-A2 specific peptide) for 60 min at 37°C. (b) Bar 
graphs showing fluorescent peptide binding to IFNγ-treated MCF-7 cells incubated with or without 1 
µM of each soluble TAPBPR variant for 15 min at 37°C, followed by addition of 10 nM of either 
NLVPK*VATV (blue) or YLLEK*LWRL (yellow) for 60 min at 37°C. Error bars represent MFI -/+SD from 
four independent experiments. ****p≤0.0001, ***p≤0.001 using unpaired two-tailed t-tests. Taken 











4.2.8. TAPBPR cannot use the L30 residue to mediate efficient peptide exchange on 
MHC class I molecules that accommodate charged residues in their F pocket 
To provide further support to my hypothesis that TAPBPR can use its L30 residue to efficiently 
mediate peptide exchange only on MHC class I molecules with F pocket specificities for 
hydrophobic amino acids, I tested the ability of the loop mutants to edit peptides on a human 
MHC class I molecule that accommodates a charged residue in its F pocket. To only explore the 
contribution of the F pocket specificity, with minimal other differences, I chose HLA-A*68:01. 
Although HLA-A*68:01 differs from HLA-A*68:02 in only 5 amino acids, most of those dictate 
the specificity of the F pocket (Figure 30d)(Niu et al., 2013). As a result, while the two 
molecules accommodate similar residues in their B pocket, the F pocket of A*68:02 binds 
aliphatic residues, whereas the F pocket of A*68:01 binds basic residues (Figure 30a). Thus, 
despite the high degree of similarity between A*68:01 and A*68:02, I predicted A*68:01 would 
not undergo loop-dependent TAPBPR-mediated peptide exchange, strictly due to it not being 
able to bind hydrophobic residues in its F pocket. 
Remarkably, as expected, in contrast to all three MHC class I molecules tested previously, all of 
which accommodate hydrophobic residues in their F pocket, TAPBPR showed a clearly impaired 
ability to load the HLA-A*68:01-specific florescent peptide KTGGPIYK*R onto HeLaM-HLA-ABCKO 
cells transduced with HLA-A*68:01 (Figure 30b and 30c). Moreover, I observed no significant 
differences in the ability of TAPBPR to mediate peptide exchange on HLA-A*68:01 upon 
mutation of the loop, all loop mutants displaying an equal ability to exchange peptides as 
TAPBPRWT (Figure 30b and 30c). Thus, in contrast to HLA-A*68:02, on which TAPBPR promotes 
highly efficient peptide exchange in a L30-dependent manner, HLA-A*68:01 is significantly less 
responsive to the TAPBPR-mediated peptide exchange, which only occurs independently of the 
loop. Strikingly, the difference in only five amino acids between the two MHC class I molecules, 
three of which resulting in different F pocket specificities, strongly influences the ability of 
TAPBPR to use its K22-D35 loop to facilitate efficient peptide exchange on them. Taken 
together, these findings support the concept that TAPBPR is capable of inserting its L30 residue 
into the F pocket of MHC class I, in order to promote effective dissociation of the bound 







4.2.9. Mutation of residue 116 in the MHC class I F pocket alters TAPBPR binding 
Following on from the idea that the L30 residue of TAPBPR is capable of binding into the F 
pocket of MHC class I molecules, I was curious to whether by artificially changing the F pocket 
specificity of MHC class I molecules, I could alter the binding of TAPBPR to those molecules. 
Given the extreme differences in F pocket specificities between HLA-A*68:02 and -A*68:01, 
which seemed to be influenced by differences in only three amino acids, namely the ones on 
positions 97, 114 and 116 (Niu et al., 2013), I hypothesised that swapping one or more of these 
residues between the two MHC class I molecules could result in swapping their F pocket 
specificities as well. Out of these three F pocket residues that differ between A*68:01 and 
A*68:02 and were previously reported to influence the F pocket specificity of MHC class I (Guo 
et al., 1992, Madden et al., 1992, Saper et al., 1991, Sidney et al., 2008), residue 116 appeared 
to be the one having the highest impact on the interaction of the F pocket with the C-terminal 
anchor residue of the peptide. Namely, HLA-A*68:02 contains a tyrosine on position 116, 
whereas HLA-A*68:01 contains an aspartic acid (Figure 32a). As it can be observed in the crystal 
structure, D116 of HLA-A*68:01 forms strong dipole interactions with both residue R114 of the 
peptide binding groove and with residue K9 of the peptide, determining a strong preference of 
the HLA-A*68:01 F pocket for basic anchor residues. In contrast, residue Y116 of HLA-A*68:02 
points away from H114 residue, keeping the hydrophobic patches of the F pocket in an open 
conformation, allowing it to accommodate hydrophobic peptide residues (Figure 32a). I believe 
that this is the reason why the L30 residue of the TAPBPR loop has access to the F pocket of 
HLA-A*68:02, but not to the one of HLA-A*68:01.   
To investigate whether altering the F pocket interactions with the anchor residue of the 
peptide impacts the ability of TAPBPR to bind to MHC class I, I swapped residues on position 
116 between HLA-A*68:01 and -A*68:02, resulting in the A*68:01D116Y and A*68:02Y116D 
mutants. I hypothesized that swapping their residues on positions 116 would more likely lead 
to a disruption in the architecture of the F pocket than swapping their residues on position 114, 





Figure 32: Swapping residue 116 between HLA-A*68:01 and HLA-A*68:02 does not impair their 
surface expression. (a) PyMOL images depicting the binding grooves of HLA-A*68:02 (PDB ID 4HX1) 
and of HLA-A*68:01 (PDB ID 4HWZ), with residues at position 114 and 116 of MHC class I, as well as 
the C-terminal residue of the bound peptide, highlighted. (b) Histograms showing the expression 
levels of HLA-A*68:02WT, -A*68:02Y116D, -A*68:01WT and -A*68:01D116Y at the cell surface, detected 
using W6/32, when transduced into HeLaM-HLA-ABCKO cells. Data is representative of three 
independent experiments. Taken from Ilca et al. (Ilca et al., 2018a). 
 
The surface expression levels of the chimeric HLA mutants were similar to the ones of their 
corresponding wild type counterparts, upon transduction into HeLaM-HLA-ABCKO cells, 
indicating that mutation of residue 116 did not significantly alter the ability of HLA-A*68:01 and 
-A*68:02 to load and present peptides (Figure 32b). When assessing the ability of TAPBPR to 
bind to these HLA class I mutants present at the cell surface, strikingly, I observed that 
A*68:02Y116D showed almost no binding to TAPBPR, compared to the high binding observed for 
A*68:02WT (Figure 33a and 33b). Correspondingly, A*68:01D116Y showed a strong enhancement 
in TAPBPR binding, compared to the extremely low levels of TAPBPR bound to A*68:01WT. I 
further validated the effect of altering the F pocket on TAPBPR binding on another MHC class I 
molecules, namely A*02:01 (Figure 33c). Similarly to A*68:02, while TAPBPR showed strong 
binding to A*02:01WT, it displayed a severely impaired ability to associate with A*02:01Y116D. 
These results demonstrate that the ability of TAPBPR to bind MHC class I molecules is directly 





Figure 33: Mutation of the MHC class I F pocket significantly alters TAPBPR binding. HeLaM-HLA-
ABCKO cells expressing the panel of HLA-A*68 molecules listed in Figure 32 were incubated with 1 μM 
of soluble TAPBPR for 30 min at 37°C, followed by detection of surface bound TAPBPR using PeTe4. (a 
and c) Histograms show the level of bound soluble TAPBPR to the surface of a) the cell lines 
expressing each HLA-A68 molecule from Figure 32 and of c) cells expressing either HLA-A*02:01WT or 
HLA-A*02:01Y116D. Staining with an isotype control antibody was included as a negative control (grey 
dashed line). (b) Bar graphs summarise the MFI of TAPBPR binding depicted in panel a), based on 
three independent experiment ± SD. ****p ≤ 0.0001. Taken from Ilca et al. (Ilca et al., 2018a). 
 
 
4.2.10. Modifying the F pocket specificity of MHC class I alters TAPBPR-mediated 
peptide editing 
I next tested the ability of TAPBPR to exchange peptides on the chimeric HLA class I mutants. 
Given that both HLA-A*68:01 and -A*68:02 contain a basic residue on position 114 (Figure 
32a), I expected that swapping the residues on position 116 between the two molecules may 
consequently lead to swapping their F pocket specificities for anchor residues. I thus assessed 
the ability of the chimeric MHC class I mutants to bind both the A*68:02-specific peptide 
ETVSK*QSNV and the A*68:01-specific peptide KTGGPIYK*R and tested whether the presence 
of soluble TAPBPR enhanced the loading of either peptide (Figure 34). As previously observed, 




not of KTGGPIYK*R on A*68:02WT (black line, Figure 34c and 34d), while on A*68:01WT, TAPBPR 
facilitated, to a considerably lower extent, the loading of KTGGPIYK*R (black line, Figure 34c 
and 34d), but did not show any loading of ETVSK*QSNV (black line, Figure 34a and 34b). 
Strikingly however, the corresponding chimeric HLA class I mutants showed complete opposite 
peptide specificities. Namely, in the presence of TAPBPR, A*68:02Y116D did not promote any 
binding of ETVSK*QSNV (red line, Figure 34a and 34b), however markedly enhanced the 
loading of KTGGPIYK*R (red line, Figure 34c and 34d). Correspondingly, on A*68:01D116Y, 
TAPBPR was not able to load KTGGPIYK*R (red line, Figure 34c and 34d), however led to a 
strong enhancement in the binding of ETVSK*QSNV (red line, Figure 34a and 34b), to 
comparable levels as observed on A*68:02WT. These results are in keeping with the fact that 
swapping residues on position 116 between A*68:01 and A*68:02 resulted in switching their 
peptide specificities, as it can be observed from the peptide binding experiments performed in 
the absence of TAPBPR (Figure 34b and 34d, right panels). Subsequently, altering the F pocket 
specificities of these MHC class I molecules altered the efficiency of TAPBPR-mediated peptide 
exchange. Nonetheless, despite the significantly lower levels of TAPBPR bound to both 
A*68:01WT and A*68:02Y116D compared to their Y116-containing counterparts (Figure 33a and 
33b), TAPBPR was still capable of mediating peptide exchange on these molecules and, thus, of 






Figure 34: Residue 116 of MHC class I is crucial for the peptide editing ability of TAPBPR. (a and c) 
Histograms showing the level of fluorescent peptide binding to IFNγ-treated HeLaM-HLA-ABCKO cells 
expressing the panel of HLA-A*68 molecules listed in Figure 32, upon incubation with 1 μM of soluble 
TAPBPR for 15 min at 37°C, followed by treatment with either (a) 10 nM ETVSK*QSNV (ETV*) or (c) 
100 nM KTGGPIYK*R (KTG*) peptide for 15 min and 60 min, respectively. (b and d) Bar graphs 
summarise the MFI of the fluorescent peptide binding depicted in a) and c) respectively, in the 
presence and absence of TAPBPR, based on three independent experiment ± SD. ****p ≤ 0.0001, 

















Given the ambiguity concerning the localization of the TAPBPR loop in relationship to the MHC 
class I binding groove (Chapter 3, Figure 6) in recently captured structures and the lack of 
functional evidence to support any involvement of the loop in peptide exchange on MHC class I 
molecules (Jiang et al., 2017, Thomas and Tampe, 2017), it was essential to experimentally test 
this involvement. In this chapter, using the novel cellular assay which I developed for measuring 
TAPBPR-mediated peptide exchange on MHC class I molecules (see Chapter 3), together with 
immunopeptidomics analysis, I have demonstrated an essential role for the K22-D35 loop of 
TAPBPR in its peptide editing function. I showed that the loop is required for TAPBPR to 
efficiently catalyse peptide dissociation from MHC class I molecules and hence promote the 
binding of an incoming high affinity peptide. Moreover, I have identified residue L30 of the loop 
to be both necessary and sufficient for the ability of TAPBPR to facilitate peptide exchange on 
both human and mouse MHC class I molecules that typically accommodate hydrophobic amino 
acid residues in their F pocket. It is important to mention that our findings prove that mutating 
the loop only impairs the catalytic function of TAPBPR and does not alter its folding, stability or 
intrinsic ability to interact with MHC class I molecules.  
The findings highlighting the impact of the loop, and particularly of residue L30, on the ability of 
TAPBPR to mediate peptide editing were similar when either the full-length (Figure 23) or the 
soluble versions of TAPBPR (Figure 25) were tested. Moreover, the crucial impact of the loop, 
and of residue L30 in particular, on the ability of TAPBPR to efficiently promote peptide 
exchange on MHC class I was further confirmed in cells, by immuno-peptidomics analysis 
(Figure 28). Namely, mutation of the TAPBPR loop led to a significant difference in the pool of 
peptides presented on MHC class I and, moreover, to a larger pool of peptides presented 
specifically on HLA-A*68:02. This further supports the role of TAPBPR in peptide selection on 
MHC class I and that the 22-35 loop of TAPBPR is a catalytic region essential for peptide editing. 
These findings together, as speculated in the previous chapter, suggests that using the luminal 
domain of TAPBPR alone to interrogate the peptide editing function of the chaperone on MHC 




5. Chapter 5: Exploring the allelic susceptibility of HLA class I to 
peptide editing by TAPBPR  
 
5.1. Background 
In Chapter 4, I found that TAPBPR functioned more efficiently on some MHC class I molecules 
(e.g. HLA-A*68:02) compared to others (e.g. HLA-A*68:01) and demonstrated that this was 
based on specific molecular properties of MHC class I. Given the extreme difference observed 
in the ability of TAPBPR to function as a peptide editing catalyst on a limited number of 
different HLA class I molecules, I was interested in exploring the HLA class I allele-preference of 
TAPBPR. To test this, I sought to assess the ability of TAPBPR to bind a wide range of HLA class I 
allotypes and to subsequently test its ability to edit peptides on a selected panel of HLA class I 
allotypes. Finally, I planned to explore the molecular basis behind any preference observed. 
Extensive exploration of this would allow us to better understand how tightly peptide editing is 
controlled across different HLA class I molecules and whether the observed differences could 




5.2.1. TAPBPR shows binding preference for HLA-A over -B and -C molecules 
Thus far, I have only assessed the ability of TAPBPR to bind and exchange peptides on a few 
HLA class I molecules, namely HLA-A*02:01, -A*68:01 and -A*68:02 (Figure 30). I have shown 
that the catalytic activity of TAPBPR is reflected by the ability of TAPBPR to associate with MHC 
class I. Thus, to perform the first comprehensive study on the allele-based preference of 
TAPBPR for HLA class I, I compared the ability of TAPBPR to bind to 97 different HLA class I 
allotypes, using Labscreen® single antigen HLA class I beads (SABs) (Pei et al., 2003). The same 
set of beads has been previously used for interrogating HLA class I interactions with various 
immune receptors, such as leukocyte Ig-like receptors (LILRs) (Jones et al., 2011) or for 
characterising allotype specificity of anti-HLA antibodies used to assess HLA class I expression 




extensively been used clinically, in assessing the pre-transplant risks of host-versus-graft 
rejection by measuring the levels of anti-HLA antibodies from patients’ sera (Wittenbrink et al., 
2018). The HLA class I molecules coupled to these beads were produced and purified from a 
mammalian expression system (Pei et al., 2003) and should therefore be representative of the 
pool of MHC class I molecules found in cells, loaded with a broad range of peptides. In my 
experimental set up, in order to quantify the level of TAPBPR binding to individual HLA class I 
allotypes comprised in the SAB library, the SABs were treated with 1 μM soluble TAPBPR, 
followed by staining with the TAPBPR specific mAb PeTe4. The level of bound TAPBPR to each 
of the bead sets was determined by flow cytometry (Figure 35a).  
The screen revealed a strong preference of TAPBPR for HLA-A over -B and -C molecules. Out of 
the 97 different HLA molecules screened, the 11 strongest TAPBPR binders were all members of 
the HLA-A group (Figure 35b). Moreover, the strongest HLA-B and -C binders, namely B*73:01 
and C*01:02 respectively (Figure 35b and 36), showed >10-fold lower level of bound TAPBPR 
compared to the strongest HLA-A binder, namely A*68:02 (Figure 35b). Overall, 14 out of 31 
HLA-A molecules showed at least intermediate levels (>500 MFI) of TAPBPR binding (Figure 37), 
while only 4 out of the 50 HLA-B and 1 out of the 16 HLA-C molecules tested presented 
intermediate abilities to bind TAPBPR (Figure 36). The staining of the beads with W6/32, a pan-
HLA class I antibody that recognizes peptide-loaded conformations of HLA-A, -B and -C 
molecules, revealed similar levels of peptide-loaded MHC class I molecules across the entire 
SAB library (Table 7). This suggests that the TAPBPR binding hierarchy obtained was indeed due 
to the intrinsic ability of TAPBPR to interact with the HLA class I molecules and not due to 
different MHC class I availability. To ensure that the observed binding of TAPBPRWT occurred 
strictly in an MHC class I-dependent manner, the binding of the recombinant TAPBPRTN5, which 
is unable to associate with MHC class I, was tested to the beads. No significant binding of 
TAPBPRTN5 was observed to any of the HLA class I allotypes coupled to beads (Figure 35c), 







Figure 35: HLA-A molecules exhibit stronger interactions to TAPBPR compared to HLA-B and -C 
molecules. (a) Schematic depiction of the LABScreen® single antigen HLA bead (SAB) assay used to 
determine soluble TAPBPR binding to individual HLA class I alloytpes. The SABs were incubated 
with 1 μM TAPBPR for 1 h, at 22°C with rotation and then stained for TAPBPR using the PeTe4 
antibody. (b) Bar graphs showing the levels of TAPBPRWT binding to the top 34 binders from the 
library of 97 different bead-coupled HLA class I allotypes, with HLA-A molecules in blue bars, HLA-
B molecules in orange bars and HLA-C molecules in red bars. The comprehensive data for all HLA-
A, -B and -C molecules can be found in Figure 37 and Figure 36, respectively. (c) Bar graphs 
showing the binding levels of the soluble TAPBPRTN5, which is unable to bind MHC class I, to the 
same HLA class I allotypes shown in panel b), when 1 μM soluble TAPBPRTN5 was added to cells for 
1 h at 22°C. Error bars show mean fluorescence intensity (MFI) -/+ SD from triplicates within one 






Figure 36: TAPBPR binding to HLA-B and -C molecules on the single HLA beads. Bar graphs showing 
soluble TAPBPRWT binding to the (a) HLA-B and the (b) HLA-C molecules of the SAB library, upon 
treatment with 1 μM TAPBPRWT. at 22°C with rotation. The data including error bars was generated 
based on triplicates within one experiment. This is a representative example of three independent 








































A*01:01 3 18527  B*13:01 97 18064  B*51:02 66 18795 
A*02:01 4 19739  B*13:02 36 19727  B*52:01 67 17497 
A*02:03 5 18974  B*14:01 37 19502  B*53:01 68 18690 
A*02:06 6 18702  B*14:02 38 17233  B*54:01 69 19465 
A*03:01 7 19116  B*15:01 40 19608  B*55:01 70 19803 
A*11:01 8 18910  B*15:02 41 19350  B*56:01 71 19119 
A*11:02 9 19415  B*15:03 42 19668  B*57:01 72 18956 
A*23:01 10 19552  B*15:10 43 20197  B*57:03 73 19594 
A*24:02 11 19068  B*15:11 98 17639  B*58:01 74 18524 
A*24:03 12 17692  B*15:12 44 19294  B*59:01 75 18090 
A*25:01 13 19499  B*15:13 45 19296  B*67:01 76 19989 
A*26:01 14 18366  B*15:16 46 18461  B*73:01 77 19542 
A*29:01 15 19014  B*18:01 47 19915  B*78:01 78 17716 
A*29:02 17 18142  B*27:05 16 19969  B*81:01 79 18679 
A*30:01 18 17818  B*27:08 48 19129  B*82:01 80 17708 
A*30:02 19 17921  B*35:01 49 19066  C*01:02 81 18988 
A*31:01 20 18716  B*37:01 50 18551  C*02:02 82 16840 
A*32:01 21 19548  B*38:01 51 18845  C*03:02 83 18982 
A*33:01 22 18132  B*39:01 52 20136  C*03:03 84 19000 
A*33:03 100 18062  B*40:01 53 19119  C*03:04 85 18943 
A*34:01 23 19320  B*40:02 54 19336  C*04:01 86 12491 
A*34:02 24 19845  B*40:06 99 18638  C*05:01 87 19122 
A*36:01 25 17031  B*41:01 55 20023  C*06:02 88 16573 
A*43:01 26 18328  B*42:01 56 20116  C*07:02 89 18133 
A*66:01 27 18555  B*44:02 57 17659  C*08:01 90 19692 
A*66:02 28 19088  B*44:03 58 18984  C*12:03 91 20447 
A*68:01 29 19016  B*45:01 59 19214  C*14:02 92 17786 
A*68:02 30 17506  B*46:01 63 19173  C*15:02 93 21276 
A*69:01 31 18749  B*47:01 61 17077  C*16:01 94 14783 
A*74:01 32 19216  B*48:01 62 19200  C*17:01 95 14369 
A*80:01 33 18535  B*49:01 60 19506  C*18:02 96 18683 
B*07:02 34 20419  B*50:01 64 19141     
B*08:01 35 20346  B*51:01 65 19516     
* The SABs were stained with the W6/32 mAb and the amount of antibody bound to each bead set was 









5.2.2. The strongest TAPBPR binders are members of the HLA-A2 and A24 
superfamilies 
Despite numerous members of the HLA-A group showing considerably stronger ability to bind 
TAPBPR compared to most -B and -C allotypes, there were numerous HLA-A molecules that 
showed very week binding to TAPBPR, such as A*01:01, A*11:01, A*26:01, A*33:01, A*36:01, 
A*68:01, etc (Figure 35b). Interestingly, all weak binders are exclusively members of the A1 and 
A3 superfamilies, whereas the top eight strongest TAPBPR binders, namely A*68:02, A*23:01, 
A*69:01, A*02:01, A*24:02, A*02:03, A*24:03 and A*02:06, are all members of the HLA-A2 and 
-A24 superfamilies (Figure 37), according to previous classifications (Sidney et al., 2008). HLA 
class I molecules were classified into supertypes based on overlapping peptide repertoires, 
chemical specificity of both B and F pockets and on the amino acid sequence similarity around 







Figure 37: Among HLA-A molecules, TAPBPR shows clear binding preference for members of the 
A2 and A24 superfamilies. (a and b) Bar charts showing the level of TAPBPR binding to all HLA-A 
molecules from the SAB library, grouped based on numerical order, with members of the HLA-A2 
(blue) and -A24 (green) superfamilies highlighted. The same TAPBPR binding hierarchy to HLA-A 
molecules was observed when either (a) 1 μM or (b) 100 nM soluble TAPBPR was added to the 
beads for 1 h at 22°C. Error bars show mean fluorescence intensity (MFI) -/+ SD from triplicates 
within one experiment. This experiment is a representative example of three independent 
experiments.   
 
 
5.2.3. TAPBPR shows the same HLA binding hierarchy in a cellular system 
Although the HLA class I molecules used for generating the SAB library were expressed and 
purified from a mammalian system (Pei et al., 2003), thus likely resembling the conformations 
of HLA class I molecules present on the cell surface, there was still limited information 




findings obtained from the LABscreen® HLA class I SABs using alternative systems. One such 
alternative involved using our novel cellular assay to determine the binding of TAPBPR to cell 
surface MHC class I molecules (see Chapter 3).  
To this end, I reconstituted the MHC class I-deficient HeLaM-HLA-ABCKO cells (Neerincx and 
Boyle, 2018) with a panel of 27 individual HLA class I molecules (Figure 38). This selection 
contained members representative of all HLA class I superfamilies described up to date and 
spanned the entire TAPBPR binding hierarchy obtained using the SAB library. Staining with 
W6/32 revealed similar surface expression levels for all 27 different HLA class I allotypes, upon 
stable over-expression in the HeLaM-HLA-ABCKO cells, except for HLA-C*02:02, which was 
expressed at lower levels (Figure 38). Additionally, each HLA class I-expressing cell line showed 
a highly homogenous population in terms of the relative levels of MHC class I present at the cell 
surface (Figure 38a).  
 
Figure 38: Different HLA class I allotypes show stable and similar surface expression levels.  
(a) Histograms measuring MHC class I levels at the cell surface, measured by staining with W6/32 
antibody, upon transduction of a wide panel of HLA class I allotypes in HeLaM-HLA-ABCKO cells. (b) Bar 
graphs summarising the MFI values in panel a) based on three independent experiments. Error bars 
show mean fluorescence intensity (MFI) -/+ SD. 
 
Upon testing the binding of soluble TAPBPR to the surface of each HLA-expressing cell line, I 
observed a highly similar TAPBPR binding hierarchy (Figure 39) as the one obtained using the 




superfamilies present in my panel, namely A*68:02, A*23:01 and A*02:01 showed the highest 
level of TAPBPR bound when present at the cell surface, while all members of the HLA-A3 and -
A1 superfamilies showed either weak or no TAPBPR binding (Figure 39a and 39b). Among   
HLA-B molecules, B*38:01 was the only one which stably associated with TAPBPR, while none 
of the HLA-C molecules seemed to bind TAPBPR. As expected, I observed a lack of TAPBPR 
binding to HeLaM-HLA-ABCKO cells (Figure 39a), as previously shown (Figure 18b). My cellular-
based assays thus confirmed the clear binding preference of TAPBPR for members of the HLA-
A2 and -A24 superfamilies over other HLA class I subgroups. Taken together, my results 
exploring HLA class I dependency on TAPBPR in a cellular system, where HLA class I molecules 
are loaded with a variety of peptides and present the naturally-occurring post-translational 
modifications, correlate well with my findings obtained using the SABs.   
 
Figure 39: HLA class I allotypes show a similar TAPBPR binding hierarchy in a cellular system as the 
one observed with the SABs. (a) Histograms show levels of soluble TAPBPR binding to each individual 
HLA class I allotypes from the panel in Figure 38, present at the cell surface, upon treating the cells 
with 1 μM soluble TAPBPR for 30 min at 37°C; blue histograms indicate significant TAPBPR binding, 
red histograms indicate non-significant TAPBPR binding and grey histograms indicate TAPBPR binding 
to HeLaM-HLA-ABCKO cells. (b) Bar graphs summarising the levels of TAPBPR binding to surface-
expressed HLA class I molecules shown in panel b). Error bars show mean fluorescence intensity (MFI) 




5.2.4. TAPBPR shows enhanced binding ability to intracellular species of HLA class I 
molecules 
Up to this point, I have only tested the ability of TAPBPR to interact with various HLA class I 
molecules when present at the cell surface or when coupled to beads, in peptide loaded 
conformations. However, TAPBPR naturally resides intracellularly and would thus have access 
to a wider variety of HLA class I conformations present at different stages of the antigen 
presentation pathway (Boyle et al., 2013). I therefore wanted to verify the ability of TAPBPR to 
bind to different HLA class I molecules from the whole cell lysates and compare this relative 
binding to the one observed at the cell surface. To this end, I performed a fishing experiment 
using recombinant soluble TAPBPR as bait to pull down MHC class I molecules from the whole 
cell lysates of the panel of HeLaM-HLA-ABCKO cell lines expressing each of the selected 27 HLA 
class I allotypes (Figure 40). When assessing the relative expression levels of the 27 different 
HLA class I allotypes, I observed that several of them, namely HLA-A*01:01, -A*23:01, -A*32:01, 
-B*57:03 and -B*57:11, were not detected by any of our HLA heavy chain-specific antibodies, 
such as HCA2 or HC10 (Figure 40a and 40b). I therefore used the level of β2m pulled down on 
TAPBPR as a surrogate read-out for TAPBPR-MHC class I interaction. As expected, I did not 
observe any β2m pulled down on TAPBPR in HeLaM-HLA-ABCKO cells, indicating the lack of 
unspecific β2m association to TAPBPR in the absence of classical MHC class I heavy chains. 
Using the pull-down system, I observed a similar trend in the relative ability of the HLA class I 
allotypes from the panel of 27 to bind TAPBPR, with A*68:02, A*23:01 and A*02:01 showing, by 
far, the highest level of TAPBPR binding (Figure 40a). However, when assessing the interaction 
of TAPBPR with the total cellular pool of MHC class I, I now observed significant interactions 
with TAPBPR for several HLA class I molecules of the A1 and A3 superfamilies (such as A*03:01, 
A*25:01, A*34:01, A*68:01) (Figure 40a), that did not appear to bind TAPBPR when present 
strictly at the cell surface (Figure 39). Nonetheless, these HLA class I molecules appeared to 
bind to TAPBPR very weakly compared to the A*68:02 and A*23:01. In fact, due to the 
extremely high levels of A*68:02 and A*23:01 pulled down on TAPBPR, the samples containing 
these allotypes needed to be diluted 10-fold to allow detection of the weak TAPBPR binders. 
Among the HLA-C molecules tested, HLA-C*01:02 appeared to be the only one able to bind 
TAPBPR, while B*08:01, B*38:01 and B*44:05 were the only HLA-B molecules found bound to 





I believe that the reason for observing interactions between TAPBPR and a wider panel of HLA 
class I molecules when taken from the whole cell lysate is the difference in conformations 
between cell surface and intracellular MHC class I molecules. In contrast to the surface pool of 
MHC class I, comprising molecules that have undergone peptide selection and are thus loaded 
with high-affinity peptides, intracellularly, MHC class I molecules occur under various 
conformations, including peptide-receptive forms. The lack of peptides should make these 
intracellular HLA class I conformations more accessible by TAPBPR, given that, according to my 
work here and to previous studies, binding of TAPBPR and peptide to MHC class I molecules 
occurs in a mutually exclusive manner (Hermann et al., 2015b, McShan et al., 2018, Morozov et 
al., 2016). In other words, TAPBPR can form a stable interaction with a peptide-bound MHC 
class I molecules once it manages to dissociate the bound peptide. Thus, the ability of TAPBPR 
to associate with MHC class I is inversely proportional to the affinity of the loaded peptide.  
 
Figure 40: Intracellular species of HLA class I molecules reveal broader reactivity to TAPBPR, while 
confirming the TAPBPR binding hierarchy. Western blot analysis on recombinant soluble TAPBPR 
immunoprecipitates from the lysates of each HLA class I-reconstituted HeLaM-HLA-ABCKO cell line, 
divided into (a) HLA-A and (b) HLA-B and -C molecules. The detergent used to lyse the cells was triton 
X-100. The membranes were probed for MHC class I heavy chain (using the HC10 and HCA2 





Next, it was important to verify that this observed binding of TAPBPR to HLA class I molecules 
was not an artefact of using soluble TAPBPR. To this end, I performed a similar immuno-
precipitation experiment in which endogenous, full length TAPBPR was pulled down from the 
whole cell lysates of several cells expressing individual HLA class I molecules (Figure 41). The 
results were highly similar to the ones obtained using soluble TAPBPR (Figure 40), namely 
TAPBPR showed the highest binding level to A*68:02 among the different HLA class I molecules 
tested, while A*68:01 was one of the weakest TAPBPR binders (Figure 41). Again, consistent 
with the systems used so far, B*38:01 showed a considerably higher ability to bind TAPBPR 
compared to all other HLA-B molecules tested. Interestingly however, when pulled down on 
endogenous TAPBPR, there was no obvious difference between the levels of HLA-B*44:05 and -
B*44:02 bound to TAPBPR. This observed discrepancy was presumably due to the low 
availability of endogenous TAPBPR in cells, resulting in the interaction between TAPBPR and 
HLA-B*44:05 being below the detection limit.  
Together, these findings suggest that HLA class I molecules exhibit a wide range of affinities for 
TAPBPR and that subtle polymorphisms naturally-occurring in HLA class I severely influence 
their ability to interact with TAPBPR. 
 
Figure 41: HLA class I molecules show a similar tapasin binding hierarchy as the one observed for 
TAPBPR. Western blot analysis on endogenous TAPBPR and tapasin pull-downs from HeLaM-HLA-
ABCKO cells reconstituted with the listed HLA class I allotypes. The detergent used to lyse the cells was 
digitonin. The membranes were probed for MHC class I heavy chain (using the HC10 antibody), 








5.2.5. HLA class I molecules that bind strongly to TAPBPR are also strong tapasin 
binders 
It is still poorly understood whether the two peptide editors on the MHC class I pathway, 
tapasin and TAPBPR, work in synergy to shape the peptide repertoire presented on MHC class I, 
or whether they perform similar functions while working independently from each other. To 
provide insight into this, I explored whether there was any correlation between the ability of 
HLA class I molecules to bind TAPBPR and their ability to bind tapasin. Immunoprecipiation of 
tapasin from the same panel of HeLaM-HLA cell lines used for TAPBPR pull-down showed that 
the HLA class I molecules which were strong TAPBPR binders, appeared to interact more 
strongly with tapasin as well (Figure 41). For instance, HLA-A*68:02 was also the strongest 
binder to tapasin, among the small panel of HLA class I molecules tested, while HLA-A*68:01 
was one of the weakest binders. Both B*44:02 and B*44:05 appeared to interact weakly with 
tapasin, similarly as observed for TAPBPR. Interestingly, the similar binding levels observed for 
these two HLA-B44 molecules to tapasin correlates well with the findings observed by Park and 
colleagues (Park et al., 2003), however contrasts with the considerable difference in their 
relative dependencies on tapasin (Williams et al., 2002, Howarth et al., 2004, Rizvi et al., 2014). 
In contrast to the data obtained for TAPBPR, there did not seem to be a significant difference in 
tapasin binding between HLA-B*38:01 and -B*39:01 (Figure 41). Nonetheless, the strong 
interaction of HLA-A*68:02 with both TAPBPR and tapasin and the very weak interaction of 
HLA-A*68:01 with the two chaperones, relative to the other HLA class I molecules tested, 
support our recycling model of MHC class I from TAPBPR back to tapasin, potentially via 




5.2.6. Peptide exchange catalysed by TAPBPR is proportional to its ability to associate 
with HLA class I 
My work on a limited number of HLA class I molecules suggests that the ability of TAPBPR to 
stably associate to HLA class I, when present at the cell surface, determines the efficiency of its 
peptide exchange function (Chapter 4). Thus, I was interested in assessing whether the 
observed binding preference exhibited by TAPBPR across the HLA class I panel tested (Figure 




tested the ability of TAPBPR to mediate peptide exchange on a broad panel of HLA class I 
molecules, present at the cell surface, using the novel cell-based peptide exchange assays 
which I developed (Figure 42). The HLA class I molecules selected for this experiment included 
7 HLA-A, 2 HLA-B and 2 HLA-C allotypes, comprising strong TAPBPR binders (HLA-A*68:02,          
-A*23:01, -A*02:01), intermediate/weak TAPBPR binders (HLA-A*32:01, -B*38:01, -A*03:01,      
-A*11:01, -C*01:02) and non-binders (HLA-B*27:05, -C*02:02). I designed fluorescently-labelled 
peptide specific for each HLA class I allotype and measured their binding to the surface of 
HeLaM-HLA-ABCKO cells reconstituted with the corresponding HLA class I allotype by flow 
cytometry, in the presence or absence of recombinant TAPBPR. 
 
Figure 42: Schematic representation of the peptide exchange assay used to determine TAPBPR-
mediated peptide exchange across a panel of HLA class I allotypes. 
 
Due to the low peptide concentration used (10 - 100 nM), very low levels of peptide binding 
were observed in the absence of TAPBPR, across all HLA class I allomorphs tested (black lines, 
Figure 43a and black bars, Figure 43b). The presence of TAPBPR however resulted in a massive 
enhancement in the peptide binding to HLA class I allotypes classified as strong binders, namely 
A*68:02, A*02:01 and A*23:01 (blue line, Figure 43a and blue bar, Figure 43b). The 
intermediate/weak TAPBPR binders, namely B*38:01, A*03:01, A*11:01 and C*01:02 still 
showed a significant increase in peptide binding in the presence of TAPBPR, however this 
observed enhancement was considerably lower compared to the one observed for the strong 
binders (Figure 43a and 43b). As expected, peptide binding to the non-binders, namely B*27:05 
and C*01:02, was not affected by TAPBPR (Figure 43). None of the peptides tested showed any 
binding to HeLaM-HLA-ABCKO cells (Figure 44), confirming that the observed peptide binding to 







Figure 43: Peptide exchange exerted by TAPBPR is proportional to its ability to bind HLA class I. 
IFNγ-stimulated HeLaM-HLA-ABCKO cells expressing individual HLA class I allotypes were incubated 
with 1 μM TAPBPR for 15 min at 37°C and subsequently with a fluorescently-labelled peptide specific 
for each corresponding HLA class I allotype (peptide sequence shown in brackets), added over an 
allotype-dependent time and peptide concentration (details described in materials and methods). (a) 
Histograms showing the level of fluorescent peptide bound to individual HLA class I-expressing cells, 
either untreated (filled grey line), treated with peptide alone (black line) or with peptide and TAPBPR 
(blue line). (b) Bar graphs summarising the levels of fluorescent peptide binding in the presence of 
either no TAPBPR (black bars), 100 nM TAPBPR (orange bars) or 1 μM TAPBPR (blue bars). Error bars 
show mean fluorescence intensity (MFI) -/+ SD from three independent experiments. n/s not 
significant, **P≤0.01, ****P≤0.0001, using unpaired two-tailed t-test. The samples in panel b) were 






Figure 44: Fluorescent peptides do not bind non-specifically to the surface of cells. (a) Histograms 
showing binding levels of the fluorescent peptides used in Figure 43 to HeLaM-HLA-ABCKO cells, in the 
presence (right) or absence (left) of 1 μM TAPBPR. Cells were treated with or without TAPBPR for 15 
min at 37°C, and then with peptide for 1 h at 37°C, as described in Figure 44. The peptides tested 
were: ETVSK*QSNV (ETV*), YLLEK*LWRL (YLL*), KTGGPIYK*R (KTG*), SHETK*IIEL (SHE*), SRYWK*IRTR 
(SRY*), LNPSK*AATL (LNP*), YVVPFVAK*V (YVV*), RVLDK*VEKW (RVL*) and PYLFK*LAAI (PYL*). The 
levels of bound fluorescent peptides were determined by flow cytometry. Data is representative of 
three independent experiments. 
 
To better illustrate the difference in the relative peptide editing efficiency of TAPBPR across 
different HLA class I allotypes, I selected a set of HLA class I allotypes, comprising both strong 
TAPBPR binders (A*68:02 and A*02:01) and weak binders (B*38:01 and A*68:01) and 
measured the TAPBPR-mediated enhancement in peptide exchange at the cell surface, when 
TAPBPR was present at different concentrations (Figure 45). Strikingly, the efficiency of TAPBPR 
in catalysing peptide exchange on A*68:02 was considerably superior to its ability to exchange 
peptides on the other HLA class I allotypes tested, including A*02:01. Namely, already at 100 
nM, TAPBPR was ~4 times more efficient at catalysing peptide exchange on A*68:02 than on 
A*02:01 and over 40 times more efficient than on A*68:01 and B*38:01 (Figure 45). Moreover, 
despite A*68:02 and A*02:01 reaching almost comparable levels of TAPBPR-mediated peptide 
exchange in the presence of 2 μM TAPBPR, the EC50 of TAPBPR for peptide exchange on 
A*68:02 was ~40 nM, while on A*02:01, the EC50 was ~500 nM. Compared to the strong 
binders A*68:02 and A*02:01, both weak TAPBPR binders, namely B*38:01 and A*68:01, 






Figure 45: Dose-dependent peptide loading by soluble TAPBPR onto surface-expressed HLA class I 
molecules. Line graphs depict difference by fold increase in peptide binding to HLA-A*68:02,                
-A*02:01, -B*38:01 and -A*68:01, in the presence of different TAPBPR concentrations, compared to 
when peptide alone was added to cells. Error bars show mean fluorescence intensity (MFI) -/+ SD 
from three independent experiments. 
 
Consistent with my previous observations using only a few different HLA class I allotypes, my 
results here show that the efficiency of TAPBPR-mediated peptide exchange across different 
HLA class I allotypes present at the cell surface is proportional to the relative levels of HLA class 
I bound to TAPBPR in the pull-down experiments (Figure 40). One exception however was   
HLA-A*32:01, a member of the A1 superfamily (Sidney et al., 2008), which showed very similar 
levels of TAPBPR-meditated peptide exchange as members of the A2 and A24 superfamilies 
(Figure 45), despite showing a considerably lower ability to bind TAPBPR than those molecules 
(Figure 39).  
Taken together, these finding suggests that the peptide editing efficiency of TAPBPR strongly 
depends on its intrinsic ability to associate stably with HLA class I molecules. The presence of 
outliers, such as H:A-A*32:01, can be attributed to specific intrinsic properties of particular HLA 
class I molecules that would allow TAPBPR to disrupt their binding groove, thus promoting 









5.2.7. The relative susceptibility of HLA class I molecules to undergo peptide editing by 
TAPBPR does not directly correlate with their relative stability at the cell surface 
Given that each HLA class I allotype presents a distinct peptide repertoire at the cell surface, 
the stability of pMHC class I complexes present at the cell surface can differ significantly among 
different HLA class I allotypes. Thus, I next tested whether the observed increased susceptibility 
of the A2 and A24 superfamily members over the rest of the HLA class I molecules tested was 
due to their intrinsic ability to form stable interactions with TAPBPR or if it was due to their 
relatively lower stability at the cell surface, which would then lower the energy required by 
TAPBPR to dissociate the bound peptides. To address this question, I selected several HLA class 
I candidates spanning the entire TAPBPR binding hierarchy (Figure 35b) and assessed their 
relative stability at the cell surface. This was done by measuring the decay rates of pMHC class I 
complexes from the cell surface upon treating the cells with brefeldin A (BFA), molecule which 
inhibits protein trafficking to the cell surface (Fujiwara et al., 1988). The results showed that 
A*68:02, which is the strongest HLA class I binder to TAPBPR from our panel, also displayed the 
highest decay rate from the cell surface and hence the lowest stability among the 6 HLA 
allotypes tested (Figure 46). In contrast, B*44:05 and B*27:05, which are among the weakest 
TAPBPR binders, showed the highest relative stability among the molecules tested, decaying by 
less than 10% after 16 hours of BFA treatment (Figure 46). Based on this comparison alone, the 
ability of TAPBPR to stably bind to MHC class I would appear to correlate with the molecular 
stability of MHC class I complexes. However, highly similar decay rates were observed for 
A*02:01 and for A*68:01, despite A*02:01 being one of the strongest TAPBPR binders and 
A*68:01 being one of the weakest among HLA-A molecules. Moreover, HLA-B*38:01 showed a 
significantly lower stability compared to A*02:01 (Figure 46), despite its much weaker 
propensity to undergo peptide editing by TAPBPR (Figures 43 b and 45). Overall, while that the 
molecular stability of HLA class I molecules may affect their propensity to undergo peptide 
editing by TAPBPR marginally, this process seems to be driven mainly by the intrinsic ability of 





Figure 46: Stability of HLA class I molecules at the cell surface does not correlate with their relative 
susceptibility to TAPBPR-mediated peptide editing. Decay rates of the W6/32-reactive A*68:02, 
A*02:01, A*68:01, B*38:01, B*27:05 and B*44:05 from the cell surface upon treatment with 10 
μg/mL Brefeldin A for different time periods. Error bars show mean fluorescence intensity (MFI) -/+ 
SD from triplicate samples. This is a representative example of two independent experiments.  
 
 
5.2.8. Molecular properties of the F pocket of HLA class I correlate well with TAPBPR 
binding ability  
I have previously proposed that F pocket specificity of HLA class I molecules for hydrophobic 
peptide residues is crucial for efficient TAPBPR-mediated peptide exchange, by allowing the 
binding of the L30 residue of TAPBPR, which was shown to promote peptide dissociation 
(Chapter 4). Given the observed preference of TAPBPR for HLA class I members of the A2 and 
A24 supertypes, I wanted to explore the molecular basis of this preference, focusing mainly on 
the F pocket region. By comparing the amino acid specificities across a wide range of HLA-A 
molecules, spanning the entire TAPBPR binding hierarchy, I observed that all members of the 
A2 and A24 superfamilies naturally accommodate aliphatic (and hence hydrophobic) amino 
acid residues (Table 8)(Sidney et al., 2008, Robinson et al., 2015). In contrast, all members of 
the A3 superfamily, which exhibit weak interactions with TAPBPR, accommodate basic residues 
in their F pocket (Table 8). The most eloquent example here is the one mentioned previously 
and namely the comparison between HLA-A*68:02 and HLA-A*68:01. Despite these two 
molecules differing in only 5 amino acid residues, HLA-A*68:02 is a member of the A2 




whereas HLA-A*68:01 is a member of the A3 supefamily and was shown to bind TAPBPR very 
weakly. These findings together highlight a strong correlation between F pocket specificity for 
hydrophobic residues of HLA class I molecules and their ability to bind TAPBPR. 
 
 Table 8: Characterization of HLA-A allotypes subjected to TAPBPR binding   









A*68:02 A2 Hydrophobic H Y 
A*23:01 A24 Hydrophobic H Y 
A*69:01 A2 Hydrophobic H Y 
A*02:01 A2 Hydrophobic H Y 
A*24:02 A24 Hydrophobic H Y 
A*02:06 A2 Hydrophobic H Y 
A*03:01 A3 Basic R D 
A*01:01 A1 Aromatic R D 
A*26:01 A1 Aromatic Q D 
A*30:01 A3 Basic / Aromatic E H 
A*30:02 A1 Aromatic E H 
A*33:01 A3 Basic Q D 
A*36:01 A3 Basic R D 
A*66:01 A3 Basic Q D 
A*68:01 A3 Basic R D 
 
 
5.2.9. Residues H114 and Y116 are conserved across all members of A2 and A24 
superfamily and are not present in any other known HLA class I allotypes 
To explore whether the actual architecture of HLA class I F pocket correlates with TAPBPR 
binding ability, I next compared the amino acid sequences across the same panel of HLA-A 
molecules, spanning residues 72-120, given the involvement of this HLA class I region in the 
binding of the C-terminal region of the peptide (Figure 47). Among the residues proposed to be 
particularly important in determining specificity of the F pocket for peptide residues (Sidney et 
al., 2008), I found residues H114 and Y116 to be conserved among all currently known 
members of the HLA-A2 and -A24 supertypes. Moreover, none of the A1 and A3 supertype 
members, nor any other HLA class I allotypes currently known contains this combination of 
residues at the specified positions (Robinson et al., 2015). These observations are in line with 
our previous finding that presence of residue Y116 in HLA class I promotes TAPBPR binding 




tested, suggest that the susceptibility of HLA class I to TAPBPR-mediated peptide editing may 
be strongly influenced by the molecular architecture of the MHC class I F pocket.    
 
Figure 47: H114/Y116 residues are conserved exclusively across all HLA class I members of the A2 
and A24 supertypes. (a) Amino acid multiple sequence alignment across different members of all 
HLA-A supertypes, consisting of residues 1-12 and 72-120; residues 114 and 116 are highlighted in 
red, while residues 12 and 105 are highlighted in blue. (b) PyMOL figure of the HLA-A*68:02 structure 
folded with peptide SVYDFFVWL (PDB ID 4HX1); residues H114 and Y116 are highlighted in red, the C-
terminal L9 residue of the peptide in light blue and the peptide backbone in grey. The MHC class I 
structure is displayed in black. Dotted yellow lines indicate the shortest distances between the 
connected amino acid residues, measured in Å.  
 
 
5.2.10. The F pocket architecture governs the ability of HLA class I molecules to 
associate with TAPBPR 
To assess whether the H114/Y116 residue combination influences the interactions of HLA class 
I with TAPBPR, I artificially reconstituted these residues in some of the weak TAPBPR binders, 




HLA-B and HLA-C molecules, contain both H114 and Y116 residues (Robinson et al., 2015), 
however, there are several HLA-B allotypes that contain one of the two, for instance HLA-
B*27:05, with H114 but D116 instead of Y116, or HLA-B*44:05, with Y116, but D114 instead of 
H114 (Figure 48a). I therefore replaced D114 with a histidine in HLA-B*44:05 and replaced 
D116 with a tyrosine in B*27:05 and assessed the effects of these mutations on the ability of 
the two HLA-B molecules to bind TAPBPR. Upon reconstitution into HeLaM-HLA-ABCKO cells, 
both HLA-B*44:05D114H and -B*27:05D116Y showed very similar surface expression levels 
compared to their corresponding wild type counterparts (Figure 48b).  
 
 
Figure 48: Designing F pocket mutants of HLA-A, -B and -C molecules and assessing their surface 
expression levels. (a) Amino acid sequence alignment of residues 72-120 between A*68:02 and 
A*68:01, B*44:05 or C*01:02, as well as their corresponding F pocket mutants; residues 114 and 116 
are highlighted in red. (b) Histograms showing surface expression levels of the individual HLA class I F 
pocket mutants (orange lines) listed in a), without A*68:02, assessed by staining with W6/32, 
compared to their corresponding wild type counterparts (black lines). Samples stained with an isotype 






As shown previously, neither B*27:05WT nor B*44:05WT was able to stably interact with TAPBPR 
at the cell surface (black lines – Figure 49a and blue bars - Figure 49b). Strikingly however, both 
B*27:05D116Y- and B*44:05D114H-expressing cells showed high levels of surface TAPBPR binding 
(orange lines – Figure 49a and red bars - Figure 49b). In fact, reconstitution of an “A*68:02-like 
F pocket” in both B*27:05WT and B*44:05WT, resulted in a similar increase in their ability to bind 
TAPBPR as the one recorded for another weak TAPBPR binder, namely A*68:01, upon 
introducing the D116Y mutation, as previously shown (Figure 33). Moreover, altering the F 
pocket of the strong TAPBPR binder A*68:02, by mutating Y116→D, triggered a severe 
decrease in TAPBPR binding (Figure 49b), as previously observed (Figure 33). Here, the 
A*68:02Y116D chimeric mutant served as an additional control to further confirm the impact of 
residues H114 and Y116 on the ability of HLA class I molecules to interact with TAPBPR.  
 
Figure 49: The H114/Y116 residue combination promotes the interaction of HLA-A, -B and -C 
molecules to TAPBPR. (a) Histograms depicting soluble TAPBPR binding to cell surface B*27:05 and 
B*44:05 (black lines), as well as to their corresponding F pocket mutants (orange lines), upon 
incubating the cells with 1 μM soluble TAPBPRWT. (b) Bar graphs showing the level of TAPBPR binding 
to cells expressing A*68:01, B*27:05, B*44:05 or A*68:02 (blue) and to their corresponding F pocket 
mutants (red), from three independent experiments. Error bars show mean fluorescence intensity 
(MFI) -/+ SD from three independent experiments. n/s not significant, ***P ≤ 0.001, ****P≤0.0001 





I next assessed the effects mutating the F pocket on the interaction of TAPBPR with HLA class I 
molecules present intracellularly, by pull down experiments using recombinant TAPBPR 
protein. The results revealed that introduction of the H114/Y116 combination into HLA-
B*44:05 resulted in a marked increase in TAPBPR binding (Figure 50a). These pulldown 
experiments also confirmed the increased ability of HLA-A*68:01 to bind to TAPBPR upon 
introduction of Y116 into this HLA class I, as previously shown when examining TAPBPR binding 
to HLA class I expressed on the cell surface (Figure 33). Furthermore, a similar increase in 
TAPBPR binding was also observed when introducing the H114/Y116 combination in an HLA-C 
molecule, namely HLA-C*01:02 (Figure 50a). The increased binding of HLA-A*68:01, -B*44:05 
and -C*01:02 to TAPBPR, upon reconstitution of the “A*68:02-like F pocket”, was also 
confirmed via endogenous TAPBPR pull downs (Figure 50a). Correspondingly, altering the F 
pocket of the strong TAPBPR binders HLA-A*68:02 and HLA-A*02:01, by mutating Y116→D, 
dramatically impaired their ability to bind TAPBPR (Figure 50b).  
 
Figure 50: Mutating the F pocket impairs HLA class I binding to TAPBPR. (a) Western blot analysis on 
recombinant TAPBPR pull-downs (top) and on endogenous TAPBPR and tapasin immunoprecipitates 
(bottom), from cells expressing A*68:01WT, A*68:01D116Y, B*44:05WT, B*44:05D114H, C*01:02WT or 
C*01:02D114H. (b) Western blot analysis on recombinant TAPBPR pull-downs on cells expressing 
A*02:01, A*68:02, as well as their corresponding Y116D mutants. Membranes were probed for MHC 







Finally, I wanted to understand to what extent these artificial mutations of the F pocket altered 
the molecular stability of the HLA class I molecules tested and whether that could have 
influenced their observed increased ability to bind TAPBPR. To this end, I measured their 
relative stability of the HLA class I F pocket mutants in comparison to their corresponding wild 
type counterparts, by performing BFA decay assays (Figure 51). While A*68:01D116Y and 
B*44:05D114H (dashed lines – Figure 51) indeed displayed significantly lower stability at the cell 
surface compared to the wild type molecules (solid lines – Figure 51), B*27:05D116Y was 
surprisingly more stable than B*27:05WT (black lines – Figure 51). Moreover, the Y116D 
mutation in A*68:02, which impaired its ability to bind TAPBPR (Figure 49b), also reduced its 
molecular stability (Figure 51). In conclusion, consistent with my observations across wild type 
HLA class I molecules (Figure 46), there does not seem to be any correlation between the 
change in pMHC class I stability caused by mutating the HLA class I F pocket and the effect of 
these mutations on TAPBPR binding.  
 
Figure 51: Mutating the F pocket of HLA class I molecules does not necessarily alter their stability at 
the cell surface. Line graphs depict the decay rates of the W6/32-reactive B*27:05, B*44:05, A*68:01 
and A*68:02 from the cell surface, as well as of their corresponding F pocket mutants, upon 
treatment with 10 μg/mL brefeldin A, for different time periods. Error bars show mean fluorescence 
intensity (MFI) -/+ SD based on triplicates from one experiment. Data is representative of two 
independent experiments.  
 
Together, these findings indicate that the residues found at position 114 and 116 strongly 
influence the intrinsic ability of HLA to interact with TAPBPR. Interestingly, I observed a similar 
increase in the binding of A*68:01D116Y and B*44:05D114H to tapasin compared to their wild type 




HLA class I molecules with TAPBPR and their net binding to tapasin, similar to the one observed 
for the panel of wild type HLA molecules tested previously (Figure 41), potentially supporting 
the recycling model of HLA class I molecules from TAPBPR back to the PLC (Boyle et al., 2013, 
Neerincx et al., 2017). 
 
 
5.2.11. The F pocket architecture strongly influences the susceptibility of MHC class I 
molecules to undergo peptide editing by TAPBPR 
I next explored whether the alterations made to the F pocket of HLA-B*44:05 and -B*27:05 
increased their susceptibility to TAPBPR-mediated peptide exchange (Figure 52). Upon addition 
of exogenous fluorescent peptide, I found that in the presence of TAPBPR, peptide loading was 
only slightly increased on HLA-B*44:05WT molecules and was not affected at all on HLA-B*27:05 
(Figure 52a and 52b). Strikingly, however, introducing an “A*68:02-like F pocket” in both HLA-
B*44:05 and -B*27:05 triggered a ~100-fold increase in TAPBPR-mediated peptide loading 
(Figure 52b). In fact, restoration of the H114/Y116 motif into two relatively non-responsive 
HLA-B molecules resulted in them undergoing TAPBPR-mediated peptide editing to the same 
magnitude as observed for HLA-A*02:01 and -A*68:02 molecules (Figure 43b). My findings 
strongly implicate that residues H114 and Y116, in combination, represent a key molecular 
signature responsible for the high susceptibility to TAPBPR observed for the HLA class I 






Figure 52: Residues H114 and Y116 promote the susceptibility of MHC class I molecules to peptide 
editing by TAPBPR. (a) Histograms showing the level of bound fluorescent peptide EEFGK*AFSF to 
cells expressing either B*44:05WT or B*44:05D114H (top) and of SRYWK*IRTR to cells expressing either 
B*27:05WT or B*27:05D116Y (bottom), upon incubation of the cells with 100 nM peptide and either no 
TAPBPR (black), 100 nM TAPBPR (orange) or without peptide (filled grey line), as a negative control. 
(b) Bar graphs summarising the level of fluorescent peptide binding in panel a), when cells were 
treated with 100 nM peptide and either no TAPBPR (black), 100 nM TAPBPR (orange) or 1 μM TAPBPR 
(blue). Error bars show mean fluorescence intensity (MFI) -/+ SD from three independent 
experiments. n/s not significant, *P≤0.05, ****P≤0.0001 using unpaired two-tailed t-test. 
 
 
5.2.12. Disease-associated HLA class I allotypes that naturally differ in residue 116 
alone show different propensities to undergo TAPBPR-mediated peptide editing 
I have thus far shown that artificially mutating residues 114 and 116 considerably alters the 
susceptibility of HLA class I molecules to peptide editing by TAPBPR (Figures 34 and 52). 
Following on from this finding, I then asked whether naturally-occurring polymorphisms in HLA 
class I molecules, at one of these two positions alone, has any impact on the propensity of HLA 
class I to undergo TAPBPR-mediated peptide editing. To address this, I first compared the effect 
of TAPBPR on peptide editing between HLA-B*27:05 and -B*27:09, which only differ in residue 
116 (D→H) (Figure 53a). This question was of particular interest also given the implication that 
this subtle polymorphism in HLA-B27 has on the susceptibility to the autoinflammatory 
condition ankylosing spondylitis. While HLA-B*27:05 is associated with this condition, HLA-
B*27:09 was suggested to be not associated with the disease (Brown, 2010, Fiorillo et al., 2003, 




allotypes, namely HLA-B*35:01 and -B*35:03, also differs in residue 116 alone (S→F) (Figure 
53a), however, rather interestingly, enable different progression levels of HIV (Gao et al., 2001).  
 
Figure 53: Wild type HLA-B molecules that differ in residue 116 alone are similarly expressed at the 
cell surface. a) Amino acid sequence alignment across residues 72-120 of A*68:02 with the HLA class I 
pairs B*27:05 - B*27:09 and B*35:01 - B*35:03; residues 114 and 116 are highlighted in red. (b) 
Histograms depict the levels of MHC class I, measured by staining with W6/32 antibody, on the 
surface of HeLaM-HLA-ABCKO cells reconstituting with each of the HLA class I allotypes in panel a). 
These histograms are representative examples of three independent experiments. 
 
Since the two HLA-B27 molecules, as well as the two HLA-B35 molecules, were reported to bind 
similar peptides respectively, I used the peptide SRYWK*IRTR for both B*27:05 and B*27:09 
(Nurzia et al., 2012) and SPAIK*QSSM for both B*35:01 and B*35:03 (www.hiv.lanl.gov). Upon 
reconstitution into HeLaM-HLA-ABCKO cells, all four HLA-B molecules showed similar expression 
levels, both at the cell surface and intracellularly (Figure 53b and Figure 54). When measuring 
the relative binding of these HLA class I molecules to recombinant TAPBPR by pull-down 






Figure 54: Natural differences in residue 116 across HLA-B allotypes do not significantly influence 
interaction with TAPBPR. Western blot analysis of recombinant TAPBPR immunoprecipitation 
experiments on cells expressing each of the HLA class I allotypes shown in Figure 53. The membranes 
were probed for MHC class I heavy chain (using the HC10 antibody), TAPBPR and calnexin, as 
indicated. Data is representative of three independent repeats.  
 
Upon testing their susceptibility to peptide editing by TAPBPR however, while TAPBPR showed 
no significant effect on peptide binding to HLA-B*27:05, it facilitated an increase of over 100% 
in the level of peptide exchange on HLA-B*27:09 (Figure 55a and 55b). Regarding the HLA-B35 
molecules, peptide exchange on B*35:01 was unaffected by TAPBPR, while B*35:03 exhibited a 
slight yet significant increase, of almost 20%, in the presence of TAPBPR (Figure 55a and 55b). 
As expected, given that none of these HLA-B molecules contain the H114/Y116 motif, the 
ability of TAPBPR to mediate peptide exchange on them was significantly lower compared to 
HLA-A2 and -A24 superfamily members (Figure 43). However, the one amino acid difference, at 
the key position 116, between the B27 allotypes as well as between the B35 allotypes, appears 
to be enough to cause a difference in the propensity of those molecules to undergo chaperone-







Figure 55: Naturally occurring differences in residue 116 alone across disease-associated HLA-B 
allotypes influence their susceptibility to peptide editing by TAPBPR. (a) Histograms depicting the 
level of fluorescent peptide binding to cells expressing B*27:05, B*27:09, B*35:01 or B*35:03, when 
cells were treated either with peptide alone (black lines) or with peptide and 1 μM TAPBPR (blue 
lines). The peptide SRYWK*IRTR was used for B*27:05 and B*27:09, while SPAIK*QSSM was used for, 
B*35:01 and B*35:03. Samples treated without peptide were used as negative controls (filled grey 
lines). (b) Bar graphs summarising the peptide binding MFI levels from panel a). Error bars show mean 
fluorescence intensity (MFI) -/+ SD from three independent experiments. n/s not significant, 
**P≤0.01, ***P ≤ 0.001, using unpaired two-tailed t-test. 
 
 
5.2.13. Residue M12 of HLA-A*68:02 is responsible for its distinct ability to interact 
with TAPBPR 
My TAPBPR binding data to HLA class I using the SABs (Figure 35b) and the cellular systems 
(Figure 39 and 40) all indicate that, while all members of the A2 and A24 supertypes interact 
strongly with TAPBPR, HLA-A*68:02 shows a much stronger association to TAPBPR than the 
rest. That implies that residues uniquely present in HLA-A*68:02 among all members of the A2 
and A24 superfamilies, not necessarily involved in the F pocket architecture, are responsible for 
its enhanced ability to bind TAPBPR. Comparison of HLA-A*68:02 with the highly similar HLA-
A*68:01 revealed, in addition residues involved in determining F pocket specificity, they differ 
in two other amino acids, at positions 12 and 105 (Figure 47a). Interestingly, despite various 
differences between HLA-A*68:02 and other members of the A2 and A24 superfamilies, the 




(Figure 47a). More specifically, while A*68:02 contains a methionine at position 12 and a 
proline at position 105, all other members of the A2 and A24 supertypes contain a valine at 
position 12 and a serine at position 105. For instance, HLA-A*69:01 shows a considerably 
reduced ability to bind TAPBPR compared to HLA-A*68:02 (Figures 35b and 37), despite 
differing in only five amino acids, two of which are the already mentioned ones, at positions 12 
and 105 (Figure 56a). Interestingly, HLA-A*02:01, that differs from HLA-A*68:02 in several 
more amino acids as compared to HLA-A*69:01 (Figure 56a), including however residues 12 
and 105, showed a similar level of TAPBPR binding to HLA-A*69:01 (Figures 35b and 37). Based 
on these observations, I hypothesized that residues M12 and/or P105 are responsible for this 
increased ability of HLA-A*68:02 to interact with TAPBPR. I therefore swapped either residue 
12 or 105 between A*68:02 and A*02:01, generating the following chimeric HLA class I 
mutants: A*68:02M12V, A*68:02P105S, A*02:01V12M and A*02:01S105P. All chimeric mutants 
showed similar surface expression levels as their corresponding wild type counterparts upon 
stable reconstitution in HeLaM-HLA-ABCKO cells (Figure 56b).  
 
Figure 56: Design of HLA-A*68:02 and HLA-A*02:01 chimeric mutants, by targeting residues M12 
and P105. (a) PyMOL images of the MHC class I binding groove, as seen from the top, emphasizing 
the amino acid differences between A*68:02 and A*68:01 (left), A*69:01 (centre) or A*02:01 (right), 
respectively (PDB ID 4HWZ was used as template for all three comparisons); conserved residues are 
coloured in blue, while amino acid differences between a strong binder (A*68:02) and the weak 
binder (A*68:01) are highlighted in red and differences between the strongest TAPBR binder 
(A*68:02) and other good binders in green. (b) Histograms depicting surface expression levels of 
A*68:02WT, A*68:02M12V, A*68:02P105S, A*02:01WT, A*02:01V12M and A*02:01S105P using the MHC class I 
specific mAb W6/32. Samples stained with an isotype control antibody were chosen as negative 




When assessing their ability to bind TAPBPR at the cell surface, I found that mutation of residue 
105 in either HLA-A*68:02 or HLA-A*02:01 had little or no effect on TAPBPR binding (Figure 
57). Strikingly however, mutation of residue M12 in HLA-A*68:02 severely decreased its ability 
to bind TAPBPR (Figure 57). Namely, a 10-fold higher TAPBPR concentration was needed to 
achieve a similar level of binding to HLA-A*68:02M12V, compared to HLA-A*68:02WT (Figure 
57b). Correspondingly, mutation of V12→M in HLA-A*02:01 led to a >10-fold increase in its 
ability to bind TAPBPR (Figure 57). Remarkably, although A*02:01 differs significantly from 
A*68:02 in its amino acid sequence, reconstitution of residue M12 alone on A*02:01 enhanced 
its ability to associate with TAPBPR to levels almost identical to the ones observed for HLA-
A*68:02WT (Figure 57b). These findings suggest that residue M12, found uniquely in A*68:02 
among all HLA-A molecules tested, is mainly responsible for its distinct ability to interact with 
TAPBPR.  
 
Figure 57: Residue M12 of HLA-A*68:02 promotes its high accessibility to TAPBPR. (a) Histograms 
displaying bound levels of soluble TAPBPR to the MHC class I variants in Figure 56, after cells were 
treated with 100 nM soluble TAPBPR for 30 min at 37°C. (b) Bar graphs summarising the levels of 
TAPBPR bound to each HLA class I allotype tested in panel a), upon treatment with either 100 nM 
(light grey) or 1 μM TAPBPR (dark grey). Bars show mean fluorescence intensity (MFI) -/+ SD from 
three independent experiments. n/s not significant, *P≤0.05, ****P≤0.0001 using unpaired two-tailed 
t-test. 
 
This result was rather unexpected, as M12V seems a much more subtle mutation compared to 
P105S, especially given the position of the two residues in the binding groove. Whereas residue 
12 sits at the end of β4 strand, pointing away from the α1 helix (Figures 56a and 58), residue 




proline at position 105 should theoretically provide a higher degree of flexibility of the β5/β6 
loop, potentially affecting the entire molecular plasticity of the peptide binding groove. I 
expected that the P105S change should in any case have a higher impact than M12V on the 
ability of HLA class I to interact with TAPBPR, mainly as TAPBPR relies on peptide-MHC class I 
kinetics to associate with MHC class I.  
Next, I overlaid HLA-A*68:02 on top of H-2Db, which was crystallised in complex with TAPBPR 
(Thomas and Tampe, 2017), to understand whether residue M12 of HLA-A*68:02 could 
potentially influence the contact points between MHC class I and TAPBPR (Figure 58). However, 
this alignment showed considerable distances, of at least 15 Å between residue M12 and the 
nearest TAPBPR regions, making it unlikely for this residue to be involved in the direct 







Figure 58: M12 residue of HLA-A*68:02 does not seem to contribute to the direct interaction with 
TAPBPR. PyMOL image of the structure of HLA-A*68:02 folded with peptide SVYDFFVWL (pink) (PDB 
ID 4HX1) overlaid onto the structure of the H-2Db:TAPBPR complex (grey and green respectively) (PDB 
ID 5OPI), viewed from different angles. Residue M12 of HLA-A*68:02 is highlighted in blue and 
emphasized in a dotted circle. Magnified views of the selected areas are depicted below the full 
structures. Residue M12 was captured in two different orientations in the crystal structure of HLA-
A*68:02. 
 
Given the observations mentioned above, I believe that residues such as M12 could affect the 
ability of HLA class I molecules to interact with TAPBPR by affecting the molecular plasticity of 
the MHC class I peptide binding groove. This would in turn affect the stability of the peptide-
MHC complex and hence the ability of TAPBPR to dissociate the peptide (McShan et al., 2018), 







5.3. Discussion  
 
This chapter follows on from my previous observations that TAPBPR facilitates peptide 
exchange in a loop-dependent manner preferentially on MHC class I molecules that naturally 
accommodate hydrophobic peptide residues in their F pocket (Figure 30). Here, I explored the 
relative susceptibility of a wide panel of HLA class I allotypes, representative to most HLA class I 
supertypes currently described, to peptide editing by TAPBPR. The results of this study show a 
clear preference of TAPBPR for HLA-A, and particularly for HLA-A2 and -A24 supertypes, over 
HLA-B and -C molecules (Figures 35 and 37). Moreover, in exploring the molecular basis of this 
observed preference, I demonstrate that certain molecular features of the F pocket, in 
particular residues 114 and 116, strongly influence the propensity of HLA class I to undergo 
TAPBPR-mediated peptide editing. These findings highlight an additional layer of complexity in 
the MHC class I allele-dependent peptide selection in cells and provide valuable insight into 
better understanding the mechanisms of peptide editing on MHC class I.  
I speculate that the higher efficiency of TAPBPR in promoting peptide dissociation from some 
HLA class I allotypes over others is dependent on the compatibility between the 22-35 loop of 
TAPBPR and the F pocket of the HLA class I molecules. However, I have not tested the ability of 
the TAPBPR loop mutants to mediate peptide exchange on all of the HLA class I molecules 
mentioned in the study, but only on a few representative examples, as described in the 
previous chapter (Figure 30). It is entirely possible that other regions of TAPBPR, such as the 
jack hairpin (Thomas and Tampe, 2017), in a similar manner to the loop, could have a stronger 
impact on peptide exchange on some HLA class I allotypes than on others.  
Finally, it is important to consider that, in this study, I only explored the relative susceptibility of 
different HLA class I allotypes to TAPBPR-mediated peptide editing, by assessing this process at 
the cell surface, which is an atypical cellular localization of TAPBPR (Boyle et al., 2013). To 
address the question of relative dependency of HLA class I molecules to TAPBPR function, one 
would need to compare the ability of a panel of HLA class I allotypes to load and present 
peptides, as well as the consequent differences in peptide repertoires for each allotype, in the 





6. Chapter 6: Investigating the therapeutic potential of using soluble 




Thus far, I have used the cellular peptide exchange assays described in Chapter 3 to address a 
series of fundamental questions regarding the molecular mechanisms governing TAPBPR-
mediated peptide editing on MHC class I (Chapter 4) and the compatibility between TAPBPR 
and MHC class I (Chapter 5). However, my findings that TAPBPR can function as an efficient 
peptide loading catalyst onto MHC class I molecules present at the surface of cells have also 
raised an interesting translational question regarding the potential use of TAPBPR as an 
immuno-modulator. More specifically, we were interested in whether by facilitating the loading 
of highly immunogenic peptides of choice directly onto MHC class I molecules present on the 






6.2.1. TAPBPR can be used to load immunogenic peptides onto human tumour cells 
To this end, I first tested whether soluble TAPBPR could promote the loading of immunogenic 
peptides, of tumour origin, onto MCF-7 cells, a breast cancer cell line expressing HLA-A*02:01 
(Figure 59). I designed fluorescent derivatives of the tumour-derived antigens specific to HLA-
A*02:01 IMDQVPFSV (derived from gp100)(Salgaller et al., 1996), ELAGIGILTV (derived from 
MART-1)(Romero et al., 1997), LLGRNSFEV (derived from p53)(Theobald et al., 1998) and 
RLLQETELV (derived from Her-2)(Rongcun et al., 1999) and measured their binding to MCF-7 
cells in the presence or absence of soluble TAPBPR. While in the absence of soluble TAPBPR, 
none of the peptides showed efficient loading onto the surface of cells, presence of TAPBPR 




manner as previously observed for the viral peptides YLLEMLWRL (from EBV) and NLVPMVATV 
(from HCMV) (Figure 31b).  
 
Figure 59: Soluble TAPBPR mediates loading of immunogenic peptides onto MHC class I molecules 
on the surface of tumour cell lines. MCF-7 cells were incubated with (solid lines) or without (dashed 
lines) 1 µM soluble TAPBPR for 15 min at 37 °C, followed by treatment with 10 nM of (left) 
IMDQK*PFSV (dark blue), ELAGK*GILTV (green), or with (right) LLGRK*SFEV (light blue), or 
RLLQK*TELV (purple) for another 60 min at 37 °C. Bound levels of each fluorescent peptide was 
measured by flow cytometry. Data is representative of three independent experiments. Taken from 
Ilca et al. (Ilca et al., 2018b). 
     
 
6.2.2. Peptides loaded by TAPBPR onto cell surface MHC class I are available for TCR 
recognition 
I subsequently tested whether the abundantly-loaded peptides by TAPBPR on surface-
expressed HLA-A*02:01 were available for TCR recognition (Figure 60). My previous 
observation that soluble TAPBPR bound to cell surface MHC class I molecules dissociates upon 
mediating loading of exogenously-added high affinity peptides (Figure 18) raised the possibility 
that peptides loaded by TAPBPR, in complex with the HLA-A*02:01 molecules, could be 
accessible for detection by the TCR. To address this question, I first treated MCF-7 cells with the 
non-labelled peptide YLLEMLWRL (derived from EBV LMP1) in the presence or absence of 
TAPBPR, having already shown that the fluorescent version of this peptide binds strongly to 
HLA-A*02:01 (Figure 19 and Figure 31). I subsequently assessed the TCR detection of the HLA-
A*02:01 molecules loaded specifically with the YLLEMLWRL peptide by staining the cells with a 
TCR-like mAb specific for this pMHC class I complex (L1) (Figure 60a and 60b). The binding of 
TCR-like mAb to MCF-7 cells (Figure 60a and 60b) was proportional to the binding of the actual 
peptide to the cells (Figure 31b). Namely, treatment with the YLLEMLWRL peptide in the 




when the peptide was added to the cells in the presence of TAPBPRWT, but not of TAPBPRTN5, a 
strong enhancement in the recognition of MCF-7 cells by the TCR-like mAb was observed 
(Figure 60a and 60b). Moreover, TCR-like mAb binding was strictly peptide-dependent, as 
treatment of the cells with TAPBPRWT alone did not promote any TCR-like mAb recognition.  
A similar TAPBPR-mediated enhancement in the binding of the TCR-like mAb was observed for 
HeLaM-HLA-ABCKO cells reconstituted with HLA-A*02:01 (HeLa-A2 cells) (Figure 60c and 60d), 
confirming that binding of the TCR-like mAb was also HLA-A*02:01-specific. These results 
together indicate that the exogenous peptides loaded onto surface-expressed MHC class I by 
TAPBPR are available for TCR recognition.   
 
Figure 60: Antigenic peptides loaded onto tumour cells by soluble TAPBPR are available for TCR 
recognition. (a and c) Histograms showing bound levels of the TCR-like mAb L1, specific for 
YLLEMLWRL/HLA-A2 complexes, to either (a) MCF-7 or (c) HeLa-A2 cells, after cells were treated with 
10 nM YLLEMLWRL (YLL), in the presence or absence of 1 μM TAPBPRWT or TAPBPRTN5. (b and d) Bar 
graphs summarising the levels of L1 binding to either (b) MCF-7 or (d) HeLa-A2 cells, as performed in 
a) and c) respectively. Bars show mean fluorescence intensity (MFI) -/+ SD from three independent 
experiments. n/s not significant, ***P ≤ 0.001, ****P≤0.0001 using unpaired two-tailed t-test. Taken 






6.2.3. TAPBPR-mediated loading of immunogenic peptides on MHC class I enhances 
recognition of tumour cells by CD8+ T cells 
Having shown that peptides loaded by TAPBPR onto surface MHC class I molecules are 
accessible by soluble recombinant TCRs, in solution, I next asked whether these resulting pMHC 
class I complexes are also available for recognition by TCRs expressed on actual CD8+ T cells. In 
collaboration with Dr. Mark Wills (Department of Medicine, University of Cambridge), I set up 
an assay to interrogate whether we can induce CD8+ T cell-mediated recognition of tumour 
cells by using TAPBPR to load the tumour cells with immunogenic peptides. To this end, I first 
treated target MCF-7 cells with the NLVPMVATV peptide, comprising residues 495-503 of the 
HCMV protein pp65 (pp65495–503), in the presence of absence of TAPBPR. I have already shown 
that the fluorescent version of the NLVPMVATV peptide is efficiently loaded by TAPBPR onto 
surface-expressed HLA-A*02:01 (Figure 19 and Figure 31). Moreover, this peptide has been 
shown to induce strong CD8+ T cell responses (Gillespie et al., 2000). Upon washing the target 
cells to remove the excess peptide, I then co-cultured them with primary CD8+ T cells that were 
harvested from HLA-A*02:01-positive patients suffering from HCMV infection and selected for 
their recognition of the NLVPMVATV bound to HLA-A*02:01. The activation level of the CD8+ T 
cells by target MCF-7 cells was measured using a FluoroSpot assay, which allowed for the 
quantification of fluorescent signal equivalent to the IFN release by the T cells.  
Due to my lack of knowledge regarding the abundance of pMHC class I complexes at the cell 
surface required to induce T cell activation, I treated the MCF-7 cells with a range of peptide 
concentrations (10 pM – 10 nM), in the presence or absence of a fixed concentration of soluble 
TAPBPR (1 μM), and measured their ability to induce T cell activation. Moreover, I subsequently 
cultured each target cell sample with T cells, at an effector to target (E:T) cell ratio of either 1:6 
or 1:12 (Figure 61). Satisfyingly, no activation of the T cells was observed upon simply co-
culturing them with non-treated MCF-7 cells (Figure 61). Second, I observed that at lower 
peptide concentrations, (either 10 pM or 100 pM), cells treated with peptide alone induced a 
low level of T cell activation and that presence of TAPBPR induced a strong enhancement in the 
activation of T cells. However, upon increasing the peptide concentration above 100 pM, cells 
treated with peptide alone started inducing T cell activation similarly to the ones treated with 
peptide in the presence TAPBPR. In fact, the level of T cell activation in the presence of TAPBPR 
seemed to saturate already at ~100 pM peptide, whereas in the absence of TAPBPR, ~10 nM 




different peptide concentrations in this experiment, these results clearly indicated that TAPBPR 
can indeed promote T cell recognition of tumour cells.  
 
Figure 61: TAPBPR induces T cell recognition of tumour cells at low peptide concentrations. MCF-7 
target cells were treated with or without different concentrations of NLVPMVATV peptide for 60 min 
in the presence (red bars) or absence (blue bars) of 1 μM soluble TAPBPRWT. Target cells were then 
washed thoroughly and then incubated with NLVPMVATV-restricted CD8+ T cells, at an E:T cell ratio of 
either 1:6 (left) or 1:12 (right). The activity of T cells, measured by IFN-γ secretion, was quantified 
using a fluorospot assay. Results are from triplicate wells representative of two independent 
experiments. Error bars ± SD.*P ≤ 0.05, ***P ≤ 0.001 using unpaired two-tailed t test. 
  
To ensure the reproducibility of these findings, I performed a similar T cell activation 
experiment using a different batch of primary CD8+ T cells. This time, I tested the effect of 
TAPBPR on the T cell-mediated recognition of an additional cell line expressing HLA-A*02:01, 
namely HeLaM-A2 cells, to ensure that the results were not restricted to the MCF-7 cells 
(Figure 62). Finally, I included two additional controls, namely treatment of the target cells with 
TAPBPRWT alone or with peptide in the presence of TAPBPRTN5, to test whether presence of 
TAPBPR alone triggered any T cell activation. The peptide concentration used in this experiment 
was 100 pM, as it offered the clearest enhancement in the T cell-mediated recognition of target 
cells by TAPBPR (Figure 61).  
Consistent with the observations from the previous experiment, very little T cell activation was 
observed to either MCF-7 cells (Figure 62a) or to HeLaM-A2 cells (Figure 62b) treated with 
peptide alone, while addition of TAPBPR resulted in a high increase, of almost 10-fold, in the 




presence of TAPBPRTN5 did not show any enhancement in T cell activation compared to when 
the target cells were treated with peptide alone. Moreover, treatment of either target cell line 
with TAPBPRWT alone did not promote T cell activation (Figure 62a and 62b), confirming that 
the activation of T cells was strictly as a result of recognition of the NLVPMVATV peptide loaded 
on HLA-A*02:01. Together, these findings demonstrate that TAPBPR can induce CD8+ T cell-
mediated recognition of tumour cells, by efficiently mediating their loading with immunogenic 
peptides added exogenously. 
 
Figure 62: TAPBPR-mediated antigenic peptide binding to tumour cells induces their recognition by 
T cells. (a) MCF-7 or (b) HeLa-A2 target cells were treated with or without 100 pM NLVPMVATV 
peptide for 60 min in the presence or absence of 1 μM soluble TAPBPRWT or TAPBPRTN5. Target cells 
were then washed thoroughly and then incubated with NLVPMVATV-restricted CD8+ T cells. The 
activity of T cells, measured by IFN-γ secretion, was quantified using a FluoroSpot assay. Results are 
from triplicate wells representative of two independent experiments. Error bars ± SD.*P ≤ 0.05, 








6.2.4. Using TAPBPR to induce T cell-mediated killing of tumour cells 
The next step was to show that the observed induction of T cell recognition of tumour cells by 
TAPBPR (Figure 62) results in a corresponding enhancement in the actual killing of the target 
cells by CD8+ T cells. To address this question, in collaboration with Dr. Maike de la Roche 
(CRUK, University of Cambridge), we decided to use a murine system. Namely, I assessed the 
effect of TAPBPR-mediated peptide loading on the killing of EL4 cells (a murine lymphoma cell 
line)(Gorer, 1950) by OT-1 T cells, which are primary CD8+ T cells that recognize the ovalbumin-
derived peptide SIINFEKL (SL8) loaded on H-2Kb (Carbone et al., 1992). There were a few 
reasons for switching to a murine system for this particular experiment. First, I have previously 
shown that the soluble version of human TAPBPR facilitates efficient peptide loading (and 
specifically of the SIINFEKL peptide) on H-2Kb expressed on EL4 cells (Figure 30b and 30c). 
Second, measuring OT-1 T cell-mediated killing of EL4 target cells has been a well-established 
and perfected assay (Jenkins et al., 2009, de la Roche et al., 2013), requiring less preparation 
and probably significantly less troubleshooting as well in comparison to a killing assay using 
human primary T cells. For instance, primary T cells required harvesting from patients’ blood, 
selection for the particular T cell clone reactive to the pMHC class I complex of interest and 
subsequent clonal expansion in culture (Weekes et al., 1999), which would ultimately yield 
significantly different T cell batches compared to one another (personal communication). In 
contrast, the primary OT-1 T cells are generated in a transgenic mouse line, in which all CD8+ T 
cells express the TCR specific for the ovalbumin-derived peptide SIINFEKL (Carbone et al., 
1992). Therefore, there was no need to select and expand a specific set/clone of T cells from 
the lymphocytes harvested from the spleens of OT-1 mice. Instead, the OT-1 T cells were 
readily available for assaying a few days after their harvest. This system also enabled high 
consistency across different T cell batches.    
Prior to attempting to measure the effect on T cell killing of the TAPBPR-mediated peptide 
loading on EL4 cells, I again wanted to test first whether the SIINFEKL peptide loaded by 
TAPBPR onto H-2Kb molecules could be accessible for recognition by TCRs. To this end, I stained 
EL4 cells treated with SIINFEKL, in the presence or absence of TAPBPRWT, with the mAb 25D-
1.16, specific for SIINFEKL in complex with H-2Kb (Porgador et al., 1997) (Figure 63a and 63b). 
This antibody is therefore similar to a recombinant TCR-like mAb. Satisfyingly, the results were 
similar to the ones recorded using the human TCR-like mAb on MCF-7 cells (Figure 60). Namely, 




treatment with peptide in the presence of TAPBPRWT, but not of TAPBPRTN5, resulted in a 
considerable increase in the recognition of the cells by 25D-1.16 (Figure 63a and 63b). Again, 
treatment of cells with TAPBPRWT alone did not promote any 25D-1.16 binding, confirming that 
25D-1.16 did not associate with TAPBPR, or with H-2Kb in the absence of SIINFEKL. 
Having clearly shown that peptides loaded using TAPBPR onto surface expressed H-2Kb 
molecules are accessible by soluble TCR-like mAb, I proceeded by measuring the effect of 
TAPBPR-mediated peptide loading on the killing of EL4 cells by CD8+ T cells (Figure 63c). To this 
end, EL4 cells were first treated with low concentrations of SIINFEKL, in the presence or 
absence of TAPBPR. Upon washing off the excess peptide, EL4 cells were incubated with OT-1 
cells and the level of target cell death was measured by the amount of LDH release (Figure 63c). 
I observed a significant enhancement, of roughly 2.5-fold, in the level of T cell killing of target 
cells in the presence of TAPBPRWT, but not of TAPBPRTN5, compared to when peptide was added 
alone to cells. This increase in TAPBPR-mediated T cell killing of EL4 cells was highly consistent 
across a wide range of E:T cell ratios (Figure 63c). However, the enhancement in T cell killing of 
murine tumour cells by TAPBPR was not nearly as high as the increase in T cell recognition of 
human cells (Figure 62). I believe that the main reason for this is, consistent with previous 
literature, that murine MHC class I molecules have a considerably higher molecular plasticity 
compared to human MHC class I molecules (Saini et al., 2013). This would make mouse MHC 
class I more receptive to TAPBPR-independent peptide binding than human MHC class I, which 
translates into a lower fold increase in peptide loading by TAPBPR. Nonetheless, our findings 
clearly demonstrate that TAPBPR can be utilised to enhance the killing of tumour cells by CD8+ 





Figure 63: Soluble TAPBPR-mediated peptide loading enhances T cell killing of tumour cells. EL4 
cells were incubated with or without 1 μM soluble TAPBPRWT or TAPBPRTN5 and subsequently treated 
with or without 1 nM SIINFEKL peptide for 30 min. (a and b) Cells were then stained with the 25-
D1.16 mAb, which recognizes SIINFEKL/H-2Kb complexes. (a) Histograms show levels of 25-D1.16 mAb 
binding and are representative of three independent experiments. (b) Bar graphs summarize the MFI 
of 25-D1.16 binding ± SD from three independent experiments. (c) % EL4 target cell killing by OT1 
cells, at different cellular ratios, when target cells were treated as stated above. Error bars ± SEM 
from triplicate wells. Data are representative of three independent experiments. ****P ≤ 0.0001 















Here, I showed that using soluble TAPBPR as a loading catalyst of immunogenic peptides onto 
MHC class I molecules expressed on the surface of tumour cells, of either human or mouse 
origin, induces their recognition and killing by CD8+ T cells. This finding provides the foundation 
for exploring potential therapeutic applications of using TAPBPR for increasing the 
immunogenicity of tumours.  
The initial observation that enabled us to explore the therapeutic potential of TAPBPR was the 
artefactual presence of TAPBPR at the surface of cells upon over-expression (Boyle et al., 2013). 
This finding enabled me to make the surprising discovery that TAPBPR present at the cell 
surface could function as an efficient peptide exchange catalyst on surface-expressed MHC 
class I molecules (Chapter 3). We then realized that we could exploit this property of TAPBPR to 
override the internal peptide editing and selection machinery, that naturally dictates which 
peptides are presented on MHC class I, by facilitating the loading of the desired peptides 
directly on surface MHC class I molecules.  
In exploring the translational applications of this finding, one question that immediately 
followed was whether TAPBPR could be used to modulate CD8+ T cell-mediate immune 
responses against specific target cell lines, by decorating them with highly immunogenic 
peptide antigens of choice. Of particular interest was the idea of enhancing the immune 
recognition of tumour cells. The recognition of immunogenic peptides presented on MHC class I 
molecules on the surface of tumour cells is crucial for the elimination of cancer by CTLs. While 
cancer cells do normally present such immunogenic peptides in the form of neoantigens, which 
arise de novo as tumour-specific mutations (Kawakami et al., 2004), for the majority of cancer 
types, presentation of neoantigens is likely to be low (Yadav et al., 2014, Kalaora et al., 2016). 
This is one of the reasons behind the low recognition and clearance of cancer cells by the 
immune system (Andersen et al., 2012). Therefore, increasing the availability of immunogenic 
peptides, such as neoantigens or viral antigens, on the surface of tumour cells, would represent 
a fundamental advance in enhancing the immune recognition of cancer. For this reason, using 
TAPBPR to efficiently promote the loading of highly immunogenic peptides onto cancer cells 





Here, I showed that using TAPBPR to facilitate the loading of exogenously-added viral peptides, 
reported to be highly immunogenic, onto different tumour cell lines, promotes their 
recognition and killing by primary CD8+ T cells. However, despite the clear enhancement in T 
cell recognition of target cells in the presence of TAPBPR, much work needed to be done in 
optimising and troubleshooting the T cell assays in order to achieve this effect. One problem 
encountered while troubleshooting the T cell assays performed on human cells was the high 
proliferation rates of both HeLaM and MCF-7 cells during the incubation period with the T cells. 
Consequently, the target cell cultures would overgrow during the incubation period and 
hamper the fluorescence read-out of the experiment. To overcome this issue, we decided to 
irradiate the target cells immediately prior to incubating them with the T cells, to stop their 
proliferation without dramatically altering their overall physiology. This relatively common 
strategy used in T cell assays allowed for considerably better detection of fluorescent spots 
corresponding to stimulated T cells. It is worth mentioning that only the target cells where T 
cell activation was measured were irradiated, and not also the ones where actual killing by T 
cell was assessed.   
Another hurdle arose after switching to mouse system, used for quantifying induction of T cell 
killing by soluble TAPBPR by measuring LDH release from target cells. Since the EL4 cells were 
highly sensitive to culturing and treatment conditions, they would often passively die during 
the incubation period of the experiment, even in the control condition, where no T cells were 
present. Due to the high level of LDH release from the cells in the negative control groups, it 
was impossible to quantify the effect of TAPBPR on T cell killing. To minimise passive cell death, 
I decided to wash and change the media of the target cells the night prior to the experiment 
and to reduce their exposure to different temperature and CO2 proportion as much as possible 
throughout the experiment. This led to almost full survival of the target cells in the absence of T 
cells during the entire duration of the experiment, allowing for accurately quantifying TAPBPR-










7.1. Summary of results 
In this dissertation, I revealed that when given access to the cell surface, TAPBPR is capable of 
functioning on as a peptide exchange catalyst on surface expressed MHC class I molecules. I 
decided to use this system as a novel cellular assay for measuring the efficiency of TAPBPR-
mediated peptide exchange on MHC class I molecules. This technique allowed me to 
demonstrate that the K22-D35 loop of TAPBPR is essential for its peptide exchange function 
and subsequently for its effect on peptide selection on specific MHC class I molecules such as 
HLA-A*68:02 and HLA-A*02:01. In particular, the L30 residue within the loop appears to be 
both necessary and sufficient for the ability of TAPBPR to efficiently dissociate peptides from 
MHC class I molecules that typically accommodate hydrophobic peptide residues in their F 
pocket. TAPBPR cannot mediate effective peptide exchange on MHC class I molecules with F 
pocket specificities for non-hydrophobic amino acids, due to the incompatibility of these F 
pockets with the L30 residue of TAPBPR. Following on from this, I investigated whether this 
compatibility model was generally applicable to a wide panel of HLA class I allomorphs, in 
determining their susceptibility to TAPBPR-mediated peptide editing. By screening a library of 
97 HLA class I allotypes for their ability to interact with TAPBPR, I revealed that TAPBPR shows a 
strong preference for HLA-A, particularly for supertypes A2 and A24, over HLA-B and -C 
molecules. Moreover, the propensity of HLA class I molecules to undergo peptide editing by 
TAPBPR appears to heavily rely on the molecular properties of the MHC class I F pocket, 
specifically residues 114 and 116. Based on the findings resulted from my work, I proposed a 
novel catalytic model for the mechanism of TAPBPR-mediated peptide editing on MHC class I 
molecules. Finally, apart from using this novel cellular assay for addressing key fundamental 
questions regarding the catalytical mechanism and molecular properties of TAPBPR, I started 
exploring the potential translational applications enabled by this discovery. Namely, I showed 
that TAPBPR can be used to load highly immunogenic peptides of choice directly onto MHC 
class I molecules present on the surface of tumour cells, thus promoting their recognition and 
killing by CTLs. These findings open an interesting translational avenue of developing TAPBPR 





7.2. Developing an improved assay for assessing TAPBPR-mediated peptide editing on 
MHC class I molecules 
Prior to this work, the peptide exchange activity of both tapasin and TAPBPR had been 
measured exclusively by cell-free assays. Namely, two techniques were developed more than 
ten years ago two assess the ability of tapasin to mediate peptide exchange on MHC class I 
molecules. One of them used recombinant tapasin-ERp57 disulfide-conjugated dimers and 
tested their ability to mediate exchange of iodinated peptides on MHC class I in a cell free 
system, whereas the other one involved artificially zippering tapasin to recombinant MHC class 
I refolds and measuring the dissociation of fluorescently-labelled peptides from MHC class I by 
fluorescence polarization experiments (Chen and Bouvier, 2007). Our lab and others had 
previously used an approach similar to the one developed by Chen and Bouvier to demonstrate 
that TAPBPR is also capable of facilitating peptide exchange on recombinant MHC class I refolds 
(Hermann et al., 2015b, Morozov et al., 2016); however, in contrast to tapasin, the luminal 
domain of TAPBPR alone, without the need of an artificial zipper, was sufficient for promoting 
peptide exchange on MHC class I in this system.      
Since TAPBPR normally mediates peptide editing on glycosylated MHC class I molecules, in a 
cellular environment, I was interested in whether a more physiological system could be 
developed to assess TAPBPR-mediated peptide exchange on MHC class I. Despite the function 
of TAPBPR being naturally restricted to intracellular compartments, I show that, when 
artificially given access to the cell surface, TAPBPR can function as a peptide exchange catalyst 
on surface MHC class I molecules (Ilca et al., 2018b). By exploring a trafficking artefact of 
TAPBPR over-expression, namely its presence at the cell surface, I was able to design two novel 
assays for assessing the efficiency of TAPBPR-mediated peptide exchange on MHC class I 
molecules on a cellular membrane. These assays rely on flow cytometry measurements to 
quantify the effect of TAPBPR on the level of fluorescently-labelled peptide bound to cell 
surface MHC class I molecules. This technique thus carries several advantages over the 
previously established assay, using soluble TAPBPR and recombinant MHC class I refolds 
expressed in bacteria (Hermann et al., 2015b, Morozov et al., 2016). For instance, unlike the 
bacterial refolds, the MHC class I molecules present in the cellular system carry the naturally-
occurring post-translational modifications, which were recently shown to strongly influence the 
interactions with TAPBPR (Neerincx and Boyle, 2018). Second, whereas recombinant MHC class 




the cell surface are loaded with a broad variety of peptides, over a wide affinity spectrum, 
which again, offers a considerably more accurate representation of the MHC class I pool that is 
naturally subjected to chaperone function in cells. Another consequence of the availability of a 
wide peptide pool on MHC class I over the presence of individual peptides of high affinity is the 
increased sensitivity of assaying the ability of a catalyst to dissociate the peptides. This is well 
reflected by the very low peptide dissociation rates from bacterial MHC class I refolds in the 
presence of TAPBPR, the reaction being not near equilibrium even after 6 hours (Hermann et 
al., 2015b). In contrast, the level of TAPBPR-mediated peptide exchange on cell surface MHC 
class I appears to saturate after only 15 minutes. Finally, by exploiting the cellular folding and 
trafficking machinery to express stable peptide-MHC class I complexes, the cellular assays 
overcome the challenge of manually expressing, refolding and purifying recombinant MHC class 
I molecules.  
 
7.3. Peptide exchange mechanisms of TAPBPR on MHC class I 
Regarding the molecular mechanisms by which TAPBPR catalyzes peptide dissociation from 
MHC class I molecules, I propose that TAPBPR uses its K22-D35 loop to displace the C-terminus 
of the peptide from the peptide binding groove of MHC class I (Chapter 4 – published in (Ilca et 
al., 2018a)). More specifically, my findings suggest that a leucine residue along this loop, which 
is the only long hydrophobic residue of this region, is both necessary and sufficient for the 
ability of TAPBPR to efficiently dissociate peptides from MHC class I molecules that typically 
accommodate hydrophobic amino acid residues in their F pocket. Interestingly, the same loop 
does not seem to have a significant effect on the peptide exchange function of TAPBPR on MHC 
class I molecules with F pocket specificities for non-hydrophobic anchor residues. The 
differences observed in the loop-dependency of the catalytic function of TAPBPR across 
multiple MHC class I molecules are remarkable, especially considering the comparison between 
HLA-A*68:02 and HLA-A*68:01, which only differ in 5 amino acids, but have different F pocket 
specificities (Niu et al., 2013). Correspondingly, swapping the different residue around the F 
pocket between these two HLA class I molecules leads to a complete reverse in the ability of 
TAPBPR to bind and exchange peptides onto them. 
While mutation of the loop significantly impairs the efficiency of TAPBPR-mediated peptide 




peptides on MHC class I, even in the absence of the loop, across MHC class I molecules with 
different peptide specificities. This indicates that TAPBPR uses alternative catalytic 
mechanisms, which may rely on other regions of TAPBPR, such as the already-described “jack-
hairpin” (Thomas and Tampe, 2017). Nevertheless, the loop-independent ability of TAPBPR to 
edit peptides seems to occur in a more generic and significantly less efficient manner and may 
be influenced more by the intrinsic ability of TAPBPR to interact with a particular MHC class I 
molecule or by the relative molecular plasticity of individual pMHC class I complexes. In other 
words, one can envisage that TAPBPR can associate, in a loop-independent manner, with MHC 
class I molecules loaded with peptides that are more prone to dissociation (i.e. sub-optimally 
loaded peptides).   
Our findings suggest that TAPBPR appears to be using the loop, and particularly the L30 
residue, to probe the content of the MHC class I groove in a highly dynamic manner. This would 
explain the ambiguities in the loop localization and conformation observed in the two crystal 
structures of TAPBPR in complex with MHC class I (Jiang et al., 2017, Thomas and Tampe, 
2017). For instance, our data suggesting that the loop seems to facilitate dissociation of the 
peptide specifically at the F pocket region of the MHC class I groove would be particularly 
important for the structure where modifications were made to H-2Dd to help stabilize the F 
pocket (Jiang et al., 2017). This artificial stabilization of the MHC class I F pocket could have 
occluded the ability of the loop to insert into the groove.  
Mechanistically, based on all data which I have managed to generate using this novel cellular 
peptide exchange assay, together with previous mechanistic views, I propose the following 
model of TAPBPR-mediated peptide editing on MHC class I (Figure 64). Whenever MHC class I 
molecules accessible by TAPBPR enter a state in which the bound peptide partially dissociates 
(“breathes”) at the C-terminus from the F pocket (step 2 – Figure 64), TAPBPR binds to MHC 
class I, inserting its 22–35 loop into the peptide binding groove (step 3 – Figure 64). At this 
point, TAPBPR and MHC class I interact in a transient manner. The loop of TAPBPR samples the 
MHC class I groove, inserting its leucine 30 residue into the F pocket, if hydrophobic. The 
binding of the loop into the F pocket subsequently inhibits the reassociation of the C-terminal 
anchor residue of the peptide, in a competitive manner. The resulting high-free energy 
intermediate TAPBPR-MHC class I-peptide complex allows TAPBPR to pull the α2–1 region of 
the peptide binding groove away from the peptide, as captured in the crystal structures, forcing 




further prevents the reassociation of the C-terminus of the peptide to the MHC class I groove 
and thus facilitates its complete dissociation (step 5 – Figure 64). Due to its stable interaction 
with peptide-receptive MHC class I molecules, TAPBPR prevents these empty MHC class I 
molecules from unfolding (“crashing”), as they would normally do immediately after the bound 
peptide dissociates (Hulsmeyer et al., 2005). I speculate that this consequently facilitates 
binding of incoming peptides to MHC class I, with affinities above the threshold required to 
outcompete TAPBPR. This entire mechanism appears to share similar features with the “tug-of-
war” model that was previously proposed for tapasin-mediated peptide exchange (Fisette et 
al., 2016).   
 
Figure 64: Proposed model of the peptide exchange mechanism on MHC class I molecules, catalyzed 
by TAPBPR, taken from Ilca et al. (Ilca et al., 2018a).  
 
Based on the data from our lab and others, the molecular mechanisms of peptide editing by 
TAPBPR and tapasin appear to be relatively similar (Fisette et al., 2016, Ilca et al., 2018a, Jiang 
et al., 2017, McShan et al., 2018, Thomas and Tampe, 2017). First, both chaperones seem to 
display similar orientations when bound to MHC class I molecules and share similar MHC class I 




be pulling the α2-1 region of MHC class I away from the peptide (Jiang et al., 2017, Thomas and 
Tampe, 2017), property which was also predicted for tapasin based on molecular dynamics 
simulations (Fisette et al., 2016). Finally, recent work suggests that tapasin also relies on a 
homologous loop to the one of TAPBPR in performing efficient peptide editing on MHC class I 
molecules (Hafstrand et al., 2019) and, furthermore, this effect seems to also be facilitated by a 
leucine residue on the loop. However, in contrast to tapasin, my data suggests that the TAPBPR 
loop enables TAPBPR to facilitate the dissociation of peptides with relatively high affinity for 
MHC class I molecules (Ilca et al., 2018b, Ilca et al., 2018a). This data is consistent with our 
model that TAPBPR can mediate peptide editing on MHC class I molecules after tapasin 
(Neerincx and Boyle, 2017, Neerincx et al., 2017). Based on work presented in this dissertation 
and from other studies, I believe that while tapasin is essential for the efficient loading of MHC 
class I molecules with stably-bound peptides (Williams et al., 2002, Howarth et al., 2004), 
TAPBPR is considerably more efficient at dissociating stably-bound peptides from MHC class I 
molecules which have already passed through tapasin-mediated peptide loading (Chapter 3 – 
published in (Ilca et al., 2018b))(Hermann et al., 2015b) but do not meet certain criteria for 
presentation at the cell surface.  
 
7.4. Criteria used by TAPBPR in selecting peptides 
Regardless of the exact cellular compartment(s) where TAPBPR facilitates peptide exchange on 
MHC class I molecules, currently, the precise selection criteria used by TAPBPR in selecting 
peptides on MHC class I for presentation remain largely enigmatic. In the case of tapasin, it has 
been rather well established that it promotes peptides exchange strictly based on affinity 
(Fisette et al., 2016, Howarth et al., 2004, Williams et al., 2002). Namely, tapasin was suggested 
to repeatedly mediate the dissociation of sub-optimally loaded peptides that get loaded onto 
peptide-receptive MHC class I molecules, until these MHC class I molecules acquire peptides of 
high enough affinity, which exceed the binding energy that tapasin needs to overcome in order 
to open the groove (Fisette et al., 2016). Moreover, once MHC class I molecules get loaded with 
high-affinity peptides, the PLC was shown to dissociate and, additionally, tapasin was shown to 
no longer be capable of accessing the resulting pMHC class I complex.  
Unlike tapasin however, based on the work presented in this dissertation, TAPBPR seems to be 




ones present at the surface of cells, upon interferon stimulation (Figures 18, 26 and 27). 
Moreover, when given access to this pool of stable pMHC class I complexes, TAPBPR dissociates 
the bound high-affinity peptides in a highly rapid and efficient manner (Figure 18). Efficient 
dissociation by TAPBPR has also been directly observed for fluorescent derivatives of high-
affinity neoantigens or self-peptides (Figure 13) that were naturally shown to be presented on 
MHC class I at the cell surface.  
There is little indication of how the observed ability of TAPBPR to dissociate peptides from MHC 
class I molecules at the cell surface, or in solution for that matter, would relate to its catalytic 
function performed intracellularly. In order to gain deeper understanding in the biochemical 
and biophysical characteristics that make a specific peptide, loaded on MHC class I, prone to 
dissociation by TAPBPR, one would need to more thoroughly compare the immuno-peptidomes 
presented on individual MHC class I allotypes, in the presence or absence of TAPBPR. The 
caveat of this approach however is that knocking out TAPBPR would potentially also alter 
UGT1-mediated quality control of MHC class I molecules, or, on the opposite, the effect of 
knocking out TAPBPR on the peptide repertoire could be partially compensated by UGT1 
(Neerincx et al., 2017, Zhang et al., 2011). An alternative approach to this question, although 
less physiologically-relevant, would be assess the effect of adding soluble TAPBPR directly onto 
the cell surface on the peptide repertoire presented on MHC class I. This would inform on the 
specific MHC class I-loaded peptides which TAPBPR alone is capable of dissociating, without any 
interference caused by other components of the pathway.  
  
7.5. Allelic preference of TAPBPR for MHC class I molecules 
 
7.5.1. Molecular basis 
Consistent with our mechanistic model of TAPBPR-mediated peptide exchange on MHC class I 
molecules is the striking preference of TAPBPR for HLA class I allotypes that naturally 
accommodate hydrophobic residues in their F pocket. Interestingly however, although many 
HLA class I allotypes, particularly belonging to the HLA-B and -C groups, appear to interact 
weakly with TAPBPR and do not undergo TAPBPR-mediated peptide editing in an efficient 




susceptibility of class I molecules to peptide editing by TAPBPR, it appears to be too vague to 
represent the sole selection criteria of TAPBPR for HLA class I.  
According to our study, it is not only the specificity of the F pocket that drives HLA class I 
susceptibility to peptide editing by TAPBPR, but also the molecular architecture of this region. 
Namely, there is a perfect correlation between presence of the HxY motif at positions 114-116 
in the F pocket region and the efficient interactions of HLA class I with TAPBPR. Interestingly, 
this motif is conserved across all known members of the HLA-A2 and -A24 superfamilies 
(Robinson et al., 2015), molecules which display high susceptibility to TAPBPR function. 
Moreover, these residues are not present in any other HLA-A allotype, nor in any HLA-B and -C 
molecules, all of which form very weak interactions with TAPBPR. This motif is also absent in all 
non-classical HLA class I molecules (Robinson et al., 2015). Further supporting the impact of the 
HxY motif at positions 114-116 is that reconstitution of these residues in HLA class I molecules 
which interact weakly with TAPBPR considerably enhances their ability to associate with, and 
undergo peptide editing by TAPBPR.    
Regarding our understanding of the molecular basis of HLA class I susceptibility to TAPBPR 
function, my findings thus far support the idea that compatibility between the 22-35 loop, and 
particularly of residue L30, of TAPBPR and the F pocket of HLA class I drives efficient TAPBPR-
peptide editing. Therefore, I believe that TAPBPR facilitates peptide dissociation from MHC 
class I molecules in a “lock-and-key” model and consequently speculate that the intracellular 
effect of TAPBPR on shaping the peptide repertoire presented by MHC class I molecules occurs 
in a highly allele-specific manner.    
 
7.5.2. Comparison to tapasin 
Interestingly, studies exploring tapasin have suggested the same residues, on positions 114 and 
116, to be particularly important for the dependence of different HLA class I molecules on 
tapasin, in terms of their ability to efficiently present peptides at the cell surface (Park et al., 
2003, Williams et al., 2002, Rizvi et al., 2014). However, these findings on tapasin have mainly 
focused on HLA-B molecules and have not yet identified a conserved motif or architecture of 
the F pocket region of MHC class I as a general driving feature for tapasin dependency. It is also 
important to point out that the studies investigating MHC class I dependency on tapasin have 




tapasin on the surface expression levels of MHC class I molecules. However, it is widely 
accepted that absence of tapasin also destabilizes TAP (Lehner et al., 1998) and thus alters the 
peptide pool available for loading on MHC class I molecules, potentially to a different degrees 
across different HLA class I allotypes.    
Furthermore, there does not seem to be any specific group or category of HLA class I molecules 
showing a clearly increased tapasin dependency compared to the rest. Namely, tapasin does 
not seem to differentiate among HLA class I allotypes based on criteria such as peptide binding 
specificity or molecular signatures along the peptide binding groove. Instead, Springer and 
colleagues have proposed that tapasin functions preferentially on MHC class I molecules with a 
high degree of molecular plasticity, particularly around the F pocket region (Sieker et al., 2007, 
Sieker et al., 2008).       
 
7.6. Biological explanation for allelic dependency of HLA class I on TAPBPR-mediated 
peptide editing 
 
7.6.1. Preference of TAPBPR for HLA-A2 and -A24 supertypes 
 
The molecular basis of the observed preference of TAPBPR for this select group of HLA class I 
allotypes raises the next obvious question regarding the biological explanation for this 
phenomenon. One potential biological reason for this preference could be that the HLA 
molecules of the A2 and A24 superfamilies might have access to significantly wider peptide 
pools, which can fit their individual binding motifs, within the ER lumen. This could be a result 
of either a wider availability of peptides carrying hydrophobic amino acids at their C-terminus 
inside the ER or to an increased promiscuity in the peptide binding grooves of HLA-A2 and -A24 
superfamily members, allowing these specific HLA molecules to naturally accommodate a 
broader variety of peptides. Thus, these HLA class I allotypes could in principle require an 
additional peptide selection checkpoint, potentially represented by TAPBPR, in order to further 
refine their peptide repertoire presented for recognition.  
Another possible explanation for this observed preference of TAPBPR could be that this 
particular group of HLA-A molecules that interacts more strongly with TAPBPR might potentially 




allelic-dependency of HLA class I on tapasin remains to be thoroughly investigated, this 
scenario would support the compensatory relationship between TAPBPR and tapasin on MHC 
class I rather than their successive, synergistic effect on peptide selection.  
The lower propensity of HLA-B and HLA-C molecules to undergo peptide editing by TAPBPR 
could also be due to the fact that they may naturally require less peptide editing compared to 
HLA-A molecules. This could be a consequence of their stronger recognition by KIRs (Figure 65), 
which has been proposed to occur in a much less antigen-specific manner than recognition by 
TCRs (Natarajan et al., 2002). However, this scenario would mainly be applicable for HLA-C 
molecules, as they are primarily involved in recognition by KIRs, while their involvement in T 
cell-mediated immune responses in still poorly defined (Blais et al., 2011). HLA-B molecules on 
the other hand, despite their broader recognition by KIRs compared to HLA-A molecules 
(Colonna and Samaridis, 1995), are also heavily involved in generating CD8+ T cell-based 
immune responses and hence in the recognition by TCRs. This would argue against chaperone-
mediated peptide editing and selection being less important for HLA-B than for HLA-A 
molecules.  
Overall, while the biological explanation for the observed preference of TAPBPR for HLA-A 
molecules, particularly the ones belonging to the A2 and A24 supertypes, over HLA-B and -C 
molecules remains largely enigmatic, it appears that these findings have introduced an 
additional layer of complexity in HLA class I biology.  
 
7.6.2. Impact of TAPBPR on susceptibility to HLA-associated diseases 
Interestingly, subtle polymorphisms occurring in specific HLA class I molecules associated with 
disease susceptibility impact their propensity to undergo peptide exchange by TAPBPR. Across 
the multitude of HLA-B27 subtypes, HLA-B*27:05 and -B*27:04 display a strong association 
with ankylosing spondylitis, while HLA-B*27:06 and HLA-B*27:09, are either not associated at 
all or only weakly associated with ankylosing spondylitis (Fiorillo et al., 2003, Brown, 2010). 
Through my work here, I reveal that HLA-B*27:05 and -B*27:09, molecules that differ in residue 
116 alone, appear to be differently susceptible to undergoing peptide editing by TAPBPR. In 
other words, natural variations in residue 116 among HLA-B27 molecules, which seems to 
correlate with disease association (Fiorillo et al., 2003, Brown, 2010), appear to also influence 




in residue 116 alone between two HLA class I allotypes that were shown to enable different 
progression rates of HIV, namely HLA-B*35:01 and -B*35:03 (Gao et al., 2001), also impacts 
their propensity to undergo peptide editing by TAPBPR.  
It is important to consider that the assays which I used to address these questions measure the 
capacity of TAPBPR to catalyse peptide exchange on HLA class I molecules expressed on the 
surface of cells, molecules which have already been selected intracellularly by quality control 
checkpoints. Therefore, the observed differences in the magnitude of TAPBPR-mediated 
peptide editing between these HLA class I allotypes is likely to be considerably greater when 
assessed in its natural intracellular setting. Since the level of peptide selection on these HLA 
class I molecules most likely contributes to their association with both ankylosing spondylitis 
and HIV progression, my findings could provide new insight regarding the mechanism by which 
apparently subtle variations in HLA I may play a significant role in disease susceptibility.   
 
Figure 65: Varying susceptibility of classical HLA class I molecules to peptide editing by TAPBPR and 





7.7. Potential role of TAPBPR in the MHC class I pathway 
 
7.7.1. Function of TAPBPR inside the ER 
Despite TAPBPR appearing to be an efficient peptide editor on MHC class I, outside of the PLC 
(Hermann et al., 2015b, Morozov et al., 2016), TAPBPR cannot compensate for the absence of 
tapasin, with respect to the efficient loading of MHC class I molecules with high affinity 
peptides (Boyle et al., 2013). However, this might be an effect of the destabilization of TAP in 
the absence of tapasin, which would impair the abundance of peptides available for loading, 
potentially by TAPBPR, onto peptide-receptive MHC class I molecules. On the other hand, 
TAPBPR was suggested to localize in different sub-compartments of the ER compared to tapasin 
and TAP, and thus away from the peptide points of peptide influx into the ER (Hermann et al., 
2015a, Neerincx et al., 2017). This favors the idea that the role of TAPBPR is more in 
dissociating peptides from MHC class I molecules already loaded with peptide by the PLC, 
functioning as a proof-reader instead of as a peptide-loader.  
The role of TAPBPR in peptide selection on MHC class I molecules following their peptide 
loading by the PLC is further supported by the observed interaction of TAPBPR with UGT1 
(Neerincx et al., 2017), enzyme which has been previously shown to proof-read MHC class I 
molecules prior to their export from the ER (Zhang et al., 2011, Wearsch et al., 2011). Finally, 
consistent with this recycling model of MHC class I molecules from TAPBPR, via UGT1, back to 
the PLC, absence of TAPBPR has been shown to reduce the interaction of MHC class I molecules 
with the PLC as well as to increase export rate of MHC class I molecule from the ER (Boyle et al., 
2013).    
 
7.7.2. Function of TAPBPR outside the ER 
Despite being mainly present inside the ER, TAPBPR has been also shown to interact with MHC 
class I outside of the ER (Boyle et al., 2013). Moreover, I have shown in this dissertation that, 
upon over-expression, TAPBPR interacts with MHC class I molecules present at the cell surface. 
The ability of TAPBPR to interact with MHC class I in different sub-cellular compartments, 
independently of additional factors, suggest that TAPBPR might be affecting/regulating the 
trafficking on MHC class I molecules through the export pathway. This idea would be further 




expression of TAPBPR downregulates surface expression of MHC class I molecules (Figure 5) 
(Boyle et al., 2013). This work raises a few interesting questions regarding the interdependence 
of MHC class I and TAPBPR in their anterograde trafficking.    
In future studies, it would be useful to better understand the biological reason behind this 
phenomenon. I currently speculate that, given its ability to traffic in complex with MHC class I 
and to edit peptides at different cellular locations, TAPBPR might facilitate peptide exchange on 
MHC class I in endosomal compartments, for the biological purpose of cross-presentation via 
the vacuolar pathway (Figure 66). I base my speculation on a number of factors which seem in 
accordance with one-another. First, we have shown that TAPBPR traffics in complex with MHC 
class I through the medial Golgi (Boyle et al., 2013), however presence of TAPBPR has never 
been detected at the cell surface. Thus, the most obvious trafficking route of TAPBPR in 
complex with MHC class I would be through endosomal compartments. Second, the capacity of 
TAPBPR to edit peptide on MHC class I molecules in a cell, but outside of the ER, would allow 
TAPBPR to catalyze the exchange of endogenous peptide bound to MHC class I for exogenously-
derived peptides internalized by pinocytosis. In fact, one of the few sub-cellular compartments 
where TAPBPR-bound MHC class I molecules would have access to an abundance of peptides 
outside of the ER would be the endosomes rich in peptides of exogenous origin. If TAPBPR will 
be indeed proven in the future to be the directly involved in MHC class I molecules acquiring 
exogenous peptides for cross-presentation, it would imply that TAPBPR fulfils a similar role on 





Figure 66: Similarities between the role of HLA-DM in the MHC class II pathway and the potential 
involvement of TAPBPR in the vacuolar pathway of cross-presentation. 
 
 
7.8. Potential therapeutic application of TAPBPR against cancer 
Apart from the contribution of the findings described here thus far towards the fundamental 
understanding of the biological role of TAPBPR in the MHC class I antigen presentation pathway 
and hence in the generation of adaptive immune responses, perhaps the most fascinating 
implication of my work is the translational potential of using TAPBPR to load immunogenic 
peptides onto the surface of tumour cells, in order to target them for recognition by CTLs. 




potential of exploiting CTL-mediated immune responses in eliminating cancer. Crucial for 
developing efficient CTL-mediated elimination of cancer is the recognition of immunogenic 
peptides presented on MHC class I molecules at the surface of tumour cells. Neoantigens, 
which are mutated versions of self-derived peptides, arisen de novo from tumour-specific 
mutations (Kawakami et al., 2004), are considered optimal targets for recognition by CTLs, as 
they are only present in cancer cells and therefore avoid central tolerance. However, their 
presentation on MHC class I is generally low and they are only present in cancer types with high 
mutational burden (Yadav et al., 2014, Kalaora et al., 2016). Therefore, a fundamental step 
forward in overcoming the low immunogenicity observed in tumour cells would to increase the 
expression levels of such neoantigens or to induce presentation of foreign antigens that are 
highly immunogenic, such as ones derived from viruses. Conclusively, the observed ability of 
TAPBPR to load immunogenic peptides, either viral or neoantigens, onto the surface of 
different cancer cell lines highlights a potential therapeutic application of using TAPBPR to 
increase tumour immunogenicity. Provided that one could achieve efficient targeting of 
TAPBPR specifically to tumour cells (e.g. in a similar manner as designing chimeric antigen 
receptors (CARs) for the engineering of CAR-T cells), this may represent a significant advance in 
the field of cancer immunotherapies, with the potential of improving treatment outcomes in 
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